An Ex Vivo Model For The Assessment Of Drug Toxicity On The Human Retina by Wright, Phillip
1 
 
An Ex Vivo Model For The 
Assessment Of Drug Toxicity On 
The Human Retina 
 
Phillip Wright 
 
THESIS PRESENTED FOR THE DEGREE OF DOCTOR 
OF PHILOSOPHY  
 
UNIVERSITY OF EAST ANGLIA, NORWICH, UK 
 
SCHOOL OF PHARMACY 
 
APRIL 2016 
 
This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with the author and that use of any 
information derived there from must be in accordance with current UK Copyright 
Law. In addition, any quotation or extract must include full attribution  
2 
 
Abstract 
Purpose: Retinal toxicity is a common cause of drug development attrition. The 
aims of this research were therefore to develop the ex vivo human retina as a suitable 
model for the assessment of retinotoxicity, and to explore the methods in which this 
may be investigated. 
 
Methods: Post mortem and living donor human eyes were obtained, and the retinas 
dissected within 24h post mortem or 1h enucleation respectively. The ex vivo human 
retina was characterised using immunohistochemistry and QRT-PCR. The effect of 
multiple retintoxins was investigated on the human retinal cell lines MIO-M1 
(Müller cells) and ARPE19 (RPE cells), and CHQ on the human organotypic retinal 
culture (HORC) using the LDH and MTS assays. TUNEL, Western blotting and 
QRT-PCR were also used to investigate the effect of CHQ on the HORC, and CDK 
expression investigated by QRT-PCR. 
 
Results: Cell specific markers were investigated in the post mortem and living 
donor, both possessed similar immunohistochemical and mRNA properties. CHQ 
was the most potent retinotoxin investigated in the cell lines, and when applied to the 
HORC, measureable toxicity was found along with an increase in the expression of 
multiple cell specific mRNA’s. The expression profile of multiple CDK’s in the ex 
vivo retina was investigated in relation to a retinotoxic Pan-CDK inhibitor, where 
differential expression was found. When exposed to the retinotoxic pan-CDK 
inhibitor, the cell lines displayed differences in toxicity. 
 
Conclusion: The ex vivo human retina is an ideal tissue to investigate retinotoxicity. 
It possesses similar properties as the in vivo human retina, and displayed measureable 
toxicity when exposed to CHQ. The ex vivo human retina also proved its usefulness 
in the investigation genes associated to a novel retinotoxin. The ex vivo human retina 
could act as a bridge between animal and human studies, providing vital information 
about a drug’s potential retinotoxicity.  
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Chapter 1 
1.1 Anatomy and function of the eye 
1.1.1 Overview of the eye 
The eye (Figure 1.1) is a specialised organ the purpose of which is to receive light 
and convert this energy into a neural signal for the brain to process this information 
to create the sense that is “sight”. In order to receive light in an effective manner the 
eye has evolved so that light is first refracted by the cornea and lens and focussed 
onto the photosensitive cells of the retina which enable visual transduction. Within 
this chapter the main regions of the eye that enable visual transduction are described, 
starting with where light first enters the eye, the cornea, and ending where it is 
converted to a neural signal within the retina.  
 
 
Figure 1.1 - Schematic diagram of the human eye in the horizontal plane. Source: 
http://www.phys.ufl.edu/~avery/course/3400/vision/eye_human_detail.gif 
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1.1.2 The Cornea and Sclera 
The cornea is the most exposed part of the eye and is also the part with the highest 
curvature; it has a vertical diameter of 10.6mm which is smaller than the horizontal 
diameter of 11.7mm (Van Buskirk, 1989). The cornea forms around one sixth of the 
surface area of the eye (Martola and Baum, 1968), with the remainder being formed 
by the tough layer called the sclera (Figure 1.1). The cornea’s most important 
features are the high refractive index it provides (the majority of refraction within the 
eye is caused by the cornea) and its transparency. The transparency comes as a result 
of the avascularity, the smoothness of the surface and the unique properties of the 
five layers which form the cornea. The five layers of the cornea in order from the 
outermost layer inwards are; the corneal epithelium, Bowmans layer, stroma, 
Descemet’s membrane and the endothelium. 
On top of the corneal epithelium lies the tear film which consists of three main 
layers, the meibomian lipid layer (outer layer), aqueous layer (middle layer) and the 
hydrated mucus layer (inner layer). The tear layer is an important layer that is in 
contact with the air and functions to maintain a wet surface, create a smooth optical 
surface and supply nutrients to the cornea. 
The tear film also protects the cornea in two main ways, one is by providing 
antibacterial protection with lysoszyme, and the other is the delicate balance of 
proteinases and proteinase inhibitors which maintain cell turnover and aid repair 
within the cornea (Remington, 2012). 
The sclera forms the remaining five sixths of the eye and provides a tough tissue 
shell to the eye. It provides resistance to external and internal forces and maintains 
the eyes shape. The sclera provides attachment points for muscle to join to allow 
movement of the eye. It is continuous with the cornea but has different properties. 
The cornea has regularly arranged lamellae which allow the cornea to possess its 
transparent properties, the sclera however has irregularly arranged lamellae which 
provide stronger and more flexible properties than the cornea, but the result is that 
the sclera is opaque. 
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1.1.3 The Anterior and Posterior Chamber 
There are two chambers that lie behind the cornea, the anterior chamber and the 
posterior chamber (Figure 1.1) within which aqueous humour is produced, held and 
drained. 
Aqueous humour is a transparent fluid which serves two main functions. Firstly, it is 
the medium through which necessary metabolites are transported to the avascular 
lens and the cornea and it also serves to remove metabolic products. Secondly it 
enables maintenance of a stable intra-ocular pressure which results from a balance 
between rate of production, and drainage of aqueous humour. Aqueous humour is 
produced and secreted into the posterior chamber (located posterior to the iris and 
anterior to the lens (Figure1.1) and is the smaller of the two chambers) from the 
ciliary processes. Active secretion is responsible for around 80 – 90% of total 
aqueous humour production with the rest produced through diffusion and 
ultrafiltration. A total of approximately 2.5µl is produced per minute with a 50% 
decrease in production at night, following a circadian pattern. Aqueous humour is 
passed from the site of production through the posterior chamber into the anterior 
chamber via the pupil. 
The anterior chamber lies between the cornea and the iris (and the pupillary part of 
the lens) (Figure1.1). It is the larger of the two chambers hosting a total of around 
250µl of aqueous humour with a central depth of around 3mm. The anterior chamber 
is the chamber from which the drainage of aqueous humour occurs. Drainage is 
either via the “conventional pathway” or the “non-conventional pathway”. The 
conventional pathway is the main route of exit, responsible for 70-80% of drainage 
via Schlemm’s canal and the trabecular meshwork. The non-conventional pathway 
involves aqueous humour passing through intercellular spaces between ciliary 
muscle fibres and loose connective tissue (Forrester, 2007). 
 
1.1.4 The Ciliary Body 
The ciliary body is a ring shaped structure which anteriorly is present in the posterior 
chamber and posteriorly extends as far as the ora serrata where it terminates.  
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A large portion of the ciliary body is formed from smooth muscle, which is 
innervated by both the parasympathetic nervous system for contraction via 
acetylcholine on muscarinic receptors, and relaxation (inhibition) of the ciliary 
muscle via noradrenaline acting on α1 and β2-adrenoceptors allowing for lens 
focussing (accommodation) (Remington, 2012). The supraciliaris is the layer which 
lays between the ciliary muscle and the sclera. This layer is formed of loose 
connective tissue and posseses a ribbon like structure which allows the ciliary body 
to slide against the sclera to prevent tissue detachment from the sclera. The 
remainder of the ciliary body is taken up by the stroma. This tissue is highly 
vascularised and contains connective tissue, fibroblasts, melanocytes and some 
immune cells. 
The ciliary body has two main functions; the first is the aiding of lens 
accommodation via contraction and relaxation of the ciliary muscle, the second is the 
production of aqueous humour. Aqueous humour is produced by the highly 
vascularised stroma and ciliary processes. Plasma and macromolecules leak through 
the permeable capillaries of the stroma and pass through the pigmented epithelial 
layer (which are joined together by leaky junctions). The non-pigmented epithelial 
layer contains tight junctions which prevents passive movement into the posterior 
chamber. This enables this layer to filter unwanted macromolecules. The non-
pigmented epithelial layer contains high levels of mitochondria and actively 
transports ions to enable aqueous humour secretion into the posterior chamber. 
 
1.1.5 The Iris 
The iris is a circular structure responsible for controlling illumination levels of the 
retina. The iris achieves this by having the ability to alter the pupil size. In bright 
light conditions the pupil can contract to 1mm (miosis), in low light levels the pupil 
can dilate to 9mm (mydriasis). The iris is approximately 12mm in diameter and cone 
shaped with the pupillary part lying on the lens anterior to the root of the iris. The iris 
is thickest at a region called the collarette which is located roughly 1.5mm from the 
pupil margin (Remington, 2012). 
The iris has 4 layers. The outermost layer is the anterior border layer which consist 
of fibroblasts laying on top of a layer of pigmented melanocytes. The next layer 
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posterior to this is the stroma and sphincter muscle, which is composed of pigmented 
(melanocytes and clump cells) and non-pigmented fibroblasts, lymphocytes, 
macrophages and mast cells with smooth muscle forming the sphincter. The anterior 
epithelium and dilator muscle lay posterior to the stroma. This layer consists of 
myoepithelial cells and elongated smooth muscle fibres which form the dilator 
muscle. The most posterior layer is the posterior epithelium which is formed by a 
single layer of heavily pigmented columnar epithelial cells (Hogan et al., 1971). 
 
1.1.6 The Lens 
The lens is a transparent, avascular elliptic structure whose purpose is to help focus 
light on the retina. It is composed of two main cell types, lens epithelial cells and 
lens fibre cells (which differentiate from lens epithelial cells). The lens is biconvex 
with the posterior surface having a steeper radius of curvature of between 5 - 8µm in 
comparison to the anterior surface which has a radius of curvature of 8 - 14µm. The 
lens has a thickness of between 3.5 and 5mm (measured from the anterior pole to the 
posterior pole) and a diameter of around 9mm when mature (Remington, 2012). The 
thickness of the lens increases by around 0.02mm each year due to the formation of 
new fibres, however the diameter does not change (Dubbelman et al., 2001). 
Altering the dioptric power of the lens is achieved by the ciliary muscles which 
either contract or relax to alter the lens shape. When the eye needs to focus on a 
distant object, the ciliary muscle relaxes which pulls the zonular fibres tight, and in 
turn stretches the lens to decrease the refractive power. The opposite occurs when 
focussing on a near object; the lens accommodates by increasing its refractive power. 
This happens by the ciliary muscles contracting, loosening the zonular fibres and in 
turn the lens curvature increases, thus increasing the dioptric power to focus the near 
object on the retina (Johnson, 1976). Unaccommodated, the lens has a refractive 
power of 20 dioptres. This is due to a multitude of factors including the refractive 
index of the lens, change in index between the lens and the aqueous humour, length 
of the optical path and the surface curvature of the lens. 
The transparency of the lens is a key factor in its functioning; the lens needs to be 
able to refract light but not scatter it. The lens gains its transparency from an absence 
of blood vessels, minimal cell organelles and an orderly arrangement of fibres 
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(Remington, 2012). The lens is attached posteriorly to the anterior vitreous face by 
the hyaloid capsular ligament. 
 
1.1.7 The Vitreous Chamber 
The vitreous chamber is the largest section of the eye, occupying around 80% of the 
total eye volume. The purpose of the vitreous is to provide support for the retina and 
the eye along with storing essential metabolites for the lens and retina. 
It consists mainly of water (98.5 – 99.7%) with a dilute solution of salts, soluble 
proteins and hyaluronic acid within a meshwork of collagen. The vitreous can be 
divided into zones depending on its density. There are three main zones within the 
vitreous; the outer (vitreous cortex) which contains a large amount of tightly packed 
collagen fibrils, the intermediate zone which consists of fibers that run from the 
vitreous base to the posterior cortex and the center zone which is surrounded by the 
intermediate zone and is also known as the hyaloid canal (Figure 1.1). 
The vitreous is bound anteriorly to the posterior part of the lens and the ciliary body 
by the hyloideocapsular ligament. The most extensive attachment of the vitreous is to 
the basement membrane of the non-pigmented epithelium of the ciliary body and the 
internal limiting membrane of the peripheral retina. This is held by vitreous fibres 
which are embedded into the epithelium and membrane (Remington, 2012). 
 
1.2 The Retina 
1.2.1 Retinal Function and Anatomy 
The retina is the region of the eye responsible for transforming light energy into 
neuronal signals which are transmitted to the brain, which in turn processes the 
information enabling vision. This process means that the retina has a high metabolic 
demand, with the highest oxygen consumption per gram of any tissue within the 
human body. 
To meet this high metabolic demand, the retina has two different blood supplies. The 
outer retinal layers are supplied by the choroidal capillary bed. Through this path 
oxygen and metabolites have to diffuse across Bruch’s membrane and the RPE to 
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reach the outer retinal layers. The choroidal pathway has a high flow rate (150 mm/s) 
but a low oxygen exchange rate (Forrester, 2007) which provides about a third of the 
retina’s total metabolic requirement. 
The remainder of the retina is supplied through the central retinal vessels. This 
pathway starts with the ophthalmic artery passing through the optic disc (Figure 1.2) 
where it branches into the superior and inferior retinal artery each of which divide 
further. The vessels ultimately form two capillary networks; the deep capillary 
network (located in the inner nuclear layer) and the superficial capillary network 
(located in the nerve fiber layer / and or the ganglion cell layer). This network 
supplies the remainding two thirds of the retina’s total requirements; it has a lower 
flow rate (25mm/s) but a higher oxygen exchange rate (Forrester, 2007). 
The retina is protected by a barrier similar to that of the blood brain barrier known as 
the blood retinal barrier (BRB). The BRB allows the retina to support the specific 
environment which is optimal for function (Remington, 2012). The BRB is 
composed of two parts, the inner BRB (composed of microvascular endothelium 
cells) and the outer BRB (formed by the RPE) (Campbell and Humphries, 2012). 
Both the inner and outer BRB possess tight junctions which regulate solute and fluid 
permeability. The tight junctions are formed from a multitude of transmembrane 
proteins from the occludin, tricellulin and claudin families along with junctional 
adhesion molecules all of which are linked to the cell cytoskeleton via zonular 
occludens.(Runkle and Antonetti, 2011). The tight junctions mean that the 
permeability of substances across the BRB will vary; this depends on the nature of 
the substances and is required to allow the access of nutrients and the prevention of 
toxic substances to the neural retina. This also means that different drugs will possess 
variable permeability to the BRB which is a consideration to make when developing 
a drug aimed at targeting the retina. 
The retina can be divided into a topographical map of regions along the surface of 
the retina (Figure 1.2) and also individual layers that run through the retina (Figure 
1.3). 
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The central retina is the region surrounded by the superior temporal artery and the 
inferior temporal artery. 
At the centre of this area is the macula, an approximate 1.5mm region which is 3mm 
lateral to the optic disc (Forrester, 2007). It has a distinctive yellow colour in 
comparison to the rest of the retina due to the pigments zeaxanthin and lutein. The 
fovea lies at the centre of the macula and is approximately 0.35mm in diameter. It an 
avascular depression where light is focussed onto, it is also where cones are at their 
highest density. 
The optic disc is an area where retinal blood vessels pass in and out of the eye and 
where ganglion cell axons exit to the optic nerve. 
The remainder of the retina is named the peripheral retina. It is a region which 
consists mainly of rods and extends to the ora serrata (the boundry between the retina 
and the start of the ciliary body) (Forrester, 2007). 
 
Figure 1.2 - Topographical map of the central retina showing the main arteries 
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The layers in the retina can be seen in Figure 1.3 where a section through the retina is 
shown. The retina is anatomically divided into 10 layers described below, from the 
most anterior layer to the most posterior. Following this a description of the different 
retinal cell types will be given. 
1. The internal limiting membrane. 
This membrane separates the retina from the vitreous humour. It primarily 
consists of the endfeet of Müller cells which are covered anteriorly by a 
basement membrane, consisting of extracellular matrix proteins such as 
laminin and fibronectin (Russell et al., 1991). 
2. The nerve fiber layer. 
The nerve fiber layer is a layer mainly consisting of ganglion cell axons 
which project to the optic disc where they bundle and exit as the optic nerve. 
This layer also contains retinal vessels and capillaries. 
 
A       B 
Figure 1.3 - Cross Section of the Human Retina 
 A Light micrograph of the retinal layers. Source: 
http://webvision.med.utah.edu/imageswv/husect.jpeg  
B Diagram of retinal layers and cell types. Source: 
http://www.netterimages.com/images/vpv/000/000/029/29736-0550x0475.jpg 
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3. The ganglion cell layer. 
The ganglion cell layer is a layer dominated by ganglion cells, however other 
cells and processes are also seen in this area such as some amacrine cells 
(termed displaced amacrine cells) and Müller cell processes (which separate 
ganglion cells). In the majority of the retina this layer is one cell thick, 
however in the macula the layer can become 8 to 10 cells thick (Remington, 
2012). 
4. The inner plexiform layer 
This layer is formed mainly from synaptic connections between bipolar cells 
and ganglion cells, with invaginating midget bipolar cells synapses being 
within the inner half and the flat midget bipolar cell synapses in the outer 
half. Other types of synapse are also present in this layer between amacrine 
and bipolar cells, amacrine and ganglion cells and also amacrine and 
interplexiform neurons. 
5. The inner nuclear layer. 
The inner nuclear layer is a layer consisting mainly of cell bodies from 
several retinal cells, primarily Müller cells, bipolar cells, horizontal cells, 
amacrine cells, interplexiform neurons and occasionally displaced ganglion 
cells. These cells tend to be in the order of amacrine cells, adjacent to the 
inner plexiform layer, then Müller and bipolar cells, then horizontal cells 
adjacent to the outer plexiform layer. This layer also contains some deep 
vascular capillary networks. 
6. The outer plexiform layer. 
This layer has two main bands within it, the thin band and the wide band. The 
thin band consists of synapses from rods and cones synapsing with bipolar 
cells and horizontal cells, and horizontal cells also forming synapses with 
bipolar cells. The wide band is made of inner fibres of the rods and cones. 
7. The outer nuclear layer. 
The outer nuclear layer consists of the cell bodies of the rod and cone 
photoreceptors. These themselves are arranged due to the length of the outer 
fibres of the photoreceptors. Cones have a short outer fibre which means the 
cone cell bodies lay very close to the external limiting membrane whereas rod 
outer fibres are longer and therefore the rods form multiple layers anterior to 
the cone cell body layer. The thickness of this layer also alters throughout the 
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retina, with 8 to 9 cell layers nasal to the optic disc and 4 layers temporal to 
the optic disc (Remington, 2012). 
8. The external limiting membrane. 
Contrary to its name this layer is not a membrane. This layer is in fact a chain 
of zonula adherens junctions between the inner layer of photoreceptors and 
Müller cells and photoreceptors themselves. This layer does have some 
membrane properties such as the restriction of passage of some large 
molecules (Remington, 2012). 
9. The photoreceptor layer 
This layer consists of photoreceptor inner and outer segments with Müller 
cell projections separating the inner photoreceptor segments. 
10. The retinal pigmented epithelium 
The retinal pigmented epithelium is a single layer of pigmented cells which 
interact with the outer segments of photoreceptors. 
 
This section described the different layers of the human retina, next a detailed 
description of the different cell types of the human retina will be given. 
 
1.2.2 Retinal Pigment Epithelium 
The retinal pigment epithelium (RPE) is a single layer of highly pigmented cells 
which exptend from the optic disc to the ora serrata. This layer is located adjacent to 
the photoreceptors as shown in Figure 1.3. The cells themselves are hexagon shaped 
and columnar within the centre of the retina (14µm tall, 10 µm wide) and flatter in 
the periphery (10 - 14µm tall, 60µm wide) (Forrester, 2007). 
The basal part of the RPE has numerous infolds and forms a part of Bruch’s 
membrane, with a strong attachment to the chorioid. The apical side of the RPE 
contains many microvilli which extend into the photoreceptor layer and envelop the 
rod and cone outer segments. Even though the microvilli envelop the outer segments 
of the photoreceptors, they do not share any intracellular junctions, which means this 
whole epithelium is separated from the photoreceptors by the inter-photoreceptor 
matrix. The RPE is part of the blood retinal barrier and is important in the 
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maintenance of the correct environment for the photoreceptors. This is achieved by 
the lateral side of the RPE cells being joined by zonula occludens (Remington, 
2012). 
The RPE has many roles to maintain correct and efficient retinal functioning. One 
such role is the absorption of light by melanin to prevent scattering or reflection of 
light back to the photoreceptors. Another major role of the RPE is the maintenance of 
the photoreceptors themselves. The RPE achieves this by phagocytosing outermost 
membranes of rod outer segments (and cone to a lesser extent) in order to turnover 
damaged photopigment. The RPE is also essential in recycling inactive 
photoisomerized visual pigment to synthesize an active isomer ready for production 
of rhodopsin (Sharma et al., 2005). This process known as the visual cycle of retinal 
involves trans-retinal being transported to the RPE, where it is reisomerized to 11-
cis-retinal and returned to the photoreceptors (Strauss, 2005). The RPE is responsible 
for the formation of the interphotoreceptor matrix, the layer of proteins and 
glycosaminoglycans present between the RPE and the photoreceptors. The RPE 
performs a vital role in pumping fluid from the sub-retinal space to the choroid. This 
creates a negative hydrostatic pressure which keeps the retina in contact with the 
RPE. The RPE also plays an important role in the protection of photoreceptors from 
oxidative stress. A reduction in RPE cells which can be caused by age related 
macular degeneration (AMD) or a build-up of toxic substances can lead to a decrease 
in important anti-oxidants such as α-tocopherol and therefore an increase in ROS 
(Strauss, 2005). 
 
1.2.3 Photoreceptors 
Photoreceptors are the cells responsible for the transduction of light into a neural 
signal. This is achieved via two types of photoreceptor cell which contain 
photopigments that absorb and become activated in response to light. Light results in 
inhibition of neurotransmitter (glutamate) release (in dark conditions glutamate is 
released). These two photoreceptors are called rods and cones both of which have a 
relatively similar structure (Figure 1.4). 
24 
 
 
The outermost region of the photoreceptor (the part closest to the RPE) contains 
stacks of membrane disks and is referred to as the outer segment. Each disk contains 
photopigment enclosed within a membrane sac, which is held within the cell by the 
plasmalemma (the outer membrane of the outer segment) and separated from each 
other by an extradisk space. There are major differences between rod and cone outer 
segments which are explained later. 
The cilium is the next part of the photoreceptor. This is a connecting stalk which 
joins the outer segment to the inner segment. The cilium has an axoneme which is 
formed from 9 pairs of microtubules. The role of the cilium is the trafficking of 
proteins for phototransduction from the inner segment into the outer segment ready 
for use. The cilium achieves this trafficking via a process called intraflagellar 
 
Figure 1.4 - Photoreceptor Structure. Source : http://2.bp.blogspot.com/-
PmNqGn4tmI8/Txw3Fh7ehKI/AAAAAAAAAQs/CEIUB7Pak6U/s1600/d_02_m_vis_1
a.jpg 
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transport (IFT). This method of transport is accomplished via IFT particles binding 
with motor proteins which transport the IFT (bound with its cargo) along the 
microtubules either towards the outer segment or towards the inner segment. For 
anterograde transport of, for example rhodopsin, the IFT particle bound with 
rhodopsin attaches to the motor protein heterotrimeric kinesin II which then travels 
along the microtubules of the axoneme. For retrograde transport to the inner segment 
the IFT particle binds to the motor protein dyenein (Ramamurthy and Cayouette, 
2009). 
The inner segment of the photoreceptors can be further subdivided into further parts. 
The ellipsoid is the subsection nearest the outer segment and contains high numbers 
of mitochondria. The myoid is the second subsection closest to the outer fiber and 
contains the protein synthesis and processing organelles such as the Golgi and the 
endoplasmic reticulum. 
The outer fiber is the section which links the myoid and the cell body together. The 
cell body is then linked to the inner fiber which is an axonal process with the 
synaptic terminal at the end. The neurotransmitter for both rods and cones is 
glutamate (Remington, 2012). 
There are many differences between rods and cones. Rods are taller than cones, at 
around 100 – 120µm long and the inner and outer segments are a similar shape 
(Forrester, 2007). Rods are specialised to work in darker conditions and use the 
photopigment rhodopsin which has a maximum sensitivity to blue-green light at 
496nm (Forrester, 2007). In the outer segment of rods, the plasmalemma (the outer 
membrane) is separate from the membrane disks and as new disks are formed at the 
base of the rod outer segment, older disks are pushed further up until eventually 
phagocytosed by the RPE. There are on average 1000 disks per outer segment in 
each rod with an average life span of 10 days for each disk before it is phagocytosed 
at the end of the outer segment. At its opposite end, the rod terminates to synapse 
forming a spherule (smaller than the cone synapse). 
Cones are shorter than rods (on average 60 - 75µm) and within the outer segment of 
cones, basal disks are often wider than the disks at the tip, giving them the conical 
shape (Forrester, 2007). This however is not always the case, with cones located 
around the fovea being long and slender and much more tightly packed. The disks 
26 
 
within cones are different to rods; they have a longer lifespan than rods and are not 
produced from the base up. The plasmalemma runs alongside the disks instead of 
being separate. Whereas rods are most efficient in dim light, cones work better in 
brightly lit conditions with each cone possessing one of three photopigments that 
work at different wavelengths. These are for blue light (420nm), green light (531nm) 
and red light (588nm) (Remington, 2012). The synaptic connection from the inner 
fiber of the cone (known as the pedicle) is also different to that of the rod: it is wider 
and contains more synaptic connections including gap junctions between other 
photoreceptors. 
 
1.2.4 Bipolar Cells 
Bipolar cells are the cells responsible for transmitting the neural signals from 
photoreceptors to ganglion cells.  
 
 
Figure 1.5 - Depolarization and hyperpolarization of ON and OFF bipolar cells 
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Bipolar cells play a large role in visual acuity, with some foveal bipolar cells 
synapsing with one cone, and further sending this information directly to one 
ganglion cell. Within the periphery, bipolar cells synapse with many photoreceptors 
where sensitivity, not acuity is the main priority. When described on a functional 
basis, there are two main types of bipolar cell, ON and OFF bipolar cells, both of 
which respond differently to the same stimulus (glutamate) within the centre of its 
receptive field. In light conditions when photoreceptors do not release glutamate, ON 
cells respond by depolarizing whereas OFF cells respond by hyperpolarizing (as 
shown in Figure 1.5). 
This difference in ON and OFF bipolar cell responses is due to different expression 
of glutamate receptors: ON cells express metabotropic glutamate receptors which 
initiate an intracellular pathway to increase conductance to depolarize, whereas OFF 
cells express more ionotropic glutamate receptors which in the absence of glutamate, 
conductance is decreased and the cells hyperpolarize (Nelson and Connaughton, 
1995). As with photoreceptors, the neurotransmitter used by bipolar cells is 
glutamate. When described morphologically, there are several types of bipolar cell, 
however only one type is associated with rod cells. 
Rod bipolar cells are the only bipolar cells that synapse with rod cells. They are 
present from approximately 1mm away from the fovea and continue into the 
periphery. Close to the fovea, each rod bipolar cell makes contact with around 15 – 
20 rods, further out into the periphery, each rod bipolar cell can contact up to as 
many as 80 rods (Kolb et al., 1992). 
There are two types of midget bipolar cells, flat and invaginating. Flat bipolar cells 
differ from invaginating in that they only contact the flat surface of the cone pedicle. 
Invaginating bipolar cells differ from flat cells because the dendrites are invaginated, 
surrounding the cone pedicle. Within these invaginations there are triads which 
consist of a single bipolar cell with two horizontal cell processes on either side which 
are surrounded by the invagination. 
Diffuse cone bipolar cells differ from other bipolar cells in that they are important in 
converging information from multiple cones with dendrites that span out as far as 
100µm and contact as many as 7 cone pedicles (Forrester, 2007).  
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Blue cone bipolar cells are named so because they appear to only contact cones 
specifically with pigment sensitive to blue light. There is also a giant cone bipolar 
cell which gains its name from the size of its dendrites. 
 
1.2.5 Ganglion Cells 
Ganglion cells are the last neural cell from the retina in the visual pathway. Ganglion 
cell axons exit the ganglion cell layer and run along the nerve fiber layer (parallel 
with the internal limiting membrane), the axons then come together at the optic disc 
and pass throughout the lamina cribrosa (a sieve like perforation at the posterior of 
the eye) to form the optic nerve. Beyond the laminar cribosa the axons become 
myelinated by oligodendrocytes. There are approximately 1.2 million ganglion cells 
within the human retina, with an average of around 100 rods and 6 cones to each 
ganglion cell (Forrester, 2007). Ganglion cells can be classified in two main ways. 
They can be classified depending on the area within the lateral geniculate nucleus 
where they terminate. Ganglion cells which terminate in the parvocellular layer are 
called P cells. There are two types of P cell, P1 and P2. P1 cells are also known as 
midget ganglion cells and are the most common retinal ganglion cell and only form 
connections with midget bipolar cells (flat or invaginating). P2 cells terminate within 
the same layer however their morphology is different with P2 cells having a dendritic 
tree that spreads horizontally (Remington, 2012). M type ganglion cells are present 
within the central retina and are named because they project to the magnocellular 
layer within the lateral geniculate nucleus. When classified morphologically there are 
18 types in the human retina 
 
1.2.6 Amacrine Cells 
There are many types of amacrine cell, which differ in shape, size and importantly 
neurotransmitter used. Amacrine cells release many types of neurotransmitter, 
however the main two are GABA or glycine, both of which are inhibitory 
neurotransmitters. Amacrine cells possess a single process that branches out and 
makes multiple connections with bipolar neurons, ganglion cells, interplexiform 
neurons and other amacrine cells. From this information it is believed that the main 
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role of these cells is the inhibitory modulation of information to the bipolar cells 
(Forrester, 2007). 
 
1.2.7 Horizontal Cells 
Horizontal cells possess processes that extend horizontally and run parallel with the 
retinal surface. They are present throughout the retina, but are much smaller in the 
foveal region (Kolb et al., 1994). The purpose of these cells is to provide inhibitory 
feedback to either photoreceptors or bipolar cells. There are three types of horizontal 
cell; HI, HII and HIII. They are differentiated depending on the contacts they make 
and their morphology. HI cells have dendritic processes that synapse with nearby 
cones (mainly green and red cones) and a large fan shaped axon that terminates in 
rod spherules. HII cell dendrites predominantly contact blue cones, whereas the HII 
cell axon exclusively contacts blue cones. HIII cells have a large dendritic field, 
however differ from HII cells in that they do not synapse with blue cones (Ahnelt 
and Kolb, 1994). 
 
1.2.8 Interplexiform Neurons 
Interplexiform neurons are found amongst amacrine cells and have processes which 
descend into the inner plexiform layer and ascend into the outer plexiform layer. The 
purpose of these cells is to provide “long range” feedback from inner retinal layers to 
outer retinal layers. Interplexiform neurons can also be divided depending on their 
neurotransmitters which include glycine, GABA, dopamine and somatostatin. The 
dopaminergic and glycine interplexiform neurons are believed to be involved in light 
adaptation. The connections that interplexiform neurons form are both pre-synaptic 
and post-synaptic to rod and cone cells, however input to the interplexiform cells is 
still unclear (Jiang and Shen, 2010). 
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1.2.9 Müller Cells 
Müller cells are the most abundant neuroglial cells in the retina, with approximately 
10 million present throughout the human retina. The cell bodies of Müller cells are 
located within the inner nuclear layer and they have extensive processes that span 
from the inner limiting membrane to the outer limiting membrane. Their primary role 
is a supportive one, both physically and metabolically. They occupy the majority of 
the space not occupied by neurons and Müller cell processes ensheath neuronal 
somata and processes as well as blood vessels, allowing the transport of nutrients, 
waste, ions, water to support neurones (Reichenbach and Bringmann, 2013). 
Müller cells importance in the support of the neural retina is shown by the variety of 
roles they play, such as the maintenance of the correct environment by, regulating 
ion and pH levels (Forrester, 2007). They are responsible for the metabolism of 
glucose to provide neurones with lactate / pyruvate for their oxidative metabolism as 
well as regulating retinal blood flow and contributing to the maintenance of the blood 
retinal barrier. Importantly Müller cells also play a role in the neuronal signalling. 
They achieve this by the rapid uptake of glutamate from the extracellular space and 
conversion to glutamine ready for neurones to produce glutamate (Bringmann et al., 
2006). 
Müller cells are also involved with most pathological alterations of the retina by 
becoming activated (known as Müller cell gliosis). They have the ability to produce 
proinflammatory cytokines in response to infection and upon activation can influence 
vasculature and immigration of blood-derived leukocytes (Bringmann et al., 2006). 
 
1.2.10 Retinal Astrocytes 
Retinal astrocytes are located within the nerve fiber layer, ganglion cell layer, inner 
plexiform layer and the inner nuclear layer. Within these layers they lay 
perpendicular to Müller cells, ensheathing nerve fibers and retinal capillaries. Their 
role in the retina is similar to Müller cells including isolating the receptive regions of 
the neurones to prevent interference from active neighbouring neurones (Forrester, 
2007). 
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1.2.11 Retinal Microglia 
Retinal microglia are phagocytic immune cells which are evenly distributed 
throughout the retina (except in the fovea where they are normally absent), but 
located in two main regions: between the nerve fiber layer and the ganglion cell 
layer, and between the inner nuclear layer and the outer plexiform layer. When 
inactive they have the characteristics of a resting macrophage, however when injury 
or inflammation occurs they then take on the appearance of an active phagocyte 
(Forrester, 2007). 
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1.3 Retinal Toxicity 
1.3.1 Introduction 
According to the Dictionary of Toxicology (2nd Edition Macmillan Reference Ltd, 
1998) toxicity is defined as the ability of a chemical to cause a deleterious effect 
when the organism is exposed to the chemical. Toxicity itself depends on many 
factors; this is shown by many chemicals / food / drugs that people are exposed to 
daily which are classed as toxic. A simple example is alcohol: too high a dose or 
extended periods of exposure can have toxic effects, however low doses have been 
found to be beneficial in some circumstances. This brings about questions of how to 
define the toxicity of a substance. The ‘Guide to Practical Toxicology, Evaluation, 
Prediction and Risk’ states that some of the determining factors of a compound’s 
toxicity are: dose (including frequency of dose), exposure, species, individuality, 
receptor presence, absorption, metabolism, protein binding (availability of site, 
competitive binding), presence of other chemicals which may enhance / inhibit the 
effect and the physical form of the toxin (Woolley, 2003). 
Toxicological studies span a wide variety of areas. Common areas of research 
include: the establishment of a dose response curve, safety assessment of new 
chemicals including pesticides, drugs and food additives (which must follow strict 
government and international guidelines), mechanistic toxicity studies, 
epidemiological studies and importantly, studies which investigate new methods to 
assess toxicity (Woolley, 2003). 
The need to investigate new methods for toxicity analysis stem from issues involving 
current testing. Investigation into cell lines is cheaper than investigation into animal 
models, however there are limitations to a single cell system. Organotypic models 
contain the multicellular property and the same structural integrity of the tissue of 
interest. Animal models are still considered the gold standard in that they provide a 
multi organ system which is currently impossible to replicate in cells, however 
species difference (if the investigation is about human health must be considered). 
This makes the development of models using human tissue very appealing since 
these can be directly related to toxicity in humans. 
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1.3.2 Drug Development Process 
In most industrialized countries any new drug under development must be assessed 
for its safety to use. The regulations for this testing are variable and depend on the 
country, however the general aim of these studies is to show that the benefits of the 
substance outweigh the risks of use (Timbrell, 1995). The research conducted to 
produce a new drug normally follows a set of common stages. 
These stages can be split into three main sections, these are drug discovery, 
preclinical development and clinical development (as shown in Figure 1.6). Drug 
discovery involves the selection of a drug candidate depending on the intended 
target. Preclinical development involves no live human investigations and involves 
toxicity and pharmacokinetic studies. Clinical development stages are when the 
compound is tested for its tolerability and side effects within healthy patients, and its 
effectivity within patients. If the drug is approved by the regulatory agencies, the 
drug is marketed and continuing surveillance is conducted (H. P. Rang, 2012). 
 
The process of drug development is time consuming and expensive. It is estimated 
by ‘The Association of the British Pharmaceutical Industry’ that the production of a 
new medicine to a high enough standard of quality, efficacy and safety will take 
approximately 12 years and 1.15 billion pounds (Industry, 2016). For this reason, 
models that have the capability to indicate any specific toxicity that may occur in the 
 
Figure 1.6 - Typical stages of drug development research. Source: (H. P. Rang, 2012). 
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early stages of drug development research (drug discovery or preclinical 
development) are of interest as they have the potential to save time and money. 
Retinal toxicity is a major reason of drug development termination. According to 
Pfizer’s internal drug development database, ocular toxicity is responsible for 7% of 
therapeutic candidate attrition of which 99% were related to retinal toxicity (Huang 
et al., 2015). 
For this reason it is important that available models and methods used to assess 
retinal toxicity are understood and utilised. 
 
1.3.2 Models and Methods Used to Assess Retinal Toxicity 
The assessment of ocular toxicity currently relies on in vitro and in vivo approaches 
which are applied mostly within the preclinical development stage of drug 
development research. in vitro toxicity screens may be conducted on cell lines and 
organotypic models, however in vivo models are still required as a pre-clinical safety 
evaluation step of drug development (Huang et al., 2015). 
In vivo approaches to assessing the safety of drugs produced for the treatment of 
retinal diseases involve a multitude of animal models. Mice and rats provide genetic 
models of disease for the drug to be tested on, whereas pigs, dogs and cats are used 
as large animal models. Rabbits are commonly used in retinal toxicity studies, 
however the gold standard for in vivo studies is still nonhuman primates (Penha et 
al., 2010). In order to assess ocular health within the in vivo approaches, common 
ophthalmologic methods used clinically are utilised in animal studies to assess 
changes in retinal function / morphology. Examples of these methods are 
ophthalmoscopic inspection, in which the fundus of the retina can be viewed and 
photographed (useful if changes over time wish to be observed). Fluorescein 
angiography, in which fluorescein dye is delivered intravascularly and traced 
throughout the eye to reveal any defects in vasculature can also be used. 
Electroretinography (ERG) may be used to assess retinal function by investigation of 
neuronal activity in response to specific light stimulus and Ocular Coherence 
Tomography (OCT), which is a non-invasive method of assessing retinal structure by 
composing a computed tomography of scattered near infrared light from a laser is 
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also a more recent and useful technique to assess retinal toxicity (W. M. Haschek, 
2013). 
There are two human retinal cell lines currently available which could be used to 
assess toxicity; the MIO-M1 cell line and the ARPE19 cell line. The MIO-M1 cell 
line is an immortalized cell line derived from human Müller cells. Müller cells are 
the principle glial cells of the retina which provide structural and metabolic support 
to neurones (Haberecht et al., 1997). The ARPE19 cell line is a human retinal 
pigmented epithelial cell line from a primary source of retinal pigmented epithelium 
(Dunn et al., 1996). 
Organotypic retinal cultures have been used from a multitude of species, for example 
rat organotypic cultures have been characterised and show a high degree of tissue 
viability for up to 17 days (Johnson and Martin, 2008). Rabbit organotypic cultures 
have also been used and show tissue viability of up to 4 days (Lye et al., 2007). 
However the problem in using tissue derived from animals is that the retina possesses 
different properties compared to the human retina. For example the rat retina has 
many differences compared to that of the human, being less vasculated, with many 
different retinal features such as no fovea and a high percentage of rods due to the 
nocturnal nature of the animals.  
 
1.3.4 Known Retinotoxins 
In order to develop a new model for the assessment of retinotoxicity, some known 
retinotoxins must firstly be used to characterise the model and to determine if the 
results match those found clinically. 
There are many different drugs / compounds which are known to cause retinopathy, 
in this section a number of known retinotoxic drugs and their potential toxic 
metabolic pathway are discussed. 
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1.3.4.1 Chloroquine 
Chloroquine has been used in the prevention and treatment of malaria since the early 
1950’s. It also has been used for the treatment of amoebic hepatitis, amoebic 
abscesses, systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE), 
protozoal infections, and most commonly rheumatoid arthritis (RA) (NHS, 2014c). 
Chloroquine is available as salts in three forms; chloroquine diphosphate, 
chloroquine sulphate and chloroquine hydrochloride (Verbeeck et al., 2005;Tzekov, 
2005). 
 
In the treatment of malaria chloroquine can be administered either orally, or via 
parenteral administration, although the oral route is most common. When 
administered orally patients are given a total dose of 25mg/kg over a period of 3 days 
according to the following protocol: 
Day 1: 10mg/kg, followed by 5mg/kg 6 – 8 hours later. 
Day 2 and 3: 5mg/kg in a single dose (WHO, 2014). 
 
Figure 1.7 - The chemical structure of (A) Chloroquine and (B) 
Hydroxychloroquine 
Source: (Tzekov, 2005) 
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Chloroquine is readily and rapidly absorbed by the gastro-intestinal tract and 
although inter-subject bioavailability varies widely, it has an average oral 
bioavailability of approximately 89% (Verbeeck et al., 2005). A study conducted by 
Zuluga-Idarraga (2014) revealed that chloroquine reaches its peak plasma 
concentration 2 hours after each oral dose, and that throughout the three day 
treatment of the normal dose described above (25mg/kg), the highest plasma 
concentration is reached on day 2, with an average plasma concentration of 
260.1ng/ml (0.31µM) (Zuluaga-Idarraga et al., 2014). 
The toxic effects of chloroquine are well documented. The most influential factors 
which affect the toxicity are dosage, the total amount of time the drug has been taken 
and the age of the patient. Chloroquine is rarely used now in the treatment of chronic 
disease due to the availability of the less toxic hydroxychloroquine (see below). 
However a report by Marks from 1982 states daily doses ranged from 100-1000mg 
per day (Marks, 1982). A study later summarised older literature and reported that 
chloroquine can cause retinal toxicity at ≥ 3mg/kg/day which is at the lower end of 
the dosage used (Marmor et al., 2002). The cumulative dose of the drug is also 
positively correlated with toxicity, which is why the total amount of time that the 
drug is given is important. A cumulative dose of ≥ 200g has been shown to give a 
high risk of toxicity (Peponis et al., 2010). Data relating to age is limited, however 
there is an indication that patients over 60 are more at risk to the toxic effects 
(Peponis et al., 2010).  
Chloroquine retinal toxicity symptoms include that of a loss of vision, either a partial 
paracentral or complete pericentral ring scotoma (blind spot). These symptoms are 
not normally noticed until the degeneration caused by chloroquine is advanced 
(Blomquist, 2011). On ophthalmological examination toxicity caused by the drug is 
seen on the fundus as granulated pigmentation within the macula region which is 
surrounded by a ring giving a “bull’s eye maculopathy”. Although not as common, 
there are also some cases of visual field loss without the bull’s eye maculopathy. 
This can progress further to give the fundus a spotted appearance (Gaynes et al., 
2008). 
A study into which cell types are affected by long term exposure to chloroquine was 
conducted in rhesus monkeys which revealed that ganglion cells were firstly 
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affected, displaying granulated cytoplasm’s, followed by photoreceptor degeneration 
and eventually RPE deterioration (Rosenthal et al., 1978). More recent studies have 
utilised OCT and other scanning techniques in the study of chloroquine toxicity in 
humans and have found that the nerve fibre layer was thinned due to chloroquine 
treatment, potentially due to a loss of ganglion cells (Pasadhika et al., 2010), 
(Bonanomi et al., 2006). This data suggesting an initial loss of ganglion cells was re-
enforced by data obtained from Costa et al (2007) in which a pair of eyes from a 
human donor who had received long term chloroquine treatment was obtained and 
investigated. No differences were found between a control retina and the long term 
chloroquine treated retina apart from a lack of large sized ganglion cells which may 
have degenerated due to chloroquine treatment (Costa et al., 2007). In contrast, a 
study on mice revealed that intraperitoneal administration of chloroquine caused the 
majority of toxicity to occur in the outer retinal layers, with a marked loss of 
photoreceptors, thinning of the outer plexiform layer and damage to the RPE 
(Gaynes et al., 2008). Long term exposure to chloroquine therefore has the potential 
to affect several cell types of the retina, including the ganglion cells, photoreceptors 
and the RPE, however the order in which these cells are affected first is still unclear. 
There are many theories relating to how chloroquine causes retinal toxicity. One 
early theory centres around binding to melanin, where it is hypothesised that the high 
affinity of the drug to melanin leads to accumulation causing toxic levels to be 
reached in the RPE. This in turn causes the RPE to become unable to phagocytose 
the photoreceptor outer segments and as a result loss of rods and cones occur (Potts, 
1964), (Bernstein et al., 1963). This theory has come under scrutiny, since there has 
been a lack of evidence to show that melanin binding causes ocular toxicity and 
chloroquine has been shown to cause retinopathy in albino rabbits, rats and cats 
(Leblanc et al., 1998). 
Another mechanism centres around oxidative stress. An experiment in which male 
albino rats were treated with chloroquine showed a reduction in retinal glucose-6-
phosphate dehydrogenase (G-6-PD) activity and glutathione (GSH) (Toler, 2004). 
This reduction in GSH concentrations may be due to the reduction in G-6-PD as G-6-
PD is involved at two points in the oxidative stage of the pentose phosphate sugar 
pathway which is important in the production of NADPH and ribulose-5-phosphate 
(Figure 1.8). A reduction in G-6-PD would inhibit the production of NADPH which 
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is essential in the reduction of glutathione disulphide (GSSG) to GSH in the 
glutathione redox cycle (Figure 1.9). This decrease in GSH would cause an increase 
in oxidative stress which could lead to cell death (Toler, 2004). 
 
 
Figure 1.8 - Oxidative stage of the pentose phosphate pathway 
Source: http://themedicalbiochemistrypage.org/pentose-phosphate-pathway.php 
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More recently it has been proposed that the cause of retinotoxicity is due to 
chloroquine’s lysosomotropic properties. This means that chloroquine accumulates in 
the lysosome, leading to the formation of vacuoles and eventually cell death. This 
has been extensively studied in RPE cells (Yoon et al., 2010; Chen et al., 2011b). 
 
Figure 1.9 - The Glutathione redox cycle. Showing the reduced form of glutathione 
(GSH) and the oxidized forms of glutathione; GS-R and GSSG. This figure also shows 
the pathway in which the oxidised forms of glutathione are reduced back to GSH via 
GSSG-Red or Trx-Red, both of which require NADPH. 
Key: 
GSH - reduced glutathione 
GS-R and GSSG – oxidized glutathione 
GSSG-Red - GSSG reductase 
Trx-Red – thioredoxin 
GSH-Px – Glutathione peroxidase 
Source: http://www.nature.com/cdd/journal/v12/n12/fig_tab/4401754f1.html 
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In an interesting paper, Yoon et al (2010) displayed that caspase dependent cell death 
appeared not to be the cause of chloroquine induced cell death, as no activation of 
caspase 3 was detected after chloroquine treatment and a broad range caspase 
inhibitor z-VAD-FMK did not reduce cell death. This paper also showed that 
oxidative stress was also unlikely to be the root cause of cell death since the 
antioxidants (NAC and trolox) failed to reduce cell death (Yoon et al., 2010). In this 
study, Yoon et al also investigated levels of autophagy and whether this could be 
responsible for the cell death induced by chloroquine. During autophagy (a process 
where cellular components are turned over) phagophores are produced (double 
membranes structure) and cellular components to be degraded are collected within 
them. Once the components have been sealed in the membrane the structure is 
known as an autophagosome. The autophagosome then binds with lysosomes to 
become the autolysosome where the internal components are degraded (Boya et al., 
2013). Levels of LC3 proteins are commonly used to assess levels of autophagy 
since LC3-I is converted to LC3-II in the formation of the autophagosomal 
membrane. LC3-II is then broken down once the autolysosome has formed (Tanida 
et al., 2008), (Mizushima and Yoshimori, 2007). Yoon et al (2010) found that LC3-II 
increased with chloroquine treatment along with p62 (a protein which interacts with 
LC-3II which is also degraded in the autolysosome) indicating an increase in 
autophagosome levels. This study also investigated if the increase in LC3-II / p62 
was due to inhibition of autophagosome and lysosome binding (to form the 
autolysosome), and therefore the build up of autophagosomes. This was achieved by 
looking at the overlap of immunohistochemically stained ARPE19 cells with LC3-II 
(present in autophagosome membranes) and LAMP1 (present in lysosome 
membranes). No overlap was found, indicating the build up of LC3-II was due to the 
inhibition of autophagosome and lysosome binding (Yoon et al., 2010). This occurs 
because chloroquine is a weak base which concentrates within acidic lysosomes, this 
in turn causes an increase in lysosomal pH and inhibits optimal functioning of the 
lysosomal enzymes and inhibits the binding of lysosomes to autophagosomes 
(Baltazar et al., 2012). This study also showed that when both chloroquine and low 
concentrations of Bafilomycin A1 were added together, chloroquine did not 
accumulate within lysosomes to cause lysosomal dysfunction and deformation into 
vacuoles. This is due to the increased pH caused by Bafilomycin A1, therefore 
inhibiting chloroquine accumulating in the lysosome. Bafilomycin A1 causes an 
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increase in lysosomal pH by inhibiting vaculolar-type ATPase and disrupting the 
vesicular proton gradient causing an increase within the pH of lysosomes (Shacka et 
al., 2006). Further to this, Yoon also showed that autophagic cellular death does not 
seem to be a likely cause of chloroquine induced toxicity since the autophagic 
inhibitor 3-MA (a potent inhibitor of autophagy) also failed to reduce chloroquine 
induced cellular death (Yoon et al., 2010). 
The experiments conducted by Yoon et al indicate the main cause of cell death to be 
due to a multitude of mechanisms which involve lysosomal dysfunction, whereby an 
increased accumulation of endocytosed proteins and lipids possess cytotoxic 
consequences (Yoon et al., 2010).  
 
1.3.4.2 Hydroxychloroquine 
Hydroxychloroquine (Figure 2.7) was synthesised in 1964 as a derivative of 
chloroquine. Since then, it has superseded the use of chloroquine due to a better 
toxicity profile (Tzekov, 2005). Chloroquine is known to cause retinal toxicity at ≥ 
3mg/kg/day, whereas this increased to ≥ 6.5mg/kg/day with hydroxychloroquine 
(Peponis et al., 2010). Hydroxychloroquine is used for the treatment of RA, SLE, 
DLE and some dermatological conditions caused by sunlight (NHS, 2014a). 
Hydroxychloroquine is available commercially as 200mg hydroxychloroquine 
sulphate tablets (Plaquenil), and due to the toxicity threshold, has a maximum 
recommended dose of 6.5mg/kg of lean body weight / day (Ophthalmologists, 2009). 
Standard doses used to treat RA are 200mg to 400mg daily (American College of 
Rheumatology). For malaria treatment and prevention, the dose of 
hydroxychloroquine recommended is 400mg as one weekly dose (CDC, 2014). 
Hydroxychloroquine is well absorbed within the gastrointestinal tract. After a single 
200mg dose of hydroxychloroquine peak plasma concentrations occurs at a mean 
time of 3.2h post treatment, with a maximum mean plasma concentration of 46ng/ml 
(0.1µM) (Tett et al., 1989). 
Patients using hydroxychloroquine are screened for ocular side effects in the same 
way as those who take chloroquine. Both drugs can cause the same clinical 
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symptoms of visual field defects such as scotomas and are known to cause a change 
in the appearance of the fundus, with granulated pigmentation and a bull’s eye 
maculopathy (Tzekov, 2005). The method of cell toxicity caused by 
hydroxychloroquine appears to be the same as that caused by chloroquine; via 
accumulation within lysosomes (Sundelin and Terman, 2002). 
 
1.3.4.3 Indomethacin 
Indomethacin was introduced in 1963 as a non-steroidal anti-inflammatory drug 
(NSAID) for the treatment of rheumatoid arthritis. It has also been used for other 
inflammatory conditions due to its anti-inflammatory properties (Graham and Blach, 
1988). Indomethacin dosage is variable depending on the degree of pain and 
inflammation and is available as 25mg and 50mg capsules to be taken orally or 
100mg as suppositories. Indomethacin can be used to treat many inflammatory 
disorders associated with pain including ankylosing spondylitis, bursitis, capsulitis, 
gout, menstrual problems, osteoarthritis, rheumatoid arthritis, spondylitis, synovitis, 
tendonitis and tenosynovitis (NHS, 2014b). 
Indomethacin is readily absorbed within the gastrointestinal tract. After a 75mg dose 
the mean peak plasma concentration (measured by HPLC) was at one hour post oral 
administration showing a concentration of 4.9µg/ml (13.7µM) (Bechgaard et al., 
1982). 
Although indomethacin retinopathy cases are rare, it is associated with other 
reactions such as neutropenia, hepatotoxicity and agranulocytosis (Toler, 2004). 
Retinopathy symptoms caused by indomethacin include difficulty with night vision, 
impaired colour vision, photophobia and reduced visual acuity (Peponis et al., 2010). 
Clinically, the changes seen with indomethacin retinal toxicity are changes in the 
RPE (granulation) along with occasional changes in electroretinogram (ERG) and 
electrooculogram (EOG). Graham and Blach (1988) also reported a bullseye 
maculopathy in a 33 year old patient who suffered arthritis and had been taking 
200mg of indomethacin daily for 8 years (in conjunction with no other medication). 
Indomethacin is thought to be toxic to the retina via the production of a reactive 
quinone. This mechanism is also thought to be the cause of toxicity to other tissues 
44 
 
including neutropenia and hepatotoxicity. Figure 1.10 shows the proposed pathway 
which involves indomethacin being O-dealkylated into O-des-methylindomethacin 
(DMI). This then undergoes N-deacetylation to produce 
desmethyldeschlorobenzoylindomethacin (DMBI) (Toler, 2004). DMBI is a major 
metabolite of indomethacin (Ju and Uetrecht, 1998) and it is DMBI that is believed 
to form the reactive quinone that can either react with GSH, leading to GSH 
depletion and consequent oxidative stress, or bind to other macromolecules to cause 
retinopathy (Toler, 2004). 
 
 
  
 
Figure 1.10 - The proposed metabolism of indomethacin to a toxic quinone 
Source: (Toler, 2004) 
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1.3.4.4 Tamoxifen 
Tamoxifen is a selective estrogen receptor modulator (SERM) which is used as 
hormone therapy in the treatment and prevention of hormone responsive breast 
cancer (Srikantia et al., 2010). 
Tamoxifen is available as tamoxifen citrate in 10mg, 20mg and 40mg tablets or a 
10mg/5ml oral solution (NHS, 2014d). It is taken as a single daily dose (normally 
between 20mg and 40mg) (Srikantia et al., 2010). 
Tamoxifen citrate is readily absorbed from the GI tract and quickly undergoes 
hepatic metabolism and excretion of its metabolites (Shin et al., 2006). Tamoxifen 
pharmacokinetics have been investigated humans and it was found that the drug 
reached an initial peak concentration of approximately 167nM in the blood 
approximately 4h after a single 30mg dose. It was also found that over time, the dose 
increased until it reached a continuous steady state of approximately 467nM after 
one month of single 30mg doses (Etienne et al., 1989). 
Retinal toxicity is rare from the use of tamoxifen alone (0.6%), but the use of 
tamoxifen alongside chemotherapy can increase the risk to 10.9% (Srikantia et al., 
2010). Although the risk is low, the numbers affected are high due to the large 
number of patients requiring the treatment. Patients who have tamoxifen induced 
retinal toxicity often have symptoms of decreased visual acuity and gradual 
diminution of vision. Clinically, cases of tamoxifen retinal toxicity can present with 
ocular abnormalities including pigmented retinopathy, macula edema, macula hole 
and yellow/white spots in the paramacular region (Watanabe et al., 2010; Lazzaroni 
et al., 1998). 
Retinal tamoxifen toxicity normally occurs in patients who have been prescribed the 
drug for an extended period of time. Early cases of tamoxifen induced retinopathy 
were seen in patients who took 240-320mg per day. Since then the dose has been 
reduced to 20-40mg per day (Srikantia et al., 2010). However extended use of the 
drug leading to a cumulative dose of higher than 16g has been known to induce 
toxicity (Lazzaroni et al., 1998). 
One proposed mechanism of toxicity caused by tamoxifen is implied due to its side 
effect of neutropenia which is similar to that seen with indomethacin, suggesting that 
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a similar mechanism may be responsible involving the production of a reactive 
quinone. The process is shown in Figure 1.11 with tamoxifen being metabolised to 4-
hydroxytamoxifen. From this point 4-hydroxytamoxifen can be metabolised through 
two main pathways, one direct metabolic pathway produces a relatively stable 
quinone methide. The other pathway can involve the enzyme tyrosinase which can 
metabolise 4-hydroxytamoxifen to 3,4-dihydroxytamoxifen. This can then be 
oxidized to produce a reactive ortho-quinone (Zhang et al., 2000) which can oxidise 
GSH, depleting GSH levels and causing oxidative stress and cell death (Fan and 
Bolton, 2001). The reactive ortho-quinone could also bind to important 
macromolecules causing cell disruption and eventually death (Toler, 2004). 
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Cho et al (2012) have investigated tamoxifen toxicity in RPE (ARPE19) and 
photoreceptor derived (661W) cell lines and suggested that multiple mechanisms 
may be responsible for the cell death found. Oxidative stress was found to be 
involved in tamoxifen induced death, with an increase in ROS and protection by the 
addition of the antioxidant N-acetyl cysteine (NAC). It was also found that zinc 
dyshomeostasis may be involved in the oxidative stress caused by tamoxifen, shown 
by a reduction in ROS and attenuation of cell death with zinc chelation. Cho et al 
 
Figure 1.11 - The proposed metabolism of Tamoxifen into a toxic quinone 
Source: (Toler, 2004) 
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(2012) also found that autophagic cell death may be involved in tamoxifen induced 
toxicity, with increased LC3-II levels, and attenuation of cell death with the addition 
of the autophagic activation inhibitor 3MA, and bafilomycin A1 which inhibits 
fusion of autophagosomes and lysosomes. Levels of p62 were also investigated (p62 
is present within the autophagosome, but is degraded in the autolysosome), showing 
that binding of the autophagosome and lysosome occurred indicating that tamoxifen 
upregulated autophagy. Finally it was also found that caspase-3 contributed to 
tamoxifen toxicity due to the attenuation of cell death with the caspase-3 selective 
inhibitor DEVD (Cho et al., 2012). A similar study was also carried out by Kim et al 
(2014) in which it was found that lysosomal destabilisation and cathepsin release 
occurred before caspase dependent and caspase independent death occurred (Kim et 
al., 2014). 
 
1.3.5 Aims of Research 
Organotypic cultures using human tissue are desirable models to assess 
retinotoxicity. Human ex vivo retinal explants possess the same structural 
architecture as the in vivo retina, allowing the investigation of toxicity to all retinal 
cell types. The ex vivo human retina has not previously been used to assess 
retinotoxicity and since the retina is known to be particularly susceptible to toxic 
insult, a model which can measure a drug’s potential toxicity to the human retina is 
of interest. This ex vivo human retina model could firstly be used to screen the 
potential retinotoxicity of a drug, and secondly as a tool, to investigate the cause of 
the toxicity. It is for this reason that the primary aim of this thesis was to assess 
human organotypic retinal cultures (HORCS) for the assessment of retinotoxicity. 
Previous work using HORCs has shown that they can be used to investigate retinal 
ganglion cell degeneration. Niyadurupola et al (2011) assessed ganglion cell viability 
within HORC’s over a course of 4 days in different media and no difference in 
THY1 expression was found when cultured in either DMEM/HamF12 medium or 
Neurobasal A medium. The study then assessed the effect of OGD (oxygen/glucose 
deprivation) and NMDA excitotoxicity on ganglion cells and found that a reduction 
in THY1 mRNA occurred as a result of both OGD and NMDA excitotoxicity, 
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showing that treatments expected to kill RGC’s caused a measurable loss of ganglion 
cells, indicating the validity of the system (Niyadurupola et al., 2011). 
It has also been shown that other markers of ganglion cells (NeuN and β-III Tubulin) 
that are used in rodents are suitable for the assessment of ganglion cells in the human 
retina, and that the age of the donor and the post mortem time (within 24h) did not 
affect ganglion cell number / density (Osborne et al., 2015b). 
The specific aims of this research are to firstly characterise the ex vivo human retina 
to gain an understanding of the structure of the retina, and the cell specific markers 
available to utilise within later research. Secondly a range of known retinotoxins will 
be applied to two retinal cell lines (ARPE19 and MIO-M1) and the potency of the 
drugs investigated, this will aid in establishing the retinal cell lines for future use in 
investigating retinotoxicity. Next one of the known retinotoxins investigated on the 
retinal cell lines will be applied to the HORC and the response investigated. Once the 
HORCS response to a known retinotoxin has been investigated, the HORC will then 
be used to investigate mRNA expression of genes relating to a novel retinotoxin. 
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Chapter 2 
2.0 Methods 
2.1 Donor Human Eyes 
Donor eyes were provided by the East Anglian Eye bank (Norfolk and Norwich 
University Hospital, UK) with written consent from the next of kin given for 
research. The eyes were donated for corneal transplant and following removal of the 
cornea the remainder of the eye was used for research. The tissue had full ethical 
approval under the tenets of the declaration of Helsinki, only donated eyes under 24 
hours post-mortem were used for research. In the case of living donor tissue, the eye 
was enucleated during surgery, transported to the lab and the retina dissected within 
1h. To ensure no personal information would identify the donor, a donor number was 
provided. Details of gender, a brief medical history, cause of death and age were 
provided and any eyes with known retina disease were not used for this research. A 
database of these details made for the donor eyes used. 
Donor eyes were transported from the eye bank in Eagles minimum essential 
medium (EMEM) (Sigma-Aldrich, Poole, UK) supplemented with the antibiotics 
gentamicin (50µg/ml), penicillin (10,000units/ml), streptomycin sulphate 
(10,000µg/ml), amphotericin B (an antimycotic, 25µg/ml) (Invitrogen, Paisley, UK). 
The lens was removed and used by the lens research group before the retina was 
dissected. 
In total 180 eyes human eyes were used in the research presented in this thesis from 
donors aged 41 to 92 years old. 
 
2.2 Retinal Dissection 
A 10mm incision was made through the sclera and the ciliary body. The sclera and 
anterior retina was then cut circumferentially below the ora serrata to remove the 
anterior sclera and all of the ciliary body. The remainder of the sclera was rotated to 
use the weight of the vitreous to detach the retina from the RPE. At this point the 
retina’s only attachment point to the sclera was the optic nerve, therefore a small cut 
around the optic nerve head was made. The retina and vitreous was transferred to a 
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60mm Petri dish (Fisher Scientific, Loughborough, UK). The vitreous was then 
carefully removed from the retina and discarded. The retina was then flattened by 
making small incisions from the outer edge of the retina, being careful to avoid areas 
of the retina needed for experimentation. The macula region was then removed using 
a 4mm diameter micro-dissecting trephine (Biomedical Research Instruments, MD, 
USA) and placed into a 35mm petri dish containing 1.5ml serum-free 
DMEM/HamF12 medium (Fisher Scientific). The remainder of the retina in the 
60mm petri dish (Fisher Scientific) was then placed over a template which allowed 
paramacula explants to be taken at a consistent distance and position from the macula 
explant (Figure 2.1). Five paramacula explants were taken and placed into one 35mm 
Petri dish (Fisher Scientific) containing 1.5ml serum-free DMEM/HamF12 medium 
(Fisher Scientific) to randomise the samples prior to experimentation. Explants were 
kept in a humidified incubator at 35°C in 95% air, 5% CO2. Explants were then 
placed into experimental conditions, or if untreated, prepared for further analysis. 
 
2.3 Cell Culture 
Cell lines were cultured in a humidified incubator at 35°C in 95% air, 5% CO2 in 
75cm2 culture flasks (Fisher Scientific). When approximately 90% confluent, cells 
were passaged. The cell medium was firstly aspirated and the cells washed in 5ml 
Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen). The DPBS was aspirated 
and 5ml 0.05% Trypsin-EDTA (Life Technologies, Paisley, UK) was applied to the 
cells and for approximately 3 minutes until the cells were no longer adhered to the 
Figure 2.1 - Diagram of Macula and Paramacula Sample Extraction Technique 
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cell culture flask. The Trypsin-EDTA was neutralised through the addition of 10ml 
10% foetal bovine serum (FBS) (Invitrogen, Paisley, UK) supplemented medium. 
This was transferred to a 25ml universal tube (Fisher, UK) and a sample was taken to 
assess cell number. Cell number was calculated using a haemocytometer (Assistant, 
Sondheim- Rhön, Germany). 
The cell suspension was centrifuged at 90 x G for 10 minutes. The supernatant was 
aspirated and the cell pellet re-suspended in 5ml 10% FBS medium. The cells were 
then seeded into 96 well plates or 35mm dishes for experimental use. Another 75cm2 
culture flask was also seeded to maintain the cell culture. 
 
2.3.1 ARPE-19 
ARPE-19 cells are derived from a primary culture of human retinal pigmented 
epithelial cells (Dunn et al., 1996) and were obtained from the American Type Cell 
Culture (ATCC, Manassas, VA, USA). The cell line expresses immunohistochemical 
cell markers for native human RPE cells such as cellular retinaldehyde-binding 
protein (CRALBP). 
The cell line is grown in DMEM/HamF12 medium with 10% FBS, 2mM L-
glutamine and 50mg/l Pen-Strep (Invitrogen). Cells were seeded at a density of 4,000 
cells per well in a 96 well plate in a volume of 100µl. 
 
2.3.2 MIO-M1 
The MIO-M1 cell is a cell line obtained from Professor Astrid Limb (University 
College London, UK) and is derived from a primary culture of human retinal cells 
(Limb et al., 2002). The cell line expresses the immunohistochemical markers of 
native Human Müller cells such as cellular retinaldehyde-binding protein (CRALBP) 
and Glutamine Synthetase (GS). 
The cell line is grown in DMEM GLUTAMAX medium with 10% FBS, and 50mg/l 
Pen-Strep (Invitrogen). Cells were seeded at a density of 5,000 cells per well in a 96 
well plate in a volume of 100µl. 
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2.4 PCR 
2.4.1 Planar Sectioning 
Retinal explants were frozen in liquid nitrogen following dissection / 
experimentation and stored at -80°C until ready for RNA extraction. A frozen block 
was prepared on which to mount the retinal explant. This involved a chuck being 
prepared with a layer of frozen optimal cutting temperature (OCT, Sakura Finetek, 
Zoeterwoude, Nederlands) on top. The chuck had a line drawn down one side for 
referencing the position within the cryostat. The chuck was then placed in the 
cryosectioner so that the line from the chuck was directly in line with a mark on the 
mounting stage. This is performed so that when the sample is sectioned, the position 
and angle of the mount within the cryostat is the same allowing for level sectioning. 
The OCT was then cryosectioned so that a flat surface was obtained. This was then 
stored in the cryostat on the quickfreeze plate at -40°C. 
Once the retinal explant was dissected, it was placed into a 35mm Petri dish 
containing 1.5ml serum-free DMEM/HamF12. The explant was then floated onto a 
triangular piece of filter paper until directly in the centre of the paper. The paper and 
explant was then lifted out of the medium and the filter paper with the explant in the 
centre was placed on top of the cryosectioned OCT on the chuck. OCT was then 
placed on top of the explant so that the explant lays between two layers of OCT. This 
was then placed back onto the quickfreeze plate to allow the OCT on top of the 
explant to freeze. Once frozen, the explant could be cryosectioned (Figure 2.2). 
To section the explants, the chuck was placed into the cryostat ensuring the line with 
the chuck is in line with the mark on the cryostat. The block was then sectioned at 
30µm sections through the top layer of OCT until the explant was visable. The 
cryostat was then set to section at 20µm. As the sample was approaching each new 
section was placed onto a slide to see if any tissue was present. When the tissue was 
reached each section was placed into an Eppendorf labelled with sample number and 
other relevant information and snap frozen in liquid nitrogen. 
54 
 
 
2.4.2 RNA Extraction 
The Qiagen RNeasy mini kit (Qiagen, Crawley, UK) was used for RNA extraction of 
whole retinal explants, and the RNeasy micro kit (Qiagen, Crawley, UK) was used 
for RNA extraction of planar sections. The protocol provided by Qiagen was 
followed and is described below. Both protocols are similar, however where 
differences arise they are highlighted.  
To extract the RNA, buffer containing β-mercaptoethanol (Sigma-Aldrich, Poole, 
UK) was added and the tissue homogenised by passing through a 20-gauge needle 10 
times. The lysate was then centrifuged at 12,000g for 3 minutes to remove insoluble 
debris. The supernatant was then transferred to a separate Eppendorf containing 70% 
ethanol. Following mixing this was transferred to the RNeasy Minispin column 
(RNeasy Minielute for the Micro kit) and centrifuged at 12,000g for 15 seconds. 
Buffer RW1 was then added and centrifuged at 12,000g for a further 15 seconds. 
DNA was then digested by adding DNase diluted in RDD buffer (Qiagen, Crawley, 
UK) to the column and leaving for 15 minutes. The column was then washed in 
 
Figure 2.2 - Diagram of the Planar Sectioning Technique 
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buffer RW1 twice at 12,000g to remove the DNase. 
Following this Buffer RPE (mixed with 100% ethanol) was added to the column and 
centrifuged for another 15 seconds at 12,000g. Buffer RPE was then added to the 
column again and centrifuged for 2 minutes at 12,000g to dry the membrane. If using 
the Micro Kit, 80% ethanol was then added to the column and centrifuged at 12,000g 
for 2 minutes, before adding the column to a new collection tube and centrifuging at 
12,000g for 5 minutes to dry the column. To collect the RNA, 50µl of RNase free 
water (Qiagen, Crawley, UK) was then added to the Mini kit column, or 14µl to the 
Micro kit column and centrifuged for 1 minute at 12,000g. 
The concentration of RNA was measured in duplicate using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, USA). 260/280 and 
260/230 ratios were also measured and a ratio of ≥1.8 for each was suitable for use. 
 
2.4.4 RNA Clean-up 
RNA clean-up (sodium acetate precipitate method) was performed on RNA extracted 
samples with a either a 260/280 or a 260/230 value of <1.8. 
During the precipitate stage either 3M sodium acetate or 5M ammonium acetate at 
pH 4.5 was added at 1/10th of the RNA sample volume. 2.5 X the volume of pre 
chilled 100% ethanol was then added and precipitated overnight at -20°C. 
The recovery stage began with a 12,000g spin at 4°C for 15 minutes. The 
Supernatant was then discarded. 0.5ml of ice cold 75% Ethanol was then added and 
centrifuged at 12,000g at 4°C for 15 minutes. The supernatant was discarded and the 
RNA sample air dried before being re-suspended in RNase-free water. 
 
2.4.5 cDNA 
Before performing PCR, the RNA needs to be converted into complimentary DNA 
(cDNA) so that PCR can be conducted. Depending on the quantity of RNA extracted, 
RNA was diluted to either 5ng/µl or 10ng/µl in RNase free water. Random primers 
(Promega, Southampton, UK) were mixed with dNTP (Invitrogen, Paisley, UK) and 
added to each sample before being briefly centrifuged to mix the two. The samples 
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were then placed in a Peltier Thermal Cycler DNA engine (PTC-200, MJ Research, 
Minnesota, USA) and heated to 65°C for 5 minutes and then chilled on ice. 5x first 
strand buffer, dithiothreitol (DTT) (Invitrogen, Paisley) and RNase inhibitor 
(Promega, Southampton, UK) were mixed and added to the samples and incubated 
for 10 minutes at 25°C and then at 42°C for 2 minutes. Samples were then chilled on 
ice and Superscript II Reverse Transcriptase (Invitrogen, Paisley, UK) was added. 
The Eppendorf’s were then centrifuged for 15 seconds to mix the contents. The 
samples were then incubated at 42°C for 50 minutes and then at 70°C for 15 minutes 
before being stored at -20°C. 
 
2.4.6 PCR 
QRT-PCR was conducted using the Applied Biosystems 7500 fast real-time PCR 
System (Applied Biosystems, Warrington, UK). cDNA was diluted with nucleotide 
free water to 0.5ng/ml and duplicates of 5ng total cDNA added to each well of the 
microAmp Optical 96 well reaction plate (Applied Biosystems, Warrington, UK). 
Mastermix, primers / probes and nuclease free water were all prepared and mixed 
together so that a total volume of 15µl per well was obtained at a ratio of: Mastermix 
8.33µl, primers / probe 1.25µl and nuclease free water 5.42µl. This was then added 
to each well to bring the total volume of the well to 25µl. 
When the plate had been loaded, it was sealed with PCR film (Thermo Scientific, 
Surrey, UK). The first stage of the PCR reaction involved heating the plate to 50°C 
for 2 minutes, followed by heating the plate to 95°C for 10 minutes to reduce non-
specific amplification. The cDNA was then amplified (40 cycles of heating to 95°C 
for 15 seconds and cooling to 60°C for 60 seconds) with the heating stage denaturing 
double stranded DNA and the cooling process allowing new primers to bind to the 
single strand DNA template. 
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Table 2.1 – List of Primers / Probes Used 
Primer / Probe Number Reporter Source 
Topoisomerase 
(TOP1) 
 FAM Primer Design, 
Southampton, UK 
Cytochrome C1 
(CYC1) 
 FAM Primer Design, 
Southampton, UK 
THY1 Hs00174816_m1 FAM Applied 
Biosystems, 
Warrington, UK 
RBFOX3 Hs00876928_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
AHNAK2 
 
Hs00292832_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Protein Kinase C 
alpha  
 
Hs00925193_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Choline 
acetyltransferase 
Hs00252848_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Calbindin 
 
Hs01077197_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Retinaldehyde 
Binding Protein 1 
Hs00165632_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
GFAP 
 
Hs00909236_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Heat Shock Protein 
70 
 
Hs01040501_sh 
 
FAM Applied 
Biosystems, 
Warrington, UK 
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Recoverin Hs00610056_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Cyclin Dependent 
Kinase 5 
Hs00358991_g1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Cyclin Dependent 
Kinase 11A/B 
Hs02341397_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Cyclin Dependent 
Kinase 16 
Hs00178837_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Cyclin Dependent 
Kinase 17 
Hs00176839_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
Cyclin Dependent 
Kinase 18 
Hs00384387_m1 
 
FAM Applied 
Biosystems, 
Warrington, UK 
 
2.4.7 PCR Analysis 
Data obtained from PCR was analysed in one of three ways depending on the 
experiment conducted. 
For whole explant data looking at expression levels across the macula and 
paramacula explants, data obtained from the PCR was quantified based on standard 
curve values, and then normalised to the housekeeping genes. The housekeeping 
genes used were; topoisomerase 1 (TOP1) which is involved in the unwinding of 
DNA (Lodish, 2000) and cytochrome C-1 (CYC1) a mitochondrial transmembrane 
protein involved in the electron transfer chain (Kokhan et al., 2010). The 
housekeeping genes were chosen because they showed the least variation between 
explants and changed the least with time in culture (Sanderson lab, unpublished 
data). 
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The delta Ct method was adopted to assess changes in expression with CHQ 
treatment. This method calculates a fold change in expression by using the following 
equation (Qiagen, 2016): 
∆Ct1 = Ct (Target A‐treated) – Ct (Ref B‐treated) 
∆Ct2 = Ct (Target A‐control) – Ct (Ref B‐control) 
∆ ∆ Ct = ∆Ct1 (treated) – ∆Ct2 (control) 
2∆∆Ct Normalized target gene expression level = 2∆∆Ct 
 
In experiments using planar sectioned retina, the level of mRNA was assessed using 
a standard curve and plotted directly. The standard curve mRNA was prepared from 
a combination of whole macula and paramacula explants converted to cDNA. 20, 10, 
5, 2.5, 1.25 and 0.625ng of cDNA was then loaded into a PCR plate and expression 
of the gene of interest analysed and the standard curve plotted. The Ct value and ng 
of cDNA from the standard curve provided a line equation which could in turn be 
used to obtain a value of “ng cDNA” in future experiments. Data was not normalised 
to housekeeping genes as these vary in level across the retinal sections. 
 
2.5 Immunohistochemistry 
2.5.1 Cryosectioning 
Retinal explants were fixed in 4% formaldehyde for 24 hours. They were then 
dehydrated in 30% sucrose solution for a further 24 hours to prevent freeze damage 
to the tissue. After this, aluminium foil cups (1 – 2cm in height, 1.5cm in diameter) 
of OCT were prepared. The explants were then placed vertically into the OCT using 
forceps, placed onto dry ice to freeze and stored at -80°C. Blocks were mounted onto 
the chuck using OCT and placed into the cryostat (Bright OTF 5000 Cryostat, Bright 
Instruments, Huntingdon, UK) and sectioned at 30µm (maximum sectioning 
thickness) until the retinal sample was 4mm in diameter (middle of the sample), 
measured using a digital vernier calliper (Clarke, Essex, UK). When the centre of the 
samples was reached it was sectioned at 13µm and placed onto either Tespa (3-
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triethoxysilylpropylamine) coated slides (Sigma-Aldrich, Poole, UK), or superfrost 
plus slides (Fisher Scientific) with 4 sections placed onto each slide. Sections were 
not consecutive to make sure that different cells were imaged; after a section was 
placed onto the slide, the two subsequent sections were discarded before collection of 
the following section. Slides were stored at -20°C. 
 
2.5.2 Fluorescence Immunohistochemistry 
Slides were washed in PBS three times (10 minutes each) to remove the OCT. 
Retinal sections then had circles drawn around them using a wax pen. Sections were 
then incubated in blocking solution (5% normal goat serum, 0.2% TritonX-100 
(Sigma-Aldrich, Poole, UK) prepared in PBS) for 90 minutes at room temperature. 
The blocking solution was carefully wiped off avoiding damage to the samples or the 
wax ring and the primary antibody (Table 2.2), prepared in blocking solution, was 
added to the sections and incubated for 24 hours at 4°C in a square Petri dish (Fisher, 
UK)with a damp piece of tissue in the tray to prevent dehydration. 
 
Table 2.2 Primary antibody’s used for immunohistochemistry 
Target Antibody Source and 
Clonality 
Dilution Source 
Choline 
acetyltransferase 
Rabbit Polyclonal 1:200 Millipore, 
Watford, UK 
Recoverin Rabbit Polyclonal 1:500 Millipore, 
Watford, UK 
Calbindin D-28K Mouse Monoclonal 1:300 Sigma-Aldrich, 
Dorset, UK 
Protein Kinase C Mouse Monoclonal 1:200 Santa Cruz, 
Bergheimer, 
Germany 
Thy1 Mouse Monoclonal 1:200 Millipore, 
Watford, UK 
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Neuronal Nuclei 
(NeuN) 
Mouse Monoclonal 1:200 Millipore, 
Watford, UK 
Neuronal Enolase Rabbit Polyclonal Pre-
diluted 
Thermo Scientific, 
Northumberland, 
UK 
Tubulin Mouse Monoclonal 1:200 Promega, 
Southampton, UK 
Glutamine 
synthetase 
Rabbit Polyclonal 1:200 Millipore, 
Watford, UK 
AHNAK2 Mouse Polyclonal 1:500 Abcam, 
Cambridge, UK 
Glial Fibrillary 
Acidic Protein 
(GFAP) 
Rabbit Polyclonal 1:500 Dako, Cambridge, 
UK 
Active Caspase 3 Rabbit Polyclonal 1:3000 Abcam, 
Cambridge, UK 
 
After 24h the primary antibody was removed and three 10 minute washes with PBS 
performed. Secondary antibody (Table 2.3) prepared in blocking solution was then 
added to the samples and incubated at room temperature for 2 hours. After 
incubation the slides were washed in PBS three times (10 minutes each) and then 
DAPI (Molecular Probes, Leiden, Netherlands) at 0.5µg/ml in PBS for 10 minutes. 
Following this, slides were again washed three times (for 10 minutes each). The 
slides were then dried and a drop of hydromount added to each sample before sealing 
with a coverslip. Slides were then allowed to set in the dark for 12 hours before 
imaging. Fluorescence microscopy was conducted on a wide-field Zeiss Axiovert 
200M fluorescence microscope and the images analysed using Zeiss Axiovision 4.8 
software. 
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Table 2.3 – Secondary antibody list 
Target Antibody Source 
and Fluorophore 
Dilution Source 
Mouse IgG (H+L) Goat AlexaFluor 
488 
1:1000 Invitrogen, 
Paisley, UK 
Mouse IgG (H+L) Goat AlexaFluor 
568 
1:1000 Invitrogen, 
Paisley, UK 
Rabbit IgG (H+L) Goat AlexaFluor 
568 
1:1000 Invitrogen, 
Paisley, UK 
 
 
2.5.3 Colorimetric Immunohistochemistry 
2.5.3.1 Ventana Discovery 
The Ventana Discovery (Roche, Burgess Hill, UK) is an automated 
immunohistochemical and in situ hybridization platform which has the ability to 
perform multiple immunohistochemical assays at the same time. This platform was 
used for colorimetric immunohistochemistry with all reagents purchased from Roche 
(Burgess Hill, UK), the customised protocol input was: 
1. Rinse slide with reaction buffer 
2. Apply coverslip (DXT) 
3. Warm slide to 37°C and incubate for 4 minutes 
4. Disable slide heater, incubate for 8 minutes 
5. Rinse slide with reaction buffer 
6. Apply coverslip (DXT) 
7. Warm slide to 37°C and incubate for 4 minutes 
8. Rinse slide with reaction buffer 
9. Apply coverslip (DXT) 
10. Apply one drop of inhibitor CM, incubate for 4 minutes 
11. Rinse slide with reaction buffer 
12. Apply coverslip (DXT) 
13. Apply one drop of primary antibody, incubate for 32 minutes 
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14. Rinse slide with reaction buffer, then apply coverslip X 3 
15. Apply one drop of secondary antibody, incubate for 20 minutes 
16. Rinse slide with reaction buffer, then apply coverslip X 3 
17. Apply one drop of DAB CM and one drop of H2O2 CM, incubate for 8 
minutes 
18. Rinse slide with reaction buffer 
19. Apply coverslip (DXT) 
20. Apply one drop of copper CM, incubate for 4 minutes 
21. Rinse slide with reaction buffer 
22. Apply coverslip (DXT) 
 
2.5.3.2 TUNEL Assay 
Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labelling (TUNEL 
assay) (Roche, Burgess hill, UK) was used to detect cells undergoing apoptosis. 
Slides underwent the standard protocol for the Ventana Discovery (section 2.5.3.1), 
in which the primary antibody stage included application of TUNEL label (TUNEL-
enzyme 1: 9 TUNEL-label) and was incubated for 1 hour at 37°C. At the secondary 
antibody stage rabbit anti-FITC (Invitrogen, Paisley, UK) was applied. 
 
2.5.3.3 Colorimetric Imaging 
Slides were scanned using the Aperio Scanscope XT (Leica Biosystems, Milton 
Keynes, UK), and images analysed using Aperio Imagescope software (Leica 
Biosystems, Milton Keynes, UK). Image analysis involved the quantification of the 
number of positive pixels (positive pixel count), in which a threshold is set for both 
positive pixels (antibody of interest) and negative pixels (haematoxylin stain). The 
number positive pixels (antibody of interest) is expressed as a percentage of all 
positive and negative pixels (haematoxylin stain), and the result given as a % 
positive pixel count. 
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2.6 Western Blot 
2.6.1 Protein extraction. 
Following experimental conditions, mammalian protein extraction reagent M-PER 
(Thermo Scientific) with 1:100 of halt phosphatase inhibitor cocktail and 1:100 
protease inhibitor cocktail along with 1:100 (0.5M) EDTA (Thermo Scientific, 
Rockford, IL, USA) was added to the retinal explant. The tissue was lysed using an 
Eppendorf pestle and lysates spun at 16,000g for 10 minutes at 4°C. The supernatant 
was collected and transferred to a 0.5ml Eppendorf and stored at -80°C until ready to 
use. 
 
2.6.2 BCA Assay 
A bicinchoninic assay (BCA) was carried out on the tissue lysates to determine the 
quantity of protein. Protein standards ranging from 0-1000 µg/mL were prepared by 
diluting bovine serum albumin (BSA) (Sigma-Aldrich) in M-PER. Protein standards 
were applied to a 96 well plate in triplicate, along with each sample in duplicate. 
Each well then received ddH20 and BCA reagents A and B (Thermo Scientific) 
mixed at a ratio of 10:50:1. The plate was then covered and placed on a shaker for 1 
minute before being incubated at 37°C for 1 hour. A BMG Labtech plate reader was 
used to measure the absorbance at 550nm. The protein concentrations of the 
unknown samples were calculated from the standard curve. 
 
2.6.3 Sample Preparation 
Samples for Western blots were diluted with ddH20 to the concentration of the lowest 
sample. Loading Buffer (4%SDS (Melford Laboratories, Ipswich, UK), 0.01% 
bromophenol blue (Sigma-Aldrich), 30% glycerol (Sigma-Aldrich), 12.5% β-
mercaptoethanol (Sigma-Aldrich) and 160mM Tris (Sigma-Aldrich) pH 6.8) was 
added to each sample and centrifuged at 16,000g for 2 minutes before heating to 
100°C for 5 minutes. 
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2.6.4 SDS-PAGE 
10% acrylamide, sodium docecyl sulphate (SDS-PAGE) gels were made 24h before 
use. The upper gel consisted of 5% acrylamide (diluted from 40% acrylamide 
solution (BIO-Rad) in ddH20), 4X upper gel buffer (0.5M Tris (Sigma-aldrich), 0.4% 
w/v SDS (Sigma-Aldrich), pH 6.8), ammonium persulphate and TEMED (Sigma-
Aldrich). The lower running gel consisted of 10% acrylamide (via dilution of 40% 
Acrylamide solution (BIO-Rad) in ddH20), 4X lower gel buffer (1.5M Tris, 0.4% 
w/v SDS, pH 8.8), ammonium persulphate and TEMED. 
 
2.6.5 Gel Electrophoresis 
Gels were placed into the electrophoresis tank (Bio-Rad Laboratories, Hercules, CA, 
USA) filled with running buffer (250mM Tris, 1.92M glycine and 1% SDS (Sigma-
Aldrich)). ECL DualVue molecular weight marker (GE healthcare, 
Buckinghamshire, UK) was loaded into the first well, and samples with loading 
buffer into the subsequent wells. Electrophoresis was conducted at 4°C with 30 
milliamps per gel and was halted once the bromphenol blue dye reached the end of 
the gel. 
 
2.6.6 Protein Transfer 
The SDS-PAGE gels were incubated in transfer buffer (48mM Tris, 39mM glycine 
(Fisher), 4% w/v methanol (Fisher), 0.0375% w/v SDS, pH 8.3) for 30 minutes. A 
polyvinylidene difluoride (PVDF) membrane (Perkin Elmer Life Sciences) was 
activated via submersion in 100% methanol for 30 seconds. Proteins were transferred 
onto the membranes by sandwiching the gel and the PVDF membrane between thick 
blotting paper which was placed on a trans-blot semi-dry transfer cell (Bio-Rad) at a 
constant 15V and a current of 0.03 A per gel for 30 minutes. 
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2.6.7 Immunoblotting 
Post protein transfer the gels were discarded and PVDF membranes washed in PBS 
(3 times for 5 minutes). Membranes were blocked for 1 hour in PBS-T (5% w/v 
reduced fat milk powder (Marvel), 0.1% v/v Tween-20 (Fisher) in PBS). PBS-T was 
removed and membranes were placed into PBS-T containing the primary antibody 
(Table 2.4) overnight at 4°C. Membranes were then washed in PBS-T (6 times for 5 
minutes), and placed in PBS-T containing 1:1000 secondary antibody (Table 2.4) for 
1 hour at room temperature. Membranes were washed in PBS-T (6 times for 5 
minutes) and then PBS containing 0.1% w/v Tween-20 (once for 10 minutes). 
 
2.6.8 Development 
The membranes were immersed in ECL Plus solution (ECL Plus Western Blotting 
Detection System, GE Healthcare) and kept in the dark for 5 minutes at room 
temperature. The ECL Plus solution was removed and the membrane placed into a 
film cartridge and taken to a dark room. In the dark, Amersham Hyperfilm ECL 
photographic film (GE healthcare) was exposed to the membrane. The photographic 
film was then passed through Kodak GBX developing solution (Kodak, Rochester, 
NY, USA), Stop Solution (SB80 photosol, Basildon, UK) and fixing solution 
(Hypam fixer, Ilford, Cheshire, UK). Bands on the photographic film were scanned 
and the area of the band measured using Image J (Wayne Rasband, National 
Institutes of Health, USA). β-actin was used as the loading control. To view multiple 
antibodies, membranes were stripped by washing twice (15 minutes each) in 200mM 
NaOH (Sigma-Aldrich) before washing for 5 minutes in PBS. The membrane would 
then be blocked for one hour in PBS-T before application of the new primary 
antibody. 
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Table 2.4 – Antibodies Used for Western Blotting 
Antibody Clonality Target 
protein Mw 
(KDa) 
Dilution Company 
Primary 
antibodies 
    
Anti-PARP Rabbit 
Monoclonal 
116, 89 1:1000 Cell Signalling 
Technology 
(Danvers, MA, 
U.S.A) 
Anti-β-actin Rabbit 
Monoclonal 
45 1:1000 Cell Signalling 
Technology 
(Danvers, MA, 
U.S.A) 
Secondary 
antibodies 
    
Anti-Rabbit 
HRP 
Conjugate 
IgG Donkey - 1:1000 GE Healthcare 
(Buckinghamshire, 
UK) 
Anti-Mouse 
HRP 
Conjugate 
IgG Sheep - 1:1000 GE Healthcare 
(Buckinghamshire, 
UK) 
 
 
 
2.7 LDH Assay 
The cytotoxicity detection kit (Roche, Indianopolis, IN, USA) (LDH assay) was 
performed to detect levels of necrosis. It achieves this by assessing the levels of the 
cytosolic enzyme Lactate Dehydrogenase (LDH) released into the culture medium 
when cell membrane integrity is lost. For explants, tissue was first removed from the 
culture dish and fixed for immunohistochemical anlaysis. The medium was pipetted 
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into an Eppendorf and centrifuged for 5 minutes at 16,000g to remove any cell 
debris. It was then diluted 1:10 in the same medium before placing 100µl into a 96 
well plate (Fisher Scientific, Loughborough, UK). For cells, medium was removed 
from the culture (Fisher Scientific), and 100µl placed directly into a new 96 well 
plate (Fisher Scientific) for assessment. 
Alongside this, 100µl of fresh medium was added to three wells so that the 
absorbance of the background could be measured and subtracted from the absorbance 
of the samples. The reaction mixture was then prepared. This consisted of the 
catalyst (Diaphorase/NAD+) and dye solution (Iodotetrazolium chloride (INT) and 
sodium lactate) mixed at a ratio of 1:45 (catalyst : dye solution). This was added to 
the samples at a 1:1 ratio. The plate was incubated for 15 minutes at 37°C and 
readings taken at 490nm and 660nm at 5 minute intervals. The results used for 
analysis were from the 15 minute time point. 
The equation used to calculate total LDH release was: 
LDH absorbance = Sample absorbance (490nm) – background absorbance (660nm) – 
background medium absorbance (490, 660nm). 
LDH release data was expressed in one of two ways when analysing cell data. Either 
a standard curve was run and the data expressed as mU/mL LDH, or one row of cells 
was lysed using 2% Triton X (Sigma-Aldrich) and the LDH released expressed in 
comparison to this as % total LDH. Explant LDH release data was measured and 
expressed as % Control. 
 
2.8 MTS Assay 
An MTS assay (96 Aqueous one solution proliferation assay, (Promega, 
Southampton, UK)) was used to assess cell viability. The MTS assay contains a 
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetra-zolium) and an electron coupling reagent (phenazine 
ethosulphate). Metabolically active cells can reduce the tetrazolium compound into a 
coloured formazan product (soluble in culture medium) causing a colour change. 
Therefore the level of colour change can be used to assess viability of the cells. 
The assay was run in triplicate and applied to cells at a 1:10 dilution (mixed in the 
69 
 
appropriate medium according to the cell type) for 1 hour at 35°C. Absorbance was 
measured at 490nm using a BMG Labtech plate reader and background readings of 
medium and MTS were taken. For retinal explants 1.5ml of MTS solution with 
DMEM/HamF12 medium at a 1:10 ratio was applied to the 35mm culture dish 
containing the explant and incubated at 35°C for 1 hour. The medium was then 
extracted and mixed well before being measured at 490nm. 
The viability was calculated as follows: 
% cell viability = ((absorbance treated –background) / (absorbance control – 
background)) * 100 
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Chapter 3 
3.0 Characterisation of retinal cell markers in the human retina 
3.1 Introduction 
The retina consists of 10 different layers with multiple cell types distributed at 
different densities throughout these layers. There are three nuclear layers: the outer 
nuclear layer consisting of the cell bodies of the photoreceptors (Rods and Cones), 
the inner nuclear layer consisting of the cell bodies of amacrine cells, horizontal 
cells, bipolar cells and the non-neuronal Müller cells and finally the ganglion cell 
layer, consisting of the cell bodies of retinal ganglion cells. 
To assess location and density of these cells, retinal cell markers may be utilised, and 
in order to establish the ex vivo human retina as a model to assess retinotoxicity, it is 
important to determine the validity of such markers in the human retina. A general 
marker of neuronal cells is neuronal specific enolase. Neuronal enolase is an enzyme 
involved in the glycolysis pathway (Bonner et al., 2000), immunohistochemically it 
has been studied in the human retina by Li et al (1995) where it was found that the 
highest density of staining was located within the inner segments of cone 
photoreceptors. Contrary to this another group which studied neuronal enolase in the 
retina found staining to be less specific, staining processes of all neurons within the 
human retina (Molnar et al., 1984). 
As a marker of photoreceptors, recoverin may be used. Recoverin is a calcium 
binding protein involved in the phototransduction of photoreceptors (Dizhoor et al., 
1991). Recoverin is known to be expressed in both rod and cone cells (Gunhan et al., 
2003) and is therefore a marker for all photoreceptors within the retina. 
Commonly used markers of the inner nuclear layer cells; horizontal, bipolar and 
amacrine are calbindin (a calcium binding protein), protein kinase C α (PKCα, an 
enzyme involved with the phosphorylation of proteins and cell signalling (Lameirao 
et al., 2009) and choline acetyltransferase (ChAT, an enzyme involved in the 
synthesis of acetyl choline) respectively. Chiquet (2005) showed that calbindin 
stained a multitude of cells in the human retina, with cone cells and horizontal cells 
being primarily stained and some bipolar cells and amacrine cells (Chiquet et al., 
2005), whereas PKCα has been used to immunostain rod bipolar cells (it does 
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however only mark rod ON bipolar cells) (Haverkamp et al., 2003), (Kolb et al., 
1993). ChAT has been used to immunolabel cholinergic amacrine cells and displaced 
amacrine cells previously (Hutchins and Hollyfield, 1987). 
Ganglion cell markers have been extensively investigated in the human retina by the 
Norwich eye research group, THY1 (a cell surface glycoprotein (Partida et al., 
2012)) and NeuN (a neuronal specific nuclear protein (Mullen et al., 1992)) have 
been used to provide information regarding changes in the number of ganglion cells 
with oxygen and glucose deprevation and changes with hydrostatic pressure 
(Osborne et al., 2015a), and NMDA excitotoxicity (Niyadurupola et al., 2011). 
Recent data published by Osborne et al (2015) has also shown that ganglion cell 
marker βIII Tubulin, a protein within microtubule used in rodent studies is also 
suitable for the assessment of ganglion cells in the human retina (Osborne et al., 
2015b). Ma (2014) has also found with use of a gene array that AHNAK (a scaffold 
protein (Marg et al., 2010)) and HSP1AB (HSP70, a protein which increases 
expression in response to elevated temperature (Kayama et al., 2011)) are also 
expressed at high levels in the human retinal ganglion cell layer, potentially 
indicating new markers of ganglion cells. 
Müller cells may be investigated with the use of glutamine synthetase (an enzyme 
responsible for the breakdown of excess glutamate), this has been shown in rat retina 
(Riepe and Norenburg, 1977), pig retina (Oh et al., 2011) as well as other species. 
For the ex vivo retina to be established as a suitable model for the assessment of 
retinotoxicity, it is important to compare the in vivo retina to the ex vivo retina to be 
aware of any changes which may occur during the post mortem period. In order to 
make such a comparison, human retina was obtained from eyes that had been 
removed during surgery. Allowing for the minimum time possible between the 
functioning retina in vivo, to experimental conditions. 
Another important factor when establishing a model is the ability to compare treated 
samples to a control, for this all samples must be equivalent at the start. QRT PCR 
can be used to investigate the expression levels of cell specific mRNA, if samples 
possess the same expression values across all samples, any change in expression 
during culture with a retinotoxin may be attributed to the treatment. 
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The aim of the research presented in this chapter is to build a cellular profile of the 
human retina, throughout the nuclear layers of the retina and across the macula and 
paramacula region, determining the mRNA expression profiles of cell specific 
marker genes of the major retinal cell types and localization of marker proteins by 
immunohistochemistry. A comparison between the post mortem donors and living 
donors will also be made to investigate any differences. This characterisation sets the 
baseline characteristics of the model prior to development of the model for 
investigation of retinotoxicity. 
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3.2 Results 
3.2.1 Immunohistochemical analysis of retinal cell marker proteins in the 
human retina 
In initial experiments the morphology of the retina was shown using antibodies to 
immune label specific cells within each layer, starting with the photoreceptor layer 
and ending with the ganglion cell layer. All retinal samples were processed directly 
following dissection. 
 
3.2.1.1 Neuronal Specific Enolase 
 
 
Neuron specific enolase was selected as a marker of neurons in the human retina. 
Figure 3.1 A-C show staining in the living human retina from neuron specific 
enolase. Staining can be found in the ganglion cell layer and the inner nuclear layer, 
 
Figure 3.1 - Neuronal Specific Enolase Presence in the Live and Post Mortem Human 
Paramacula Retina 
Cross section of the paramacula human retina immunostained for neuronal specific enolase (red). 
Fig 3.1 A - C shows immunostaining from a cross section of retina from a living donor. Fig 3.1 D 
- E shows the immunostaining from a cross section of retina from a post mortem donor (pre-24h). 
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however the highest intensity of staining was seen in the photoreceptor layer. Figure 
3.1 D-E displays staining from a post mortem donor in which a similar pattern of 
staining was found. 
 
3.2.1.2 Recoverin 
 
 
Recoverin was used as an immunohistochemical marker of photoreceptor cells. 
Figure 3.2 showed recoverin to stain the photoreceptor layer, including cell bodies in 
the outer nuclear layer and photoreceptor outer segments. This was similar in both 
the living donor (Figure 3.2 A-C) and the post mortem donor (Figure 3.2 D-F), 
however more outer segments can be seen in the retina of the live donor. 
  
 
Figure 3.2 - Recoverin Presence in the Live and Post Mortem Human Paramacula Retina 
Cross section of the paramacular human retina immunostained for Recoverin (red). Fig 3.2 A - C 
shows the immunostaining from a cross section of retina from a living donor. Fig 3.2 D - E shows 
the immunostaining from a cross section of retina from a post mortem donor (pre-24h). 
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3.2.1.3 Calbindin 
 
 
Calbindin was selected as a immunohistochemical marker of horizontal cells. 
Calbindin identified multiple cells in both the living donor and the post mortem 
human retina (Figure 3.3). Remnants of some photoreceptor outer segments were 
stained in the living donor as well as the post mortem donor, however interestingly, 
no cell bodies were stained in the outer nuclear layer. Both donors displayed staining 
of cell bodies in the inner nuclear layer, and to a lesser extent cell bodies in the 
ganglion cell layer, the nerve fibre layer also displayed staining in both. 
  
 
Figure 3.3 - Calbindin Presence in the Live and Post Mortem Human Paramacula Retina 
Cross section of the paramacular human retina immunostained for Calbindin D-28K (green). Fig 
3.3 A - C shows the immunostaining from a cross section of retina from a living donor. Fig 3.3 D 
- E shows the immunostaining from a cross section of retina from a post mortem donor (pre-24h). 
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3.2.1.4 Protein Kinase C α 
 
 
PKCα was selected as a marker of bipolar cells within the inner nuclear layer (Figure 
3.4). It identified a specific subset of cells in the inner nuclear layer of both the living 
donor and the post mortem donor, processes which extend from the inner nuclear 
layer to the ganglion cell layer can also be seen. 
Supplementary data 1 (SPD 1) also shows PKCα staining across a macula explant, 
staining was found to be in the inner nuclear layer throughout the macula explant 
apart from the fovea where PKCα was absent. 
  
 
Figure 3.4 - Protein Kinase C α Presence in the Live and Post Mortem Human Paramacula 
Retina 
Cross section of the paramacular human retina immunostained for PKCα (green). Fig 3.4 A - C 
shows the immunostaining from a cross section of retina from a living donor. Fig 3.4 D - E shows 
the immunostaining from a cross section of retina from a post mortem donor (pre-24h). 
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3.2.1.5 NeuN 
 
 
NeuN was selected to identify retinal ganglion cells in the ganglion cell layer. NeuN 
immunostained cell bodies within the ganglion cell layer of both the living donor and 
the post mortem donor. Some cell bodies were also stained in the inner nuclear layer, 
although these were infrequent. 
  
 
Figure 3.5 - NeuN Presence in the Live and Post Mortem Human Paramacula Retina 
Cross section of a paramacular human retina immunostained for NeuN (green). Fig 3.5 A - C 
shows the immunostaining from a cross section of retina from a living donor. Fig 3.5 D - E shows 
the immunostaining from a cross section of retina from a post mortem donor (pre-24h). 
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3.2.1.6 THY1 
 
 
THY1 was also selected as a retinal ganglion cell marker. THY1 staining was seen in 
the retinal ganglion cell layer of both the living donor and the standard donor. 
  
 
Figure 3.6 - THY1 Presence in the Live and Post Mortem Human Paramacula Retina 
Section of a paramacular human retina immunostained for THY1 (green). Fig 3.6 A - C shows the 
immunostaining from a cross section of retina from a living donor. Fig 3.6 D - E shows the 
immunostaining from a cross section of retina from a post mortem donor (pre-24h). 
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3.2.1.7 βIII Tubulin 
 
 
βIII Tubulin was also selected as a retinal ganglion cell marker. Tubulin 
immunostaining was present within cell bodies of the ganglion cell layer, and within 
the nerve fibre layer. This was consistent between the living donor and the post 
mortem donor as shown in Figure 3.7. 
  
 
Figure 3.7 - βIII Tubulin Presence in the Live and Post Mortem Human Paramacula Retina 
Cross section of the paramacula human retina immunostained for Tubulin (green). Fig 3.7 A - C 
shows the immunostaining from a cross section of retina from a living donor. Fig 3.7 D - E shows 
the immunostaining from a cross section of retina from a post mortem donor (pre-24h). 
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3.2.1.8 Glutamine Synthetase 
 
 
Glutamine synthetase was selected as a marker of Müller cell presence within the 
human retina. Throughout the retina of the living donor (Figure 3.8 A-C) a distinct 
staining was seen in the inner retina corresponding to the area where the Müller cell 
end feet would be found. Müller cell bodies were also stained within the inner 
nuclear layer and the processes from these can be seen extending into the outer 
nuclear layer. A similar staining pattern was found in the retina of the post mortem 
donor (Figure 3.8 D-E), however the staining appeared to be stronger in the outer 
nuclear layer. 
 
  
 
Figure 3.8 - Glutamine Synthetase Presence in the Live and Post Mortem Human 
Paramacula Retina 
Cross section of the paramacula human retina immunostained for Glutamine Synthetase (green). 
Fig 3.8 A - C shows the immunostaining from a cross section of retina from a living donor. Fig 
3.8 D - E shows the immunostaining from a cross section of retina from a post mortem donor 
(pre-24h).  
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3.2.1.9 AHNAK2 
 
 
AHNAK2 was selected as a marker of the inner retina. AHNAK2 was found to 
strongly stain the nerve fibre layer in both the post mortem donor and the living 
donor, ganglion cell bodies were also stained with both donors. A small amount of 
staining was also apparent in the outer plexiform layer of the living donor. 
 
 
  
 
Figure 3.9 - AHNAK2 Presence in the Live and Post Mortem Human Paramacula Retina 
Cross section of the paramacula human retina immunostained for AHNAK2 (green). Fig 3.9 A - 
C shows the immunostaining from a cross section of retina from a living donor. Fig 3.9 D - E 
shows the immunostaining from a cross section of retina from a post mortem donor (pre-24h). 
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3.2.1.10 Heat Shock Protein 70 
 
 
Heat Shock Protein 70 (HSP70) was also investigated due to data obtained by Ma et 
al (2012) which indicated high levels of HSP70 mRNA in the ganglion cell layer. 
The living donor (Figure 3.10 A-C) showed HSP70 to be present in all nuclear 
layers, however the strongest staining was found to be in the ganglion cell layer, 
whereas the post mortem donor (Figure 3.10 D-E) displayed widespread staining 
throughout the retina. 
  
 
Figure 3.10 - Heat Shock Protein 70 Presence in the Live and Post Mortem Human 
Paramacula Retina 
Cross section of the paramacula human retina immunostained for Heat Shock protein 70 (Red). 
Fig 3.10 A - C shows the immunostaining from a cross section of retina from a living donor. Fig 
3.10 D - E shows the immunostaining from a cross section of retina from a post mortem donor 
(pre-24h). 
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3.2.2 mRNA Expression of Cell Specific Markers Within Whole Macula and 
Paramacula Samples 
Distribution of the mRNA of key cell specific markers was investigated throughout 
the five paramacula samples and the macula sample in order to investigate the 
density and distribution of cell specific markers throughout the human retina. 
 
 
Figure 3.11 - Expression of Outer and Inner Nuclear Layer Markers in Whole 
Explants. Expression of outer nuclear layer cell marker RCVN and inner nuclear layer 
markers CALB1, PKC and CHAT within paramacula samples 1 -5 (mean + SEM n=5) and 
macula samples (mean + SEM n=4) relative to the housekeeping genes TOP1 and CYC1. * 
Indicates a significant difference between the sample and all other samples (P<0.05) (One-
way ANOVA with Tukeys post hoc test) 
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Expression of the outer nuclear layer cell marker RCVN and inner nuclear layer 
markers CALB1, PKCa and CHAT was investigated within the 5 paramacula and the 
macula samples (Figure 3.11) to investigate the distribution and density of 
photoreceptor cells, horizontal cells, bipolar cells and amacrine cells (respectively) 
within these regions. 
RCVN is a marker of photoreceptors. RCVN showed a trend of increasing expression 
from paramacula sample 1 to paramacula sample 5. A trend of lower expression 
within the macula compared to all paramacula samples was also seen, however 
variability was high and no significant differences were seen. 
CALB1 was used as a marker of horizontal cells. CALB1 showed even distribution 
throughout all 5 paramacula samples and the macula sample. 
PKCα is a marker of rod on bipolar cells. PKCα displayed even distribution 
throughout the 5 paramacula samples and significantly lower expression within the 
macula compared to the paramacula samples. 
CHAT is a marker for amacrine cells. CHAT showed similar levels of expression 
throughout the five paramacula and macula samples although it was noted that 
variation between samples for different donors was high. 
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Expression of the ganglion cell markers THY1, BRN3A, AHNAK2 and RBFOX3 
(NeuN) were investigated within the 5 paramacula samples and the macula sample 
(Figure 3.12) to explore the distribution and density of ganglion cells within these 
regions. It was interesting to compare different markers for one cell type to 
determine which might be the most appropriate for use in the human retina. 
 
THY1, AHNAK2 and RBFOX3 all showed a significantly higher level of expression 
in the macula compared to the paramacula as would be expected for markers of 
 
Figure 3.12 - Expression of Ganglion Cell Layer Markers in Whole Explants. 
Expression of known ganglion cell markers: RBFOX3, THY1, BRN3A and AHNAK2 within 
paramacula samples (mean + SEM n=5) and macula samples (mean + SEM n=4) relative 
to the housekeeping genes TOP1 and CYC1. * Indicates a significant difference between 
the sample and all other samples (P<0.05) (One-way ANOVA with Tukeys post hoc test) 
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retinal ganglion cells. BRN3A did not show typical ganglion cell expression, with 
variable expression throughout the paramacula and macula samples. 
 
 
Expression of the Müller cell markers GLUL, RLBP, GFAP and the cell stress 
marker HSP70 were also investigated in the 5 paramacula and the macula samples 
(Figure 3.13). 
 
Figure 3.13 - Expression of Müller Cell Markers in Whole Explants. Expression of 
known Müller cell markers: GLUL, RLBP and GFAP, and the cell stress marker HSP70 
within paramacula samples 1 -5 (mean + SEM n=5) and macula samples (n=4) relative to 
the housekeeping genes TOP1 and CYC1. * Indicates a significant difference between the 
sample and all other samples (P<0.05) (One-way ANOVA with Tukeys post hoc test) 
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The Müller cell markers GLUL, RLBP and GFAP displayed similar trends in 
expression, with lower expression in the macula compared to paramacula samples. 
This lower expression in the macula was significant for RLBP expression. 
HSP70 (a cell stress marker) differed to the other Müller cell markers in that 
expression was similar throughout all paramacula and macula sections. 
 
3.2.3 mRNA Profiling of Retinal Cell Markers in the Human Retina 
 
Planar sectioning allows the analysis of mRNA expression throughout the different 
layers of the retina to be conducted. The expression profile of cell specific markers 
throughout the different layers of the retina was investigated in the retina, comparing 
macula and paramacula regions and also retina from post mortem and living donors. 
This will provide information about the location and strength of expression of the 
cell specific markers throughout the retina in the macula and paramcula regions as 
well as any differences that may occur as a result of post mortem changes.  
 
3.2.3.1 mRNA Profiling of Retinal Cell Markers in the Post Mortem Macula 
 
The post mortem macula was first investigated to determine the expression profile of 
the cell specific markers THY1, AHNAK2, RBFOX3, CHAT, RLBP, PRKCA, CALB1 
and RCVRN (Figure 3.14). 
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Figure 3.14 - Planar Sectioned 
Macula Explant From a Post 
Mortem Donor 
Expression profile of THY1, 
AHNAK2, RBFOX3, CHAT, 
RLBP, PRKCA, CALB1, RCVRN 
mRNA in macula sections of 
post mortem human retina (mean 
+ SEM; n=4). 
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mRNA analysis of the planar sectioned macula samples revealed the location of peak 
expression of the cell specific marker being investigated. 
The outermost retina displayed peak expression of RCVRN. The highest level of 
expression was in sections 1 and 2, which was followed by small a decrease in 
expression at section 3. Expression plateaued from section 3 to section 5 which was 
followed by a gradual decrease in expression until baseline expression was reached 
at section 14. 
The mid-section, corresponding to the inner nuclear layer displayed peak expression 
of the markers CALB1 PRKCα, RLBP and ChAT. 
CALB1 expression displayed baseline expression in the outer retina until section 3, 
followed by an increase in expression until peak expression was reached at section 8. 
This was followed by a decrease in expression until baseline expression was reached 
again in the inner retina at section 16. 
PRKCα displayed low levels of expression in the outer retina at section 1, this was 
followed by a gradual increase in expression until peak expression occurred at 
section 7. This peak was followed by a gradual decrease in expression towards the 
inner retina at section 16. 
RLBP expression displayed low levels of expression in the outer retina until section 
3, this was followed by an increase in expression until peak expression was reached 
in section 9. This peak expression was followed by a decrease in expression until 
section 17 where baseline expression was reached in the inner retina. 
CHAT expression was baseline within the outer retina until section 6 where a gradual 
increase in expression followed until peak expression was reached at section 11. A 
decrease in expression then occurred until section 16. 
The inner retina displayed peak expression of the markers RBFOX, AHNAK2 and 
THY1. RBFOX3 expression was baseline in the outer retina until section 4 where a 
gradual increase in expression occurred until a plateau of peak expression was 
reached from section 12 -15. This was then followed by a slight decrease in 
expression in sections 16 – 18. 
AHNAK2 expression was baseline in the outer retina until section 4. This was 
followed by a gradual increase in expression until section 11 where there was a sharp 
increase in expression. Expression then remained high and peaked at section 17. 
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THY1 expression was baseline from section 1 – 4 followed by a gradual increase to 
peak expression at section 14. Expression then remained high until section 17 
followed by a slight reduction in expression at section 18. 
 
3.2.3.2 mRNA Profiling of Retinal Cell Markers in the Living Donor Macula 
 
The expression profile of the live donor Macula sample was then investigated 
(Figure 3.15), allowing a comparison between the expression profiles of the standard 
donor, and the live donor to be made.  
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Figure 3.15 - Planar Sectioned 
Macula Explant from a Living 
Donor 
Expression profile of THY1, 
AHNAK2, RBFOX3, CHAT, 
RLBP, PRKCA, CALB1, RCVRN 
mRNA in macula sections of a 
living donor (mean + SEM, n=2). 
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Planar PCR data from themacula region of a living donor (Figure 3.15) showed the 
same pattern of expression as the post mortem human retina (Figure 3.14). 
The outer retina displayed peak expression of RCVRN. This was shown by peak 
expression occurring in sections 1 – 4. A gradual decrease in expression then 
followed. 
The central region sections displayed peak expression of the following markers 
CALB1, PRKCα, RLBP and ChAT. CALB1 displayed peak expression in the inner 
nuclear layer in the macula of the post mortem donor (Figure 3.14), however within 
the macula of the live donor there were variable results. This is likely due to the 
small number of repeats available. 
PRKCα displayed peak expression within the inner nuclear layer between section 6 
and section 10. There was also some variability seen with PRKCα expression due to 
the small number of repeats. 
RLBP displayed a low level of expression at section 1. This was followed by a 
gradual increase in expression to section 3 where a sharp increase in expression 
occurred to display peak expression at section 6. There was a slight decrease in 
expression which was followed by another peak in expression at section 10 and then 
a decrease to basal expression at section 15. 
ChAT expression was baseline within the outer retina until section 3, this was 
followed by a gradual increase in expression until peak expression was reached at 
section 10. A decrease in expression was then found from section 12. 
The ganglion cell layer displayed peak expression of the ganglion cell markers 
RBFOX3, AHNAK2 and THY1. These all displayed a similar pattern of expression of 
baseline expression in the outer retina until section 3, followed by a gradual increase 
in expression until peak expression is reached at approximately section 9 until 
section 15. 
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3.2.3.3 mRNA Profiling of Retinal Cell Markers in the Post Mortem 
Paramacula 
 
Whole section analysis of cell specific mRNA displayed differences between 
paramacula sections and macula sections, reflecting a difference in cell density 
between the two regions. 
To build a comprehensive profile of cell specific mRNA, the potential differences 
that may also occur within the distribution of cells throughout the nuclear layers of 
the retina was investigated between planar sectioned macula and paramacula 
sections. 
For this reason the expression profile of cell specific mRNA was then investigated 
within standard donor paramacula sections (Figure 3.16).  
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Figure 3.16 - Planar Sectioned 
Paramacula Explant from a 
Post Mortem Donor  
Expression profile of THY1, 
AHNAK2, RBFOX3, CHAT, 
RLBP, PRKCα, CALB1 and 
RCVRN mRNA in paramacula 
sections of a post mortem human 
retina (mean + SEM n=4). 
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The expression profile of cell specific marker genes from planar sectioned 
paramacula samples was similar to the expression profile of planar sectioned macula 
samples. The main difference being the number of sections, there were more sections 
available from the macula due to the tissue being thicker at this region.  
The outer retina displayed peak expression of RCVRN. This peak expression 
occurred at section 2, and high levels of expression were maintained until section 4. 
A decrease in expression then occurred until basal expression levels were reached at 
section 8. 
The inner regions displayed peak expression of the following markers CALB1 
PRKCA, RLBP and CHAT. 
CALB1 expression was low in the outer retina, expression then increased from 
section 3 where peak expression was reached at section 7. A gradual decrease then 
followed this until section 12. 
PRKCA expression was low in the outer retina and gradually increased until peak 
expression was reached at section 6, this was followed by a gradual decrease in 
expression. 
RLBP expression was low in the outer retina. Expression gradually increased until 
section peak expression was reached at section 7. High expression levels were 
present until section 9 where a decrease in expression occurred to section 12. 
CHAT expression was baseline in the outer retina. Expression then gradually 
increased until section 8 where a large increase in expression occurred until section 
11. 
The ganglion cell layer displayed peak expression of the markers RBFOX3, AHNAK2 
and THY1. These markers followed a similar expression pattern of baseline 
expression in the outer retina, followed by a gradual increase until peak expression 
was reached from sections 9 – 12. 
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3.2.3.4 mRNA Profiling of Retinal Cell Markers in the Living Donor 
Paramacula 
 
Analysis of planar sectioned paramacula sample (Figure 3.17) was performed to 
ensure the pre-24 hour post mortem retina possesses the same expression properties 
as the live donor. 
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Figure 3.17 - Planar Sectioned 
Paramacula Explant from a 
Living Donor 
Expression profile of THY1, 
AHNAK2, RBFOX3, ChAT, 
RLBP, PRKCα, CALB1 and 
RCVRN mRNA in paramacula 
sections of a retina from a living 
human donor (mean + SEM, 
n=2). 
Outer Retina               Inner Retina 
E
x
p
re
ss
io
n
 R
el
at
iv
e 
to
 t
h
e 
S
ta
n
d
ar
d
 C
u
rv
e
 
98 
 
As in the macula region, the paramacula retina from the living donors possessed very 
similar expression properties to the post mortem donor. 
The outer retina possessed peak expression of RCVRN. High expression began at 
section 1, however peak expression was not reached until section 4. A decrease in 
expression then followed through to section 12. 
The inner regions of the retina displayed peak expression of the markers CALB1 
PRKCα and RLBP 
CALB1 expression was low in the outer retina. Expression gradually increased and 
reached peak expression at section 7, this was followed by a gradual decrease until 
section 12. 
PRKCα expression was low in the outer retina, an increase in expression was seen 
from section 3 until peak expression was reached at section 9. The peak at section 9 
was found to possess some variability (due to the small number of repeats) and 
therefore may be a false peak, whereas the peak at section 6 displayed little 
variability. This peak was then followed by a gradual decrease in expression. 
RLBP expression was baseline in the outer retina. Expression gradually increased 
until peak expression was reached at section 6, this was followed by a decrease in 
expression. 
ChAT expression was baseline in the outer retina until section 6, expression then 
increased and reached peak expression at section 9 and remained high. 
The inner retina displayed peak expression of the markers RBFOX3, AHNAK2 and 
THY1. These markers displayed similar expression patterns of baseline expression in 
the outer retina, followed by an increase to peak expression at section 9, high 
expression levels remained until section 12. 
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3.3 Discussion 
Before any investigation into the toxicity of compounds on the human retina can be 
performed, three important factors must be considered. 
The first is the profile of the various cell types within the human retina. This profile 
will prove useful when investigating the effect of retinotoxins by helping identify the 
cell types affected by such compounds. This was investigated using both 
immunohistochemistry and QRT-PCR. 
The second is whether changes take place in terms of structure and expression as a 
result of the retina being taken from post mortem material. This is important as any 
changes that may occur due to the tissue being post mortem could have the potential 
to hide the effect of any retinotoxin being investigated. The immunohistochemical 
properties of the living donor retina and the post mortem retina were therefore 
investigated to find any differences that may occur. Alongside this, mRNA 
expression profiles of cell specific marker genes were investigated, again comparing 
the profile of the live retina to that of the standard retina. 
Finally, when investigating the distribution of mRNA expression, the equivalence of 
expression throughout the five paramacula samples needs to be considered. This will 
aid in the development of the ex vivo model to assess retinotoxicity in that if the 
samples are found to possess equivalent expression throughout the five paramacula 
samples, then one paramacula sample may be used as a control, whilst the effect of 
varying concentrations of a retinotoxin on expression of the other four paramacula 
samples can be analysed. 
Neuronal specific enolase is an enzyme which is involved in the glycolysis pathway 
in neurons (Kirino et al., 1983) (Bonner et al., 2000). The immunohistochemical 
results show staining was present throughout the retina, however it can be seen to 
mark the outer plexiform layer and the photoreceptor cell bodies most strongly 
(Figure 3.1). A slight difference was found between the live donor and the post 
mortem donor in that the outer plexiform layer was labelled more clearly in the post 
donor than in the live donor. Although this marker was interesting to use, it did not 
stain all neurons equally and therefore is not a good marker of all neuronal cells of 
the retina. 
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Recoverin binds specifically to a 23-kilodalton calcium binding protein which 
regulates the activation of guanylate cyclase, an enzyme which is stimulated during 
bright conditions via a decrease in cytosolic calcium in the photoreceptor outer 
segments (Dizhoor et al., 1991). It was seen to clearly immunostain photoreceptor 
cell bodies and the photoreceptor outer segments where this enzyme is most present 
(Figure 3.1). Whole explant mRNA analysis of recoverin showed equivalent 
expression throughout the five paramacula samples and a trend of lower expression 
in the macula sample (Figure 3.11A), and planar analysis revealed peak expression in 
the outer retina. Previous data has indicated that recoverin is expressed in both rods 
and cones (Gunhan et al., 2003), however data obtained here indicates that recoverin 
may be more highly expressed in rods than cones, with the higher density of cones in 
the macula causing the lower expression of recoverin compared to the paramacula 
regions. Overall recoverin was a good marker of photoreceptors and will prove to be 
useful in further studies involving photoreceptor investigations. 
Calbindin-28k is a protein consisting of six E-helix-loop-F-helix-hand motif’s (of 
which only four are active). This protein binds to Ca2+ to act as a calcium buffer to 
help maintain fluctuations with intracellular Ca2+ (Mojumder et al., 2008). The 
antibody for Calbindin-28k effectively marked the cone outer segments along with 
horizontal cells and to a lesser extent some amacrine cells (Figure 3.3). There is a 
slight difference between the live donor and the standard donor with calbindin in that 
more cone outer segments were immunostained within the photoreceptor layer of the 
live donor, however this is most likely due to the retinal extraction process. 
Photoreceptor outer segments are particularly delicate and can easily become 
detached during retinal dissection. During removal of the retina, the retina becomes 
detached from the RPE and due to the engulfed outer segments the outer segments 
can break off from the photoreceptor cell bodies at any point between the external 
limiting membrane and the end of the outer segments. Therefore variance in number 
of outer segments varies between donors. Whole sample mRNA analysis of calbindin 
revealed similar expression throughout the five paramacula sections and the macula 
sample, indicating even distribution of the cells which express calbindin. Planar 
sectioning revealed calbindin to be most highly expressed in the inner nuclear layer, 
with peak expression occurring in the outer parts of the INL, indicating that 
horizontal cells may be responsible for the high expression. Although calbindin 
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proved to be an effective marker of inner nuclear layer cells, it also stained other 
cells not in the inner nuclear layer, therefore is not a marker exclusive enough for 
further investigation of inner nuclear layer cells. 
PKC is a family of enzymes which are involved in cell signalling pathways 
downstream of second messengers (Lameirao et al., 2009). PKC-α specifically 
identified rod ON bipolar cells within the inner nuclear region of the retina (Figure 
3.4). Further to this, a whole macula image of a PKCα immunostained section was 
performed and is shown in supplementary data 1 (SPD1), in this image it can be seen 
that stained bipolar cells become less dense towards the fovea, where there are no 
stained bipolar cells. This is in line with other research which has shown that Rod 
ON bipolar cells only appear approximately 1mm away from the fovea (Lameirao et 
al., 2009). Whole explant mRNA analysis of PKCα showed expression equivalence 
throughout the five paramacula samples, and significantly lower expression within 
the macula. This significantly lower expression of PKCα in the macula re-enforces 
data showing that PKCα marks rod ON bipolar cells. Planar analysis also revealed 
that peak expression occurs within the inner nuclear layer. PKCα is therefore a good 
marker of the inner nuclear layer and may be used further to investigate rod on 
bipolar cells in the inner nuclear layer. 
ChAT has previously been used to immunolabel cholinergic amacrine cells and 
displaced amacrine cells in the human retina (Hutchins and Hollyfield, 1987). These 
experiments were attempted to be replicated, however the antibody showed no 
specificity towards any cells and therefore the images were not included. Whole 
explant analysis of ChAT mRNA expression showed that expression was equivalent 
throughout the paramacula sections and the macula, whereas planar sectioning 
revealed a difference between the expression pattern in paramacula and macula. 
Macula peak expression was found within the inner nuclear layer, whereas the 
paramacula was more associated with with the ganglion cell layer. This difference 
may be due to the higher presence of displaced amacrine cells within the ganglion 
cell layer in the paramacula region. This is re-enforced by previous studies which 
have shown that only 3% of central retinal cells are displaced amacrine cells, 
whereas ~80% of cells present within the peripheral retina are displaced amacrine 
cells (Curcio and Allen, 1990). Overall, ChAT would be useful for further 
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investigation of amacrine cells though mRNA, however investigation of amacrine 
cells through the ChAT antibody used in this research would not be viable. 
Neuronal nuclei (NeuN) is a neuron specific nuclear protein which is expressed in 
most neuronal cell types within vertebrates (Mullen et al., 1992). Within the retina, 
NeuN is an effective ganglion marker in the post mortem donor and the living donor 
(Figure 3.5). Whole section mRNA analysis of RBFOX3 (NeuN) displayed 
equivalent expression throughout the five paramacula sections and significantly 
increased expression in the macula. Planar sectioning analysis of NeuN revealed 
peak expression in the ganglion cell layer in both macula and paramacula samples. 
The significantly higher expression of NeuN in macula whole explants compared to 
paramacula explants can be explained by the macula’s thick ganglion cell layer. The 
thick ganglion cell layer contains high numbers of ganglion cells and provides a low 
photoreceptor to ganglion cell ratio. This (in particular the fovea where the majority 
of light is focussed) leads to a high visual acuity in the macula, whereas in the 
paramacula region there is a thinner ganglion cell layer, and therefore fewer ganglion 
cells. This increases the photoreceptor to ganglion cell ratio and decreases visual 
acuity, but increases sensitivity to light in the peripheral retina. Overall, NeuN is a 
good marker of ganglion cells and would prove to be a useful in future studies of 
ganglion cells. 
THY1 is a glycosylphosphatidylinositol anchored protein (Partida et al., 2012) which 
is expressed within approximately 80% of retinal ganglion cells (Chauhan et al., 
2012). Figure 3.6 showed THY1 stained the ganglion cell layer of the retina to a 
similar degree in both the living donor and the post mortem donor. Like NeuN, 
THY1 expression in whole explants showed equivalent expression through the five 
paramacula sections and significantly higher expression within the macula section. 
Planar analysis also showed THY1 expression peaked within the ganglion cell layer. 
THY1 is also a good marker of ganglion cells and could be useful for future studies 
of human retinal ganglion cells. 
Beta III tubulin is a core protein within microtubules. The antibody for tubulin 
marked the nerve fibre layer and the ganglion cell bodies (Figure 3.7), a region 
which has a high density of microtubules. Beta III tubulin expression was not 
investigated in whole explants due to the use of other ganglion cell markers, however 
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in a recent paper by Osborne it has been shown to be a suitable marker of ganglion 
cells (Osborne et al., 2015b). 
The AHNAK family is a family of scaffold PDZ proteins which have multiple 
cellular process functions such as membrane repair (Marg et al., 2010). AHNAK2 
possessed similar marking to beta III tubulin, it also marked the nerve fibre layer and 
some ganglion cells (Figure 3.8). Whole section analysis of AHNAK2 showed 
similar expression properties as the other ganglion cell markers NeuN and THY1, 
with equivalent expression throughout the five paramacula sections and significantly 
higher expression within the macula section. Planar sectioning also revealed peak 
expression of AHNAK2 to reside within the ganglion cell layer. AHNAK2 is not 
known as a marker of human retinal ganglion cells, however this research and 
previous research by Ma (2012) has shown that it is a good marker, it is however not 
as specific as NeuN or THY1 (shown by the incorporation of the nerve fibre layer in 
the immunohistochemical results).  
BRN3A has been shown to be a suitable marker of retinal ganglion cells in rats and 
mice (Nadal-Nicolas et al., 2009). Whole explant mRNA expression was analysed, 
and unlike the ganglion cell markers THY1, AHNAK, and RBFOX3, BRN3A did 
not show consistent expression throughout the five paramacula samples or 
significantly higher expression in the macula and therefore does not appear to be an 
appropriate ganglion cell marker to be used within the human retina. 
Glutamine synthetase is the primary enzyme responsible for the breakdown of 
excessive glutamate to prevent excitotoxicity from glutamate. It is normally present 
within Müller cells of the retina and is in high concentrations in regions which 
surround glutamergic synapses (Moreno et al., 2005). The immunohistochemical 
images obtained showed the antibody against glutamine synthetase marked Müller 
cell end feet to the highest degree and Müller cell bodies to a lesser extent (Figure 
3.8). 
Müller cell mRNA expression was also investigated using the known markers 
GLUL, RLBP and GFAP (Hollborn et al., 2011). All of the Müller cell markers 
displayed equivalent expression throughout the 5 paramacula samples and lower 
expression within the macula sample. This may be due to the lower number of 
Müller cells in the foveal region, which overall reduces the number of these cells in 
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the macula sample. Only RLBP expression was investigated using planar sectioning 
as this gave the clearest results in whole explant analysis. Peak expression of RLBP 
was found to reside in the inner nuclear layer, re-enforcing this as a useful marker of 
Müller cells. 
Heat shock protein 70 (Hsp70) is named so because of its molecular weight (70kDa) 
(Kayama et al., 2011), they are also named this because of their increase in 
expression with elevated temperature. The role of these proteins is the maintenance 
of the health of the cell, they aid in cellular processes such as the folding of proteins 
and the disposal of irreversibly damaged proteins (Urbak and Vorum, 2010). HSP is 
not only increased due to hyperthermia, it can also become increasingly expressed 
due to other stressors such as ischemia, osmotic and oxidative stress (Urbak and 
Vorum, 2010). Another vital role that HSP’s play is the prevention of apoptosis. 
Hsp70 can achieve this by interfering with; the translocation of Bax and the Apaf-1 
apoptosome (Urbak and Vorum, 2010). Hsp70 was stained to the highest extent in 
the nerve fibre layer of the live donor and to a lesser extent throughout the rest of the 
retina. Within the post mortem donor Hsp70 immunostaining was high throughout 
the retina (Figure 3.10). Since Hsp70 is increased due to stressors, this protein may 
naturally be at higher levels within post mortem tissue due to expression changes 
after death. Expression of HSP70 mRNA was also investigated and displayed similar 
levels of expression throughout macula and paramacula samples. As an mRNA 
investigator, Hsp70 may be useful as an indicator of stress, however 
immunohistochemically it would be hard to investigate any changes in Hsp70 levels 
due to the strong presence in post mortem tissue. 
The immunohistochemistry results provided by this research have given information 
regarding the location and density of cells within the retina. Importantly no major 
differences were found between the living donor and the pre-24 hour post mortem 
retina. This indicates that the in vivo human retina possesses the same structural and 
immunohistochemical properties as the post mortem retina, and therefore the pre-24 
hour post mortem retina is a useful tissue. This data will be helpful when using the 
retina as a model to assess retinotoxicity, allowing the investigation into specific cell 
sensitivities to retinotoxic compounds, for example, through the use of co-
localisation with cell death markers such as TUNEL or cleaved caspase 3. 
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Whole explant PCR analysis allowed investigation into the density and distribution 
of retinal cells throughout paramacula and macula samples. The differences in 
expression between the macula and paramacula samples shows that expression levels 
of cell specific markers can be used as a measure of cell density / population. 
Another important factor determined from whole explant analysis was the equivalent 
expression throughout the 5 paramacula sections. This enables the cell specific 
markers to be used within a toxicity study, by using one control paramacula sample, 
and applying varying concentrations of a retinotoxic compound to the remaining 4 
paramacula samples. Any changes in cell specific marker expression may reflect a 
decrease in that cell type, and the relative sensitivities of specific cell types to the 
retinotoxins to be determined. 
 
It should be noted that a different method of analysis was used when investigating 
mRNA expression throughout planar sections. Previously planar data had been 
normalised to the highest value, leading to the highest expression always being 1 
(Osborne et al., 2015b), however this would not allow for further investigation into 
the effect of retinotoxins on expression due to the fact the highest value will always 
be 1. This new method of analysis opens up opportunities to investigate the effect of 
retinotoxins on expression by looking into raw expression values. This new method 
of analysis does not distort the pattern of expression and each nuclear layer is still 
well represented by peaks of expression related to cell specific markers with little 
variability. 
 
3.4 Conclusion 
This chapter gives evidence supporting the use of this model in relation to three 
important areas. Firstly the similarity between the living donor and the post mortem 
donor as shown by the immunohistochemical and PCR results, providing good 
evidence on the suitability of the post mortem retina for use in subsequent 
experiments. 
Secondly, expression equivalence throughout the five whole paramacula samples 
enables this method of cell density / population analysis to be used when 
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investigating the retinotoxicity of compounds on the retina. For example one of the 
five paramacula samples can be used as a control and varying concentrations of a 
potential retinotoxic compound can be applied to the remaining four paramacula 
samples. Expression of the cell specific markers can then be investigated and the 
sensitivity of specific cell types to the retinotoxins determined. 
Finally, data from planar sectioned macula and paramacula samples provided 
confirmation of the location of expression and the cell type associated with 
expression. The new method of mRNA expression analysis of planar sections also 
opens opportunities to use this method for the investigation of cell sensitivities to 
retinotoxins and genes related to retinotoxins. 
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Chapter 4 
4.0 The Effect of Known Retinotoxins on Retinal Cell Lines 
4.1 Introduction 
 
Cell lines are commonly used in initial studies of drug development where lead 
compounds are sought. During this, many compounds can be screened on cell lines 
in search of a compound which matches the specific activity sought (Woolley, 2003). 
Cell lines may also be utilised in later toxicology studies for investigations of a 
single endpoint, such as; does compound x induce autophagy, and / or induce cell 
death via apoptosis. 
In this research two retinal cell lines were used: ARPE19 cells, a cell line derived 
from a primary culture of human RPE cells (retinal pigmented epithelium cells) 
which exhibit similar characteristics to native RPE cells (Dunn et al., 1996). And 
MIO-M1 cells, a cell line derived from a primary culture of human retinal cells 
which also exhibit similar characteristics to native Müller cells (Limb et al., 2002). 
These cell lines were exposed to a variety of retinotoxins to obtain information 
regarding the relative toxicity of the compounds. 
Chloroquine and hydroxychloroquine are known retinotoxins. They are anti-malarial 
agents which also possess therapeutic properties in the treatment of other diseases 
including systemic lupus erythematosus and rheumatoid arthritis. Cases of 
chloroquine retinotoxicity are well documented with clinical effects such as a “bulls 
eye maculopathy” (Gaynes et al., 2008). Hydroxychloroquine causes fewer side 
effects and is less toxic and therefore is used more commonly than chloroquine as an 
anti-malarial agent. 
Tamoxifen is a selective oestrogen receptor modulator (SERM) used in the treatment 
of hormone responsive breast cancer. It is also a known retinotoxin which can cause 
retinopathy and retinitis pigmentosa (Watanabe et al., 2010; Lazzaroni et al., 1998). 
Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is 
commonly used within the treatment of rheumatoid arthritis. Indomethacin is not 
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commonly known for its retinotoxic properties, however it has been recorded in one 
patient (Graham and Blach, 1988). 
It is useful to compare the effects of the retinotoxins to a positive control which is 
known to cause cell death. The positive control used here is the reactive oxygen 
species (ROS) hydrogen peroxide (H2O2), a chemical compound which is a strong 
oxidizer and is created as a by-product of metabolism in mitochondria (Giorgio et al., 
2007). Cells possess defence mechanisms against ROS, such as antioxidants (e.g. 
glutathione) and the enzymatic conversion of ROS to a less reactive product. 
However damage occurs to cells when an imbalance in favour of pro oxidants (ROS) 
occurs which may eventually lead to cell death. Cell death induced by H2O2 has been 
studied in ARPE19 cells and it was found that low levels of H2O2 induced apoptosis 
whereas high concentrations of H2O2 induced necrosis (Kim et al., 2003). Many 
retinal diseases are associated with oxidative stress, where an imbalance between pro 
oxidants such as H2O2 and anti-oxidants occurs. One example of this is age related 
macular degeneration (AMD) in which necrosis occurs in RPE cells as a result of 
oxidative stress (Hanus et al., 2013). Diabetic retinopathy is also associated with 
oxidative stress, and it has been found that Lutein (an anti-oxidant) prevented the 
neurodegenerative effect of diabetes within mice (Sasaki et al., 2010).  
The aim of the research in this chapter is to establish retinal cell lines for use 
alongside an ex vivo retina as models to assess retinotoxicity. This will be achieved 
by firstly investigating the effect of specific retinotoxins on the two retinal cell lines 
ARPE19 cells and MIO-M1 cells.  
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4.2 Results 
4.2.1 ARPE19 Cells Response to Retinotoxins 
Initial experiments were conducted on ARPE19 cells. The effects of retinotoxins on 
the ARPE19 cell line were assessed with two assays, one to assess levels of cell 
death (the LDH assay), and the other to assess cell viability (the MTS assay). 
 
4.2.1.1 Hydrogen Peroxide 
The positive control was firstly investigated (H2O2) and Figure 4.1 displays the effect 
of increasing concentrations of H2O2 on levels of cell death (A) and cell viability (B) 
on ARPE19 cells. 
 
 
Hydrogen peroxide caused a dose dependent increase in cell death as measured by 
LDH release and decrease in cell viability. A significant increase in cell death was 
found from 1mM (A) and a significant decrease in cell viability found from 500µM 
(B).  
 
Figure 4.1 - ARPE19 cell death / viability in response to H2O2 - (A) Cell death (LDH 
release) and (B) cell viability (MTS assay) in response to varying concentrations of H2O2 
(10µM-2mM) in ARPE19 cells (n=4) ± SEM. * indicates significance (P<0.05) using one 
way ANOVA with Dunnets post-hoc test. 
A B
H2O2 (M) H2O2 (M)
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4.2.1.2 Indomethacin 
ARPE19 cells were exposed to varying concentrations of indomethacin to reveal the 
effect of a relatively unknown retinotoxin on levels of cell death (A) and cell 
viability (B) of the retinal pigmented epithelial cell line. 
 
 
 
Figure 4.2 shows a dose dependent increase in LDH release / decrease in cell 
viability with increasing concentrations of indomethacin. A significant increase in 
cell death was found at the highest concentration (2mM) (A) whereas a significant 
decrease in levels of cell viability was found at 50µM (B). 
  
 
Figure 4.2 - ARPE19 cell death / viability in response to Indomethacin - (A) Cell 
death (LDH release) and (B) cell viability (MTS assay) in response to varying 
concentrations of Indomethacin (10µM-2mM) in ARPE19 cells (n=4) ± SEM. * indicates 
significance (P<0.05) using one way ANOVA with Dunnets post-hoc test. 
 
A B
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4.2.1.3 Tamoxifen 
ARPE19 cells were exposed to varying concentrations of tamoxifen to reveal the 
RPE cells response to a well-documented retinotoxin.  
 
 
Figure 4.3 shows a dose dependent increase in LDH release (A), and a decrease in 
cell viability (B) with increasing concentrations of tamoxifen. A significant increase 
in levels of cell death was found from 500µM and a significant decrease in cell 
viability from 500µM. 
  
 
Figure 4.3 - ARPE19 cell death / viability in response to Tamoxifen - (A) Cell death 
(LDH release) and (B) cell viability (MTS assay) in response to varying concentrations of 
Tamoxifen (10µM-2mM) in ARPE19 cells (n=4) ± SEM. * indicates significance 
(P<0.05) using one way ANOVA with Dunnets post-hoc test. 
A B
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4.2.1.4 Chloroquine 
ARPE19 cells were exposed to varying concentrations of chloroquine to provide an 
understanding of the retinal cells response to a well-documented retinotoxin.  
 
 
 
Figure 4.4 shows a dose dependent increase in LDH release (A), and a decrease in 
cell viability (B) with increasing concentrations of chloroquine. A significant 
increase in cell death was found from 200µM (A) and a significant decrease in cell 
viability from 100µM (B). 
 
ARPE19 cells responded to all of the compounds in a dose dependent manner. The 
LD50 values and the concentration from which there is a significant difference from 
the control value are summarised in Table 4.1 
  
 
Figure 4.4 - ARPE19 cell death / viability in response to CHQ - (A) Cell death (LDH 
release) and (B) cell viability (MTS assay) in response to varying concentrations of 
chloroquine (10µM-2mM) in ARPE19 cells (n=4) ± SEM. * indicates significance 
(P<0.05) using one way ANOVA with Dunnets post-hoc test. 
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A - LD50 Values 
 LDH MTS Average LD50 
H202 439µM 257µM 348µM 
Indomethacin 900µM ~1mM $ 950µM 
Tamoxifen 335µM ~290µM $ 312.5µM 
Chloroquine ~150µM $ ~350mM $ 250µM 
 
B – Significant From Values 
 LDH MTS Average  
H202 ≥1mM ≥500µM ≥750µM 
Indomethacin ≥2mM ≥50µM ≥1.025mM 
Tamoxifen ≥500µM ≥500µM ≥500µM 
Chloroquine ≥200µM ≥100µM ≥150µM 
 
Table 4.1: Summary of data obtained from treated ARPE19 cells. A - LD50 values, B – 
significant from values. $ indicates value calculated by hand. 
The LD50 values were initially calculated by Graphpad Prism (A). However, some 
of the LD50 values calculated in this way did not correspond well with the dose 
response shown by the ARPE19 cells. For this reason LD50 values were also 
calculated by hand (indicated by $). If the LD50 calculated by hand was similar to 
that of the Graphpad calculation, the Graphpad value was used. The value from 
which the response became significant was also calculated for all drugs (B). 
This data revealed that chloroquine was the most potent retinotoxic drug assessed on 
the ARPE19 cell line, with an average LD50 of 250µM and a significant increase in 
LDH release occurring from ≥200µM and a significant decrease in cell viability 
occurring at ≥100µM (overall an average significant increase from 150µM). 
Tamoxifen appeared to be the second most potent drug on the ARPE19 cell line, with 
an average LD50 of 312.5µM and a consistent increase in cell death / decrease in cell 
viability at ≥500µM. 
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H202 was the third most potent compound assessed, producing an average LD50 of 
348µM and an average significant increase in cell death / decrease in cell viability of 
≥750µM. 
Indomethacin was the least potent drug assessed and displayed an average LD50 of 
≥950µM. Contradictory results were found regarding the significant increase in LDH 
release and significant decrease in cell viability, with a significant increase in LDH 
release occurring at 2mM, whereas a significant decrease in cell viability occurred 
much earlier at ≥50µM. This overall produced an average significant increase of 
≥1.025mM. 
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4.2.2 MIO-M1 Cells Response to Retinotoxins 
MIO-M1 cells were then exposed to the same retinotoxins as the ARPE19 cell line, 
to investigate the differences in the sensitivity of the two cell lines to the 
retinotoxins. 
 
4.2.2.1 Hydrogen Peroxide 
MIO-M1 cells were firstly exposed to varying concentrations of H2O2, to gain an 
understanding of the cells response to oxidative stress 
 
 
 
Figure 4.5 shows a dose dependent increase in LDH release (A), and a decrease in 
cell viability (B) with increasing concentrations of H2O2. No significant increase in 
levels of cell death were found, however a significant decrease in levels of cell 
viability was found from 1mM. 
  
 
Figure 4.5 - MIO-M1 cell death / viability in response to H2O2 - (A) Cell death (LDH 
release) and (B) cell viability (MTS assay) in response to varying concentrations of H2O2 
(10µM-2mM) in MIO-M1 cells(n=4) ± SEM. * indicates significance (P<0.05) using one 
way ANOVA with Dunnets post-hoc test. 
 
A B
H2O2 (M) H2O2 (M)
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4.2.2.2 Indomethacin 
MIO-M1 cells were exposed to varying concentrations of indomethacin to show the 
response of the Müller cell line to a relatively unknown retinotoxin.  
 
 
 
Figure 4.6 shows a significant increase in LDH release from 1mM, with a steep dose 
response curve (A). A dose dependent decrease in cell viability was found with 
increasing concentrations of indomethacin, and a significant decrease was found 
from 500µM (B). 
  
 
Figure 4.6 - MIO-M1 cell death / viability in response to Indomethacin - (A) Cell 
death (LDH release) and (B) cell viability (MTS assay) in response to varying 
concentrations of indomethacin (10µM-2mM) in MIO-M1 cells (n=4) ± SEM. * indicates 
significance (P<0.05) using one way ANOVA with Dunnets post-hoc test. 
 
A B
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4.2.2.3 Tamoxifen 
MIO-M1 cells were then exposed to varying concentrations of tamoxifen. 
 
 
 
Figure 4.7 shows a dose dependent increase in LDH release (A), and a decrease in 
cell viability with increasing concentrations of tamoxifen (B). A significant increase 
in LDH levels were found from 200µM (A) and a significant decrease in cell 
viability was found from 500µM (B). 
  
 
Figure 4.7 - MIO-M1 cell death / viability in response to Tamoxifen - (A) Cell 
death (LDH release) and (B) cell viability (MTS assay) in response to varying 
concentrations of tamoxifen (10µM-2mM) in MIO-M1 cells (n=4) ± SEM. * 
indicates significance (P<0.05) using one way ANOVA with Dunnets post-hoc 
test. 
 
A B
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4.2.2.4 Chloroquine 
MIO-M1 cells were exposed to varying concentrations of chloroquine to show the 
response of the Müller cell line to a well-documented retinotoxin.  
 
 
 
Figure 4.8 shows a dose dependent increase in LDH levels (A), and a decrease in cell 
viability (B) with increasing concentrations of chloroquine. A significant increase in 
LDH release and decrease in cell viability was found from 50µM. 
 
MIO-M1 cells responded to all compounds in a dose dependent manner, the LD50 
values of the compounds calculated from LDH and MTS results are shown in Table 
4.2 
  
 
Figure 4.8 - MIO-M1 cell death / viability in response to CHQ - (A) Cell death (LDH 
release) and (B) cell viability (MTS assay) in response to varying concentrations of 
chloroquine (10µM-2mM) in MIO-M1 cells (n=4) ± SEM. * indicates significance 
(P<0.05) using one way ANOVA with Dunnets post-hoc test. 
 
A B
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A - LD50 Values 
 LDH MTS Average LD50 
H202 591µM ~700µM 
$ 645.5µM 
Indomethacin N.A ~800µM $ 800µM 
Tamoxifen 183µM 204µM 193.5µM 
Chloroquine 35µM 40µM 37.5µM 
 
B – Significant From Values 
 LDH MTS Average 
H202 N.A ≥1mM ≥1mM 
Indomethacin ≥1mM ≥500µM ≥750µM 
Tamoxifen ≥200µM ≥500µM ≥350µM 
Chloroquine ≥50µM ≥50µM ≥50µM 
 
Table 4.2: Summary of data obtained from treated MIO-M1 cells. A - LD50 values, B - 
significant from values. $ indicates value calculated by hand. 
 
As with the data regarding the ARPE19 cells, the LD50 values were initially 
calculated by Graphpad Prism (A). However, some of the LD50 values calculated in 
this way did not correspond well with the dose response shown by the ARPE19 cells. 
For this reason LD50 values were also calculated by hand (indicated by $). If the 
LD50 calculated by hand was similar to that of the Graphpad calculation, the 
Graphpad value was used. The value from which the response became significant 
was also calculated for all drugs (B). 
The MIO-M1 cell line displayed a similar pattern of sensitivity as the ARPE19 cell 
line with chloroquine being the most toxic drug investigated. Chloroquine displayed 
an average LD50 of 37.5µM and a significant increase in LDH release / decrease in 
cell viability both occurring from 50µM. 
Tamoxifen was also the second most potent drug, with an average LD50 of 
193.5µM, and an average significant difference from 350µM. 
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Indomethacin and H202 required high concentrations to cause a significant difference 
in LDH release / decrease in cell viability which was matched by high LD50 values. 
 
4.2.3 ARPE19 Cells Response to 24, 48 and 72h Chloroquine and 
Hydroxychloroquine Exposure 
 
Results suggested that chloroquine was the most potent retinotoxic drug in both the 
RPE and the Müller cell lines (ARPE19 and MIO-M1). Chloroquine has been 
superseded by hydroxychloroquine on the basis that hydroxychloroquine is less 
toxic, therefore the difference in toxicity between CHQ and HCQ on ARPE19 cells 
was investigated. It was also interesting to determine toxicity at longer time points, 
therefore experiments were conducted at 24, 48 and 72h time points. 
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Exposure to chloroquine for 24 hours (Figure 4.9 A, B) caused a significant increase 
in cell death / decrease in cell viability from approximately 200µM. 
Hydroxychloroquine caused a gradual increase in LDH release from 200µM, with a 
significant increase occurring at 500µM. Hydroxychloroquine also caused a dose 
dependent decrease in cell viability, with a significant decrease occurring from 
100µM (Figure 4.9 C, D). 
  
 
Figure 4.9 - ARPE19 cell death / viability in response to 24h CHQ / HCQ. Cell death 
(LDH release) (A, C) and cell viability (B, D) in response to differing concentrations of 
CHQ and HCQ (10µM-2mM) in ARPE19 cells after 24h exposure (n=4) ± SEM, * 
indicates significance (P<0.05) using one way ANOVA with Dunnets post-hoc test. 
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Exposure to chloroquine for 48 hours (Figure 4.10 A, B) caused gradual increase in 
cell death (LDH) / decrease in cell viability from approximately 50µM. A significant 
increase in cell death was not found until 200µM and a significant decrease in cell 
viability at 100µM. 
48 hours of exposure to hydroxychloroquine (Figure 4.10 C, D) caused gradual 
increase in cell death from approximately 50µM and a gradual decrease in cell 
viability from 100µM. A significant difference in both cell death and cell viability 
occurred at 200µM treatment. 
  
 
Figure 4.10 - ARPE19 cell death / viability in response to 48h CHQ / HCQ. Cell 
death (LDH release) (A, C) and cell viability (B, D) in response to differing 
concentrations of CHQ and HCQ (10µM-2mM) in ARPE19 cells after 48h exposure 
(n=4) ± SEM * indicates significance (P<0.05) using one way ANOVA with Dunnets 
post-hoc test. 
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Exposure to chloroquine for 72 hours (Figure 4.11 A, B) caused a sudden increase in 
cell death (LDH) / decrease in cell viability with significant differences occurring 
with 100µM treatment. 
Hydroxychloroquine exposure for 72 hours (Figure 4.11 C, D) also caused a sudden 
increase in cell death (LDH) / decrease in cell viability again, with significant 
differences occurring with 100µM treatment. 
 
ARPE19 cells responded to chloroquine and hydroxychloroquine in a dose 
dependent manner, with increasing concentrations of both causing an increase in 
 
 
Figure 4.11 - ARPE19 cell death / viability in response to 72h CHQ / HCQ. Cell 
death (LDH release) (A, C) and cell viability (B, D) in response to differing 
concentrations of CHQ and HCQ (10µM-2mM) in ARPE19 cells after 72h exposure 
(n=4) ± SEM, * indicates significance (P<0.05) using one way ANOVA with Dunnets 
post-hoc test. 
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LDH release and a decrease in cell viability. ARPE19 cells also showed a difference 
in response with the length of time exposed to the toxins with LD50 values 
decreasing with increasing time (Table 4.3). 
 
A - LD50 values of 24, 48 and 72h CHQ and HCQ Treated ARPE19 cells 
Cell Line Exposure to 
Drug  
LDH LD50 (M) MTS LD50 (M) Average LD50 
ARPE 19 24h CHQ 181µM 170µM 175.5µM 
ARPE 19 48h CHQ ~90µM $ ~100µM $ 95µM 
ARPE 19 72h CHQ 71.3µM 80.4µM 75.85µM 
 
ARPE 19 24h HCQ 170µM ~350µM $ 188.5µM 
ARPE 19 48h HCQ 96µM 78.4µM 87.2µM 
ARPE 19 72h HCQ 97µM 110µM 103.5µM 
 
B - Significant Difference’s of 24, 48 and 72h CHQ and HCQ Treated ARPE19 
cells 
ARPE19 CHQ HCQ 
Time 
Exposed 
LDH MTS Average of 
LDH and 
MTS 
LDH MTS Average of 
LDH and 
MTS 
24h ≥200µM ≥200µM ≥200µM ≥500µM ≥100µM ≥300µM 
48h ≥200µM ≥100µM ≥150µM ≥200µM ≥200µM ≥200µM 
72h ≥100µM ≥100µM ≥100µM ≥100µM ≥100µM ≥100µM 
 
Table 4.3: Summary of data obtained from 24, 48 and 72h treated ARPE19 cells. A- 
LD50 values of CHQ and HCQ treated ARPE19 cells. B – Significant differences of CHQ 
and HCQ treated ARPE19 cells. $ indicates value calculated by hand. 
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ARPE19 cells displayed a time dependent response of increased LDH release and 
decreased cell viability with increasing time exposed to CHQ and HCQ. This is 
shown by the decreasing LD50 with increasing time exposed to both drugs. 
CHQ possessed a lower LD50 at the 24 and 72h time points, but not the 48h 
timepoint, displaying CHQ’s higher toxicological properties over HCQ. 
 
The data regarding the value from which there is a significant difference from the 
control also indicates that CHQ was slightly more toxic to the ARPE19 cells than 
HCQ, as shown by the lower concentration causing a significant difference in cell 
death / cell viability at 24 and 48h treatment. With 72h treatment, this data indicated 
that CHQ and HCQ were equally toxic as each other. 
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4.2.4 MIO-M1 cells response to 24, 48 and 72h Chloroquine and 
Hydroxychloroqine exposure 
 
The time course experiments investigating the toxicity of chloroquine and 
hydroxychloroquine in ARPE19 cells were repeated using MIO-M1 cells 
 
 
Exposure to CHQ for 24 hours (Figure 4.12) caused a trend of increased LDH release 
(cell death), however no significant difference was found compared to untreated 
cells. A gradual decrease in cell viability began from approximately 20µM CHQ, 
with a significant decrease occurring from 50µM. 
 
Figure 4.12 - MIO-M1 cell death / viability in response to 24h CHQ / HCQ. Cell 
death (LDH release) (A, C) and cell viability (B, D) in response to differing 
concentrations of CHQ and HCQ (10µM-2mM) in MIO-M1 cells after 24h exposure 
(n=4) ± SEM, * indicates significance (P<0.05) using one way ANOVA with Dunnets 
post-hoc test. 
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24 hours exposure to HCQ also caused an increase in LDH release, with a significant 
increase occurring at 2mM. A trend of decreased cell viability was found from 50µM 
HCQ, with a significant difference occurring from 100µM. 
 
 
Exposure to CHQ for 48 hours (Figure 4.13) caused an increase in LDH release (cell 
death) with a significant increase in LDH release found from 50µM. At higher 
concentrations there also appeared to be a small decrease in LDH release. A gradual 
decrease in cell viability begun from approximately 10µM, with a significant 
difference occurring at 20µM CHQ. 
48 hours of exposure to HCQ also caused an increase in LDH release, with a 
 
Figure 4.13 - MIO-M1 cell death / viability in response to 48h CHQ / HCQ. Cell 
death (LDH release) (A, C) and cell viability (B, D) in response to differing 
concentrations of CHQ and HCQ (10µM-2mM) in MIO-M1 cells after 48h exposure 
(n=4) ± SEM, * indicates significance (P<0.05) using one way ANOVA with Dunnets 
post-hoc test. 
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significant increase occurring at 50µM. A trend of decreased cell viability was seen 
from 10µM HCQ, with a significant decrease occurring at 20µM. 
 
 
72 hours exposure to CHQ (Figure 4.14) caused little change in LDH release with no 
significant difference found, however a significant decrease in cell viability was 
found from 10µM CHQ. 
72 hours exposure to HCQ caused an increase in LDH release, with a significant 
increase occurring from 50µM. The LDH release started to decrease from the peak 
release (at 200µM) to 2mM. A significant decrease in cell viability was also found 
from 10µM HCQ. 
 
Figure 4.14 - MIO-M1 cell death / viability in response to 72h CHQ / HCQ. Cell 
viability (LDH release) (A, C) and cell viability (B, D) in response to differing 
concentrations of CHQ and HCQ (10µM-2mM) in MIO-M1 cells after 72h exposure 
(n=4) ± SEM, * indicates significance (P<0.05) using one way ANOVA with Dunnets 
post-hoc test. 
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MIO-M1 cells responded to CHQ and HCQ in a dose dependent manner when 
assessed with the MTS assay, whereas the LDH assay provided variable results. 
MIO-M1 cells also displayed a correlation of decreasing cell viability with increasing 
time exposed to CHQ and HCQ, the results of which are summarised in Table 4.4. 
 
A – LD50 values for 24, 48 and 72h CHQ and HCQ Treated MIO-M1 cells 
Cell Line Exposure to 
Drug  
LDH LD50 (M) MTS LD50 (M) Average LD50 
MIO-M1 24h CHQ N.A ~150µM $ 150µM 
MIO-M1 48h CHQ N.A 43.7µM 43.7µM 
MIO-M1 72h CHQ N.A ~20µM $ 20µM 
MIO-M1 24h HCQ N.A ~200µM $ 200µM 
MIO-M1 48h HCQ N.A ~60µM $ 60µM 
MIO-M1 72h HCQ N.A ~40µM $ 40µM 
 
B – Significant Differences for 24, 48 and 72h CHQ and HCQ Treated MIO-M1 
cells 
MIO-M1 CHQ HCQ 
Time 
Exposed 
LDH MTS Average of 
LDH and 
MTS 
LDH MTS Average of 
LDH and 
MTS 
24h N.A ≥50µM ≥50µM ≥2mM ≥100µM ≥1.05mM 
48h ≥50µM ≥20µM ≥35µM ≥50µM ≥20µM ≥35µM 
72h N.A ≥10µM ≥10µM ≥50µM ≥10µM ≥30µM 
 
Table 4.4: Summary of data obtained from 24, 48 and 72h treated MIO-M1 cells. A- 
LD50 values of CHQ and HCQ treated MIO-M1 cells. B – Significant differences of CHQ 
and HCQ treated MIO-M1 cells. $ indicates value calculated by hand. 
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Assessment of LDH release in response to CHQ and HCQ gave complex data in that 
they did not give a standard dose response curve. This can be seen in Figures 4.12 – 
4.14 and in Table 4.4. The MTS assay however displayed a clear dose dependent 
decrease in viability and provided an LD50 and data regarding the dose causing 
significant changes. 
 
4.3 Discussion 
 
The aim of this chapter was to use two retinal cell lines to assess the toxicity of 
compounds with known retinotoxicity. These cell lines could then provide 
preliminary information about the relative toxicity of the drugs of interest, and the 
information gathered from this could be used to determine the concentration of 
retinotoxins to be applied to the ex vivo retina. 
The two retinal cell lines were firstly exposed to a variety of retinotoxins and H2O2 
as a positive control (section 4.2.1 and 4.2.2). The retinotoxins applied to the cell 
lines were indomethacin, tamoxifen and chloroquine. It was expected that due to the 
different nature of the cells, and the compounds, the sensitivity of both cell lines 
would differ for each of the compounds. 
The two retinal cell lines used were ARPE19 cells and MIO-M1 cells. The ARPE19 
cell line is a human retinal pigmented epithelial cell line from a primary source of 
retinal pigmented epithelium. Retinal pigmented cells are highly active cells which 
are responsible for phagocytosing outer segments of photoreceptors. The cells exhibit 
a similar physiology to RPE cells, and display similar RPE specific markers such as 
CRALBP and RPE65 (Dunn et al., 1996).  
The MIO-M1 cell line is an immortalized cell line derived from human Müller cells. 
They are the principle glial cells of the retina, providing structural and metabolic 
support to neurones and blood vessels. They play an important role in glutamate 
uptake in order to prevent neurotoxicity from excess glutamate (Haberecht et al., 
1997). The MIO-M1 cell line expresses known markers of Müller cells such as EGF-
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R (epidermal growth factor receptor), glutamine synthetase, αSMA and CRALBP 
(Limb et al., 2002).  
The cells were firstly exposed to the positive control H2O2. H2O2 is an oxidative 
stressor which has the ability to cause cell death via the apoptotic pathway with low 
concentrations of H2O2 and the necrotic pathway with high concentrations of H2O2 
(Kim et al., 2003; Li et al., 2010). When exposed to H2O2 ARPE19 cells and MIO-
M1 cells displayed a dose dependent increase in LDH release / decrease in cell 
viability. 
In ARPE19 cells, the increase in cell death and decrease in cell viability was seen to 
occur over a small concentration range from 200µM and 500µM in which cells 
responded in an all or nothing manner producing variability. This was followed by a 
significant increase in LDH release from ≥1mM and a significant decrease in cell 
viability from ≥500µM.  
MIO-M1 cells displayed large variability in LDH release which produced no 
significantly different data. The cell viability data represented the cells response to 
H2O2 better than the LDH release data, showing a dose dependent decrease in cell 
viability with increasing concentrations of H2O2 and a significant decrease in cell 
viability occurring from ≥1mM. 
Even though the LDH data was variable from MIO-M1 cells, the cell viability data 
and the LD50 data from both MIO-M1 and ARPE19 cell line indicated that the MIO-
M1 cells displayed a higher resilience to H2O2 than ARPE19 cells. This may indicate 
that MIO-M1 cells are more effective at processing oxidative stressors better than 
RPE cells. 
Indomethacin was the second drug investigated on the cell lines. It is an anti-
inflammatory agent with few reported cases of retinopathy (Graham and Blach, 
1988). On the basis of clinical data it would therefore be expected to cause the least 
toxicity of the drugs investigated. 
ARPE19 cells exposed to indomethacin showed no toxicity at lower concentrations 
with a trend of increased LDH release from ≥500µM. A significant increase in LDH 
release was not found until 2mM. However, surprisingly the LDH data showed a 
significant decrease in cell viability from ≥50µM. This concentration is very low, 
however what can be seen is little dose dependent decrease in viability until a 
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concentration of 1mM is reached. 
MIO-M1 cells displayed a significant increase in LDH release from ≥1mM. This was 
similar to the MTS data which displayed a significant decrease in cell viability from 
≥500µM treatment. Both cell lines displayed a high LD50 which may reflect the 
relatively non retinotoxic properties of indomethacin in vivo. There is little research 
investigating the specific method of toxicity which occurs in indomethacin induced 
retinopathy. It has been speculated that a reactive iminoquinone forms from the 
oxidation of DMBI (a major metabolite of Indomethacin) (Ju and Uetrecht, 1998) 
which could bind to GSH and cause GSH depletion. GSH depletion has been shown 
to cause unregulated oxidative stress and apoptosis in the mouse retina (Roh et al., 
2007). 
Tamoxifen is used in the treatment of hormone responsive breast cancer (Srikantia et 
al., 2010). It is known to possess retinotoxic properties and with prolonged use can 
lead to decreased visual acuity, pigmented retinopathy, macula oedema and macula 
holes (Watanabe et al., 2010), (Lazzaroni et al., 1998). 
ARPE19 cells displayed a dose dependent increase in cell death / decrease in cell 
viability with increasing concentrations of tamoxifen, and a significant increase in 
LDH release and a significant decrease in cell viability found from ≥500µM. 
MIO-M1 cells also displayed a dose dependent increase in cell death / reduction in 
cell viability with increasing concentrations of tamoxifen with a significant increase 
in LDH release occurring from ≥200µM and a significant decrease in cell viability 
occurring from ≥500µM. 
The data indicated that MIO-M1 cells may be slightly more sensitive to tamoxifen 
than ARPE19 cells. The LD50 values obtained in which MIO-M1 cells displayed an 
average LD50 of 193.5µM and ARPE19 cells displayed an average LD50 of 
312.5µM. It is commonly thought that RPE cells (and photoreceptors) are the 
primary target of tamoxifen induced retinopathy (Cho et al., 2012; Engelke et al., 
2002), with lysosomal disruption causing a release of hydrolases such as cathepsins 
which in turn can cause cell death via a multitude of pathways such as apoptosis, 
necrosis and pyroptosis (Kim et al., 2014). However data obtained here suggests that 
Müller cells sensitivity to tamoxifen may also influence the retinopathy associated 
with tamoxifen treatment. 
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Chloroquine is a lysomotropic agent which was commonly used as an anti-malarial 
agent, although due to widespread resistance it is now mainly used in the treatment 
of rheumatoid arthritis (NHS, 2014c). 
ARPE19 cells responded to chloroquine in a dose dependent manner, with an 
increase in LDH release and a decrease in cell viability with increasing 
concentrations of chloroquine. A significant increase in LDH release was found from 
≥200µM, and a significant decrease in cell viability from ≥100µM.  
MIO-M1 cells also responded to chloroquine in a dose dependent manner with a 
significant increase in LDH release and decrease in cell viability from ≥50µM. 
This data indicates that MIO-M1 cells are more susceptible to chloroquine toxicity 
than ARPE19 cells, with chloroquine causing a significantly higher LDH release / 
lower cell viability at a much lower dose in MIO-M1 cells. LD50 values in MIO-M1 
cells displayed an average LD50 of 37.5µM and ARPE19 cells displayed an average 
LD50 of 250µM 
Chloroquine retinopathy is commonly associated with long term use of the drug. 
Patients may present with visual defects such as central visual loss, night blindness 
and a loss of colour vision. Clinically, chloroquine retinopathy appears as pigmentary 
changes, with advanced retinopathy appearing as a bulls eye maculopathy (Pasadhika 
et al., 2010), (Nogueira and Gama, 2009). The method through which chloroquine is 
believed to cause retinopathy is due to lysosomal dysfunction. It is believed that the 
RPE is primarily affected due to its role of phagocytosing shed outer segments of 
photoreceptors, in turn affecting photoreceptors. However an early study by 
Rosenthal et al (1978) showed that in the rhesus monkey, ganglion cells are affected 
first, followed by the photoreceptors and RPE. The current data (Figure 4.4 and 4.8) 
suggests that Müller cells may be more sensitive to chloroquine toxicity than RPE 
cells, and this may also contribute to the retinopathy seen with CHQ treatment 
clinically. 
Chloroquine displayed the most retinotoxic properties in both ARPE19 and MIO-M1 
cells. The next most retinotoxic drug assessed was tamoxifen and finally 
indomethacin. This data relates to the clinical prevalence of retinopathy induced by 
the drugs, in which chloroquine has the highest prevalence of reported retinopathy of 
the drugs investigated. The actual value of prevalence of chloroquine induced 
retinopathy in chloroquine treated patients is variable across multiple studies, and 
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ranges from as high as 24.7% to as low as 0.1% (Browning, 2014). Tamoxifen is the 
next most reported retinotoxic drug investigated, with an incidence of 0.9% (in a 
study of 274 patients) (Tang et al., 1997) whereas for indomethacin, only one case of 
retinopathy has been reported (Graham and Blach, 1988). 
Hydroxychloroquine is also an anti-malarial agent that is used in the treatment of 
rheumatoid arthritis, which superseded the use of chloroquine in the treatment of 
rheumatoid arthritis and systemic lupus due to its better safety profile (Michaelides et 
al., 2011). For this reason the difference in toxicity between chloroquine and 
hydroxychloroquine was investigated on ARPE19 and MIO-M1 cells, to find out if 
the better safety profile of hydroxychloroquine was reflected in the retinal cell based 
toxicity assays. A time course was also conducted in order to establish the effect of 
longer exposure to the drugs.  
Both chloroquine and hydroxychloroquine caused a dose dependent decrease in cell 
viability / increase in LDH release at all-time points in ARPE19 cells, with longer 
exposure to the drugs causing increased cell death (Figure 4.9, 4.10 and 4.11). 
Chloroquine caused a significant decrease in cell viability / increase in LDH release 
at a slightly lower concentration than hydroxychloroquine at all time points, 
reflecting the better safety profile of hydroxychloroquine. The LD50 values also 
reflect this data apart from at the 48h time point in which HCQ possessed a lower 
LD50. 
 
Figures 4.12, 4.13 and 4.14 display the effect of 24, 48 and 72h exposure to CHQ 
and HCQ on MIO-M1 cells. CHQ and HCQ caused a dose and time dependent 
decrease in cell viability, however the LDH release data did not show expected 
patterns of release. Control cells showed release of 10% total LDH at 24h, 20% of 
total LDH at 48h and 30% at 72h. This indicates that culturing in serum free medium 
was having a detrimental effect on the MIO-M1 cell line. More surprisingly there 
was little change in LDH release with treatment of CHQ and HCQ, and interestingly, 
the LDH results from MIO-M1 cells at later time points displayed a decreasing trend 
of LDH release with high concentrations of treatment. This may be due to high 
concentrations of both drugs inducing rapid cell death at early stages, causing early 
release of LDH which then degraded over time. Whereas concentrations around the 
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100µM induced slower cell death with a prolonged LDH release, resulting in less 
LDH degredation and an apparent higher LDH release at the time assessed. This 
shows that for the MIO-M1 cell line, the LDH assay is not a suitable assessment for 
investigation of the effects of longer term culture in CHQ or HCQ. 
The MTS assay however (cell viability assay) worked in an expected manner, and for 
this reason the MTS assay was used to interpret the sensitivity of MIO-M1 cells to 
CHQ and HCQ. This data showed CHQ to be slightly more toxic to the MIO-M1 cell 
line at all time points than HCQ. 
This data reinforces the clinical evidence of HCQ’s better safety profile, with CHQ 
possessing more toxicological properties than that of HCQ in both ARPE19 cells and 
MIO-M1. The fact that the better safety profile of HCQ is reflected in the cell lines is 
important, it shows that the cell lines are suitable for the assessment of retinotoxicity 
and that results which are found clinically may be matched by those within the cell 
lines. 
 
4.4 Conclusion 
 
Experiments within this chapter investigated the sensitivity of human RPE and 
Müller cell line’s to multiple retinotoxins. 
The cell lines showed the predicted responses when assessing the various 
retinotoxins, with high concentrations of the least retinotoxic drug (Indomethacin) 
required to cause a significant increase in cell death, and lower concentrations of the 
known retinotoxins tamoxifen and chloroquine required to cause a significant 
increase in cell death. 
Importantly, both cell lines showed a high degree of sensitivity when determining the 
toxicity of hydroxychloroquine and chloroquine and the cells displayed a better 
safety profile for hydroxychloroquine compared to chloroquine. 
The Müller cell line was more sensitive to tamoxifen, chloroquine and 
hydroxychloroquine than the RPE cell line, potentially indicating that RPE cells 
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display a higher resilience to agents which effect lysosomal activity. A primary 
function of RPE cells is the degradation of shed photoreceptor outer segments by 
phagocytosis, and the breakdown of the phagosome through fusion with endosomes 
and lysosomes (Kevany and Palczewski, 2010). A proposed major mechanism of 
retinal toxicity is the disruption of lysosomal function which would affect the 
degradation of photoreceptor outer segments and would therefore cause disruption of 
the photoreceptor turnover. This research only investigated cell death in response to 
the retinotoxins, however it may also indicate that Müller cell toxicity also plays a 
role in retinotoxicity induced by CHQ, HCQ and tamoxifen. 
 
To summarise, this research indicates the usefulness of human retinal cell lines in the 
establishment of a model to assess retinotoxicity. It has provided information 
regarding the relative toxicity of the drugs investigated, which in the future could be 
used alongside the ex vivo retina and animal models to provide information about the 
toxicity of the drugs, and potentially the mechanisms involved with the associated 
toxicity.  
137 
 
Chapter 5 
5.0 Effect of Chloroquine on Human Organotypic Retina Cultures 
5.1 Introduction 
 
Organotypic models are a useful tool in the process of drug development. They 
possess the same cellular and structural properties as the tissue of interest and may 
provide an accurate insight into the effects of a drug on its target tissue. This makes 
the development of human organotypic retinal cultures (HORCs) as a model to 
assess retinotoxicity desirable. HORCs maintain comparable structural and cellular 
properties to the living retina (as shown in Chapter 3) and would enable a correlation 
to be made of a drug’s potential toxicity in the human retina. 
Non-human organotypic retinal cultures have previously been utilised to assess the 
toxicity of specific compounds. The mouse organotypic retinal culture has also been 
used for toxicity studies in which the effect of gold and silver nanoparticles were 
investigated (Soderstjerna et al., 2014). The porcine organotypic retina has also been 
utilised to investigate the effects of bevacizumab (Kaempf et al., 2008). Rat 
organotypic retinal cultures have been utilised to investigate the role of adenosine A3 
receptor activation in the protection of retinal cells from NMDA exitotoxicity 
(Galvao et al., 2015), as well as the protective effect of hydrogen against 
peroxynitrate (Yokota et al., 2015). Human organotypic retinal cultures (HORCS) 
have been utilised previously for a similar purpose in which Niyadurupola (2011) 
showed that THY1 expression (a ganglion cell marker) decreased in response to 
NMDA excitotoxicity and oxygen / glucose deprivation, representing a decrease in 
ganglion cell density and health (Osborne et al., 2015a; Niyadurupola et al., 2011). 
Such data demonstrated the possibilities of using HORCs to investigate degenerative 
effects on ganglion cells, and opened up the possibilities of investigating 
degeneration of other retinal cell types in response to stressors including retinotoxins. 
Research presented in the previous chapter demonstrated the effect of a variety of 
known retinotoxins on the RPE cell line ARPE19 and the Müller cell line MIO-M1. 
Chloroquine was found to be the most potent retinotoxin investigated on both cell 
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lines; for this reason the effect of chloroquine retinotoxicity on the HORC was 
investigated. 
Research presented in this chapter aims to explore methods to analyse the toxicity of 
chloroquine in human organotypic retinal cultures (HORCs). The first stage will 
involve investigating cell death and cell viability in response to chloroquine. The 
next stage involved investigation of the cells affected by chloroquine, carried out 
through the use of immunohistochemistry, and the assessment of levels of cell 
specific mRNA in response to differing concentrations of chloroquine. The 
mechanism of cell death induced by chloroquine was also investigated. 
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5.2 Results 
5.2.1 The Effect of Hydrogen Peroxide on Cell Death in the HORC 
 
Initial experiments used hydrogen peroxide was used as a positive control to find out 
if LDH was released from paramacula HORCs as a result of cell death. 
 
 
Paramacula sections showed a dose dependent increase of LDH release with 
increasing hydrogen peroxide concentrations, a significant increase in LDH release 
was found at 2mM. 
  
 
Figure 5.1 - LDH release in response to H2O2. Mean + SEM control, 1mM, 2mM, 
3mM (n=3). * indicates a significant difference compared to the control (P<0.05) using 
one way ANOVA with Dunnet’s post hoc test. 
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5.2.2 The Effect of Chloroquine on Cell Death / Cell Viability in the HORC 
 
LDH was used then to assess the extent of cell death caused by varying 
concentrations of CHQ in paramacula HORCS. The MTS assay was also used to 
assess any changes in cell viability that occur with 24h CHQ treatment. 
 
 
 
Exposure to CHQ caused LDH release from HORCs. A trend of increased LDH 
release was found from ≥ 200µM treatment, and a significant increase in LDH 
release occurred at 2mM. The MTS assay showed a decreased trend in expression at 
500µM, and a significant decrease in cell viability at 2mM. 
  
 
Figure 5.2 - HORC LDH release and cell viability in response to CHQ. A - Mean + 
SEM of cell death (LDH release) in response to 50µM CHQ (n=31), 200µM (n=31), 
500µM (n=4), 1mM (n=4) and 2mM (n=31). B – Mean + SEM of cell viability in 
response to 50µM CHQ (n=4), 200µM (n=4), 500µM (n=4), and 2mM (n=4) after 24h 
exposure. * indicates a significant difference from the control (P<0.05) using one way 
ANOVA with Dunnets post-hoc test.  
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5.2.3 Investigation of Chloroquine Induced Cell Death in the HORC 
 
HORCS were exposed to CHQ for 24h and cell death investigated using colormetric 
immunohistochemistry and analysed using ScanScope software in which the result is 
expressed as percent positive pixels relative to total pixel count (positive being 
antibody of interest and negative haematoxylin stain). Firstly a marker of cell death 
(TUNEL) was investigated (Figure 5.3). Note that in these experiments an antibody 
to FITC was used to allow the colorimetric analysis to be used. 
 
 
 
Figure 5.3 showed the TUNEL assay to be a sensitive method of cell death analysis 
in HORCS, displaying a significant increase in TUNEL positive cells from ≥200µM 
CHQ. This was a more sensitive assay than LDH or MTS assay, which only showed 
a significant increase in cell death from 2mM. 
  
 
Figure 5.3 - TUNEL % Positive Pixels in Response to CHQ Mean + SEM of cell death 
(% positive pixel) using the TUNEL assay in 24h CHQ treated HORCS (n=5). * indicates 
a significant difference to the control (P<0.05) using one way ANOVA with Dunnets 
post-hoc test. 
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Another marker of apoptotic cell death (active caspase 3) was then investigated using 
the same method. This was analysed as a positive pixel count and the results are 
shown in Figure 5.4. 
 
 
Figure 5.4 indicated that there was no change in the amount of active caspase 3 
positive cells with CHQ treatment. Figure 5.2 and 5.3 showed there was a gradual 
increase in cell death with increased CHQ treatment, indicating that assessment of 
active caspase 3 may not be a good method to assess CHQ induced cell death. 
  
 
Figure 5.4 - Active Caspase 3 % Positive Pixels in Response to CHQ Mean + SEM of 
cell death (% positive pixel of Active Caspase 3) in CHQ treated HORCS (n=5). * 
indicates a significant difference to the control (P<0.05) using one way ANOVA with 
Dunnets post-hoc test. 
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The positive pixel count method was then utilised to investigate any loss in ganglion 
cells that may occur (Figure 5.5). Ganglion cells were chosen due to previous 
research which had shown a decrease in NeuN labelled cells with NMDA 
excitotoxicity and oxygen glucose deprivation (Osborne et al., 2015a; Niyadurupola 
et al., 2011). For this experiment, the positive pixel count of the ganglion cell marker 
NeuN was investigated with varying concentrations of CHQ to determine if any loss 
of ganglion cells occurred due to CHQ toxicity. 
 
 
The NeuN positive pixel count did not change after 24h of CHQ treatment, either 
indicating no change in ganglion cell number occurred with CHQ treatment, or that 
this method of analysis may not be suitable for assessing changes in ganglion cell 
number. 
  
 
Figure 5.5 - NeuN % Positive Pixels in Response to CHQ Mean + SEM of NeuN (% 
positive pixel) in CHQ treated HORCS (n=5). * indicates a significant difference to the 
control (P<0.05) using one way ANOVA with Dunnets post-hoc test. 
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5.2.4 Effect of Chloroquine on mRNA Expression of Retinal Cell Markers in 
HORCs  
 
TUNEL analysis provided a sensitive means of assessing cell death in CHQ treated 
HORCS. However since the analysis was carried out using an automated system, this 
did not provide information regarding specific cell types affected by chloroquine 
toxicity. In order to investigate specific cell loss in the retina that may occur due to 
CHQ toxicity, paramacula samples were exposed to varying concentrations of CHQ 
and the expression of cell specific mRNA markers investigated. Previous research 
has shown that THY1 mRNA expression can be used a sensitive measurement of 
ganglion cell health / density (Nash and Osborne, 1999; Niyadurupola et al., 2011). 
THY1 expression was assessed to determine ganglion cell density, alongside CHAT 
(Amacrine cell), RLBP (Müller cell), PRKCA (Bipolar cell), CALB1 (Horizontal cell) 
and RCVRN (Photoreceptor cell).  
 
Figure 5.6 shows the mRNA expression of cell specific markers in response to 24h 
CHQ treatment. 
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Figure 5.6 - Fold Change in mRNA Expression in Response to CHQ (Delta CT 
method) (normalised to the housekeeping genes TOP1 and CYC1) in HORCs exposed to 
CHQ for 24h A THY1, B ChAT, C RLBP, D PKCA, E CALB1, F RCVRN expression. 
Control (n=8), 50µM (n=4), 200µM (n=8), 500µM (n=4), 1mM (n=4) and 2mM (n=8). * 
indicates a significant difference to the control (P<0.05) using one way ANOVA with 
Dunnets post-hoc test. 
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THY1 showed a decreased trend in expression after 50µM and 200µM CHQ 
treatment for 24h, however the decreased trend was not significant (Figure 5.6 A). 
This was followed by increased expression at higher concentrations of CHQ, with a 
significant increase at 1mM and 2mM. 
ChAT displayed a similar pattern of expression to THY1 after exposure to CHQ 
(Figure 5.6 B), with a trend of decreased expression with 50µM and 200µM CHQ 
followed by an increase in expression which became significant at 500µM, 1mM and 
2mM. 
Figure 5.6 C displayed RLBP expression in response to CHQ treatment. A trend of 
decreased expression at 200µM can be seen followed by an increase in expression at 
500µM and a significant increase in expression with 1mM and 2mM CHQ treatment. 
PKCA expression did not change in response to low concentrations of CHQ 
exposure, with no change in expression up to 200µM treatment (Figure 5.6 D). 
However there was a significant increase from ≥500µM. 
Changes in CALB1 expression were similar to THY1, ChAT and RLBP with 
significant increases see at 1mM and 2mM (Figure 5.6 E). Trends of CALB1 were 
also similar to RCVRN (Figure 5.6 F), however RCVRN expression displayed no 
significant change with any concentration of CHQ treatment. 
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5.2.5 Western Blot Analysis of Chloroquine Treated Samples 
 
The previous data provided evidence that cell death that occurred in HORCs with 
CHQ treatment. Subsequent experiments aimed to further investigate the method 
through which cell death occurred were carried out on HORCs exposed to CHQ for 
24h. It is known that levels of PARP cleavage can be used as a measure of apoptosis 
(Mullen, 2004), therefore protein extracted from HORCs was analysed by western 
blotting for PARP cleavage and active caspase 3 to help determine if apoptosis was 
the cause of cell death in the treated samples. 
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Levels of PARP cleavage were firstly assessed in hydrogen peroxide treated samples 
as a positive control (Figure5.7). 
 
The western blot for PARP (Figure 5.7 A) clearly shows a loss of whole PARP 
(116kDa) with H2O2. This appears to be dose-dependent, with very little whole 
PARP detected at the higher concentrations of H2O2. Cleaved PARP also decreased 
with H2O2, but not as quickly as whole PARP. When analysed using densitometry 
the ratio of whole PARP to cleaved PARP displayed a dose dependent decrease with 
increasing concentrations of H2O2. It should be noted that this was only n=2, 
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Figure 5.7 - PARP Cleavage in Response to H2O2 - A Representative western blot for 
PARP following 24h H2O2 treatment of HORCs (n=2) ± SEM. B Whole PARP to 
Cleaved PARP ratio. No significant difference was found with increasing concentrations 
of CHQ (P>0.05) (one way ANOVA with Dunnets post-hoc test). 
H2O2 Concentration 
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however the clear trend showed that this may be a useful method to investigate 
apoptosis. 
PARP cleavage was then investigated on CHQ treated samples. 
 
Figure 5.8 shows the effect of CHQ on PARP in the HORC. What can be seen is 
very little change in levels of β actin with increasing concentrations of CHQ (Figure 
5.8A). Whole PARP also changes very little until 2mM treatment where a decrease 
can be seen (Figure 5.8 B), this is matched by cleaved PARP (Figure 5.8 C) which 
 
D 
 
Figure 5.8 - Representative Western blot of PARP following 24h CHQ treatment. 
A – β-actin, B – Whole PARP, C – Cleaved PARP 
D - Whole PARP : Cleaved PARP ratio after normalisation of each to β actin (n=4). No 
significant difference was found with increasing concentrations of CHQ (P>0.05) (one way 
ANOVA with Dunnets post-hoc test). 
150 
 
also only shows a decrease with 2mM treatment. Overall this resulted in no change in 
the ratio of whole PARP to cleaved PARP (Figure 5.8 D). 
 
5.3 Discussion 
 
The aim of this research was to determine whether the HORC could be a suitable 
model for the assessment of retinotoxicity. This was investigated by assessing the 
effects of the known retinotoxin CHQ on the ex vivo retina. 
Levels of cell death were firstly assessed in the positive control treated HORCs 
(H2O2). Figure 5.1 showed that 2mM H2O2 was required to cause a significant 
increase in cell death as measured by the LDH and MTS assays in the HORC. This 
corresponded well with the cell line data in Chapter 4 in which H2O2 caused a 
significant increase in cell death / decrease in cell viability in ARPE19 cells with 
1mM and 500µM H2O2
 treatment respectively, and a significant decrease in cell 
viability was found with 1mM H2O2
 treatment in the MIO-M1 cell line. 
Since the LDH assay proved to be useful in measuring levels of cell death induced by 
H2O2 it was decided that this assay would also be used to assess CHQ induced cell 
death in HORCs. It was also decided that the MTS assay would be utilised to find out 
if the assays differed in sensitivity. It was found that CHQ caused a dose dependent 
increase in cell death in the HORCs (Figure 5.2), with a significant increase in cell 
death, and a significant decrease in cell viability found at a concentration of 2mM. 
LDH appeared to provide a more sensitive means of assessing cell death, displaying 
a gradual increase in cell death from low concentrations of CHQ, whereas the MTS 
assay did not show a decreased trend of cell viability until 500µM CHQ. 
Previous data from the ARPE19 and MIO-M1 cell lines indicated that CHQ caused a 
significant increase in cell death at concentrations of ≥200µM and ≥50µM 
respectively. It was therefore be expected that the concentrations of CHQ required to 
induce a significant level of cell death in the HORC would be lower than 2mM. This 
may indicate that either the LDH and MTS assay are not sensitive enough to assess 
changes in levels of cell death in the HORC, or that higher concentrations of toxins / 
151 
 
compounds are required to cause a significant increase in cell death in the HORC due 
to the detoxification of the compound by the retina. 
To further investigate CHQ induced toxicity, other methods of assessing cell death 
were used, specifically TUNEL activation, caspase 3 cleavage and ganglion cell 
number (levels of NeuN positive cells). 
This was accomplished through the use of the Ventana Discovery (Roche, Burgess 
Hill, UK), a high throughput immunohistochemical platform which allows for the 
efficient staining of multiple slides with multiple antibodies. The platform was used 
for colorimetric immunohistochemistry where samples were stained for either active 
Caspase 3, Anti-FITC (TUNEL) or NeuN. The slides were then scanned and a 
positive pixel count performed of antibody specific pixels, normalized to the number 
of haematoxylin pixels using the image analysis software Scanscope. The TUNEL 
anti-FITC colorimetric method had not been used before in HORCs and was 
developed for the purpose of assessing CHQ induced toxicity using a high 
throughput method.  
The TUNEL assay is designed to detect cells undergoing apoptosis, more specifically 
the late stages of apoptosis, in which DNA degradation from endonuclease activation 
occurs. The DNA degradation produces double stranded DNA fragments of 
approximately 180 – 200bp in length. The double stranded breaks are recognised by 
terminal deoxynucleotidyl transferase (TdT), which catalyses the addition of FITC 
labelled dUTP’s to the 3’-OH termini, which can then be visualised through 
fluorescence microscopy (Kyrylkova et al., 2012). In this method a HRP anti-FITC 
antibody was used to allow colorimetric assessment of the samples to be used. It 
should also be noted that TUNEL has also been found to detect cells undergoing 
necrosis (Kyrylkova et al., 2012), suggesting that DNA fragmentation is not 
specifically a feature of apoptosis, meaning that care must be taken when interpreting 
data using this assay (de Torres et al., 1997; Grasl-Kraupp et al., 1995). 
 
Figure 5.3 shows a dose dependent increase in % TUNEL positive pixels with CHQ 
treatment, with a significant increase from ≥200µM. This assay displayed much 
higher sensitivity compared to the LDH and MTS assay which only showed a 
significant increase in LDH with 2mM treatment.  
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Active caspase 3 was then investigated, as measuring levels of active caspase 3 is a 
well-established method of analysing apoptotic cells. When cells die they commonly 
follow two routes of cell death, apoptosis and necrosis. Apoptosis is programmed 
cell death that is controlled and does not create an inflammatory response, whereas 
necrosis is uncontrolled cell death which is predominantly due to disruption of the 
cell membrane or interference with the energy supply of the cell which induces an 
inflammatory response (Kim et al., 2003; Elmore, 2007). 
Apoptosis normally follows one of two main pathways, the extrinsic (death receptor) 
pathway and the intrinsic (mitochondrial) pathway. However there are other routes 
such as T-cell mediated cytotoxicity (Elmore, 2007). It is also possible for the 
extrinsic and intrinsic pathway to influence each other (Igney and Krammer, 2002). 
The extrinsic pathways initiation of apoptosis includes the activation of 
transmembrane receptor proteins. More specifically these are part of the tumour 
necrosis factor (TNF) receptor family which transmit the death signal into an 
intracellular signal. The T cell mediated cytotoxicity pathway mentioned earlier 
induces apoptosis via the extrinsic pathway (Brunner et al., 2003). 
The intrinsic pathway of apoptosis is activated by a range of intracellular signals 
which act on internal targets within the cell. There are two types of stimuli which 
have the ability to activate the intrinsic pathway; these are negative and positive 
signals. Negative signals are induced by a lack of certain hormones, cytokines and 
growth factors which normally inhibit the initiation of a death signal. Positive signals 
are stimulants which induce the apoptosis signal including toxins, temperature 
change and viral infections. The death signal starts with the loss of the mitochondrial 
transmembrane potential, the opening of the mitochondrial permeability transition 
pore and the release of apoptosis inducing proteins (Saelens et al., 2004; Elmore, 
2007).  
Once either one of these pathways are activated they follow the same termination 
pathway which starts with the cleavage of Caspase 3. Following a series of 
intracellular events including; breakdown of cytoskeletal and nuclear proteins, DNA 
fragmentation and expression of ligands of phagocytes, the death of the cell occurs 
(Elmore, 2007). 
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Cleavage of caspase 3 is a common step in apoptosis enables the use of an antibody 
against active caspase 3 to identify cells which are undergoing apoptosis. In the 
experiments performed no change in levels of active caspase 3 was detected. This 
data leaves the root cause of cell death open. The lack of change in active caspase 3, 
and the significant increase in TUNEL levels with CHQ treatment indicates that 
either apoptosis is not the cause of cell death and TUNEL is displaying another form 
of cell death such as necrosis. Or that the tissue is undergoing apoptosis which 
TUNEL is showing, and the assessment of active caspase 3 is not appropriate for 
assessing levels of cell death in the human retina. The latter is likely to be the case as 
others have tried to use caspase 3 cleavage to assess apoptosis in the human retina, 
but without success (Osborne, personal communication). 
Immunohistochemistry was also used to investigate ganglion cell susceptibility. It 
has been shown that CHQ treatment causes an initial loss of ganglion cells in the 
retina of rhesus monkeys, with other nuclear layers affected at later time points 
(Rosenthal et al., 1978). There is also clinical data from CHQ treated patients who 
are affected by CHQ induced retinopathy which indicates that there is a thinning of 
the nerve fibre layer in advanced stages of toxicity which may be due to ganglion cell 
damage / loss (Bonanomi et al., 2006; Korah and Kuriakose, 2008). 
The percentage positive pixel method was used to investigate NeuN 
immunohistochemistry in HORCs after exposure to CHQ to find out if ganglion cell 
numbers were effected by CHQ treatment. The results (Figure 5.5) displayed no 
change in NeuN positive pixels with any concentration of CHQ treatment. This may 
indicate that ganglion cells which express NeuN do not change in number with CHQ 
treatment, or that ganglion cells are not affected by CHQ. 
The next area of interest was to try and determine cell specific loss that occurred in 
the ex vivo retina as a result of CHQ toxicity. This was investigated through changes 
in expression levels of cell specific markers in response to CHQ induced toxicity. 
THY1 mRNA expression has previously been used to assess ganglion cell health / 
density (Nash and Osborne, 1999; Niyadurupola et al., 2011), however no other cell 
specific markers have been used for this purpose in the ex vivo retina. For this reason 
expression levels of THY1 (Ganglion cells), CHAT (Amacrine cells), RLBP (Müller 
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cells), PRKCA (Bipolar cells), CALB1 (Horizontal cells) and RCVRN (Photoreceptor 
cells) were assessed to investigate cell health / density of the respective cells. 
A common theme throughout these results is the decreased trend in expression with 
200µM treatment, followed by an increased trend / significant increase in expression 
with 500µM, 1mM and 2mM CHQ treatment. This decreased trend in expression at 
200µM could be indicative of cellular loss as a result of CHQ toxicity, however this 
is not matched by results from higher concentrations of CHQ treatment (1 and 
2mM), which consistently led to increased expression of the cell specific markers. 
This increased trend / significantly higher expression of cell specific markers with 
high concentrations of CHQ was not expected as previous work with THY1 as a 
marker of RGC survival showed a decreased expression correlating with RGC loss. It 
was possible that the increase in expression could be explained by alterations in 
expression of the housekeeping genes, however after reviewing the data, no changes 
in housekeeping gene expression was found, which indicates that CHQ was 
responsible for the upregulation of expression of multiple cell specific genes. 
The reason for the increase in expression of the cell specific markers is not clear, 
however it has shown that the method of looking at decreased expression of cell 
specific markers in response to CHQ toxicity is unsuitable for the analysis of cell 
death associated with CHQ induced cell death. 
It should be noted that even though the previous chapter showed that increased time 
exposed to CHQ induced higher levels of cell death in MIO-M1 and ARPE19 cells, 
the 24h time point was decided upon for HORC investigation. This time point was 
chosen because of previous research conducted into the expression of mRNA cell 
specific markers within the human retina over time. This research displayed a 50% 
decrease in the expression of the ganglion cell marker THY1 after 24h in culture, 
followed by a further 25% decrease after 48h and reaching basal levels after 72h 
(Niyadurupola et al., 2011). If a decrease in markers are to be used as an assessment 
of a specific cell types vulnerability to CHQ, there must be as little change in the 
initial levels of that marker itself. 
The next aim was to provide further information regarding the cause of cell death 
within the HORC. Protein from CHQ treated HORCs was extracted and analysed for 
PARP cleavage. 
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To help confirm whether CHQ toxicity causes apoptosis, PARP cleavage was 
investigated. Poly (ADP-ribose) polymerase (PARP) is a DNA repair enzyme which 
binds to DNA strand breaks and catalyses the formation of poly (ADP-ribose) 
polymers using NAD+ as a substrate. PARP then detaches from the DNA, and the 
poly (ADP-ribose) polymers are degraded by poly (ADP-ribose) glycohydrolase 
(PARG) allowing DNA repair complexes to repair the DNA (Herceg and Wang, 
2001). When a cell undergoes apoptosis, caspases cleave PARP from a single 116kD 
unit into two fragments (89kD and 24kD), to prevent DNA repair from occurring 
(Mullen, 2004). All caspases have the ability to cleave PARP, however caspase 3 and 
caspase 7 are the most efficient at this process (Ghayur et al., 1997). 
PARP cleavage may be quantified and used to measure of apoptosis (Mullen, 2004). 
Due to the nature of cleavage by caspases, the amount of cleaved PARP can be used 
as an indication of apoptosis within the tissue / cells investigated. This method of 
investigation was of interest as it would provide more information regarding the 
mechanism of cell death caused by CHQ. Previous data indicated that CHQ 
treatment caused no rise in active caspase 3, however this does not rule out 
apoptosis. Many other caspases are involved with apoptotic cell death, and since all 
caspases have the ability to cleave PARP, PARP cleavage should indicate if 
apoptosis occurs as a result of CHQ toxicity. 
In order to investigate if PARP cleavage is a suitable method to assess cell death in 
HORCs, a positive control was firstly investigated. PARP cleavage is known to be 
caused by caspases, therefore any inducer of apoptosis should act as a positive 
control. For this reason H2O2 was firstly investigated as it has been shown to induce 
apoptosis at low concentrations in ARPE19 cells (Kim et al., 2003). 
Figure 5.7 showed a decrease in whole PARP, cleaved PARP also decreased and 
when the whole PARP : cleaved PARP ratio was measured there was a decreased 
trend with increasing concentrations of H2O2. Although this decrease was not 
significant, due to the positive nature of the trend it was decided that PARP cleavage 
would be assessed in response to CHQ treatment. 
Figure 5.8 shows the effect of CHQ treatment on PARP cleavage. Figure 5.7 D 
displays the ratio of whole PARP : cleaved PARP normalised to β actin in response 
to differing concentrations of CHQ. Although a decrease could be seen in both whole 
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PARP and cleaved PARP, there was no significant difference in this ratio with CHQ 
treatment, indicating that apoptosis may not be the route of cell death caused by 
CHQ treatment. 
CHQ is a known inhibitor of autophagy, which is primarily linked with roles in pro-
survival; it has however also been linked with roles in cell death. It is known to aid 
with numerous roles such as adaptation to starvation, immunity and recycling of 
organelles. For the process to be termed autophagy, the targeted cell constituents 
must be delivered into lysosomes for degradation (Boya et al., 2013). There are 
currently three well described types of autophagy described below: 
Chaperone mediated autophagy is a form of autophagy in which a subset of soluble 
cytosolic proteins are recognised and transported into the lysosome for degradation. 
Chaperone mediated autophagy requires the protein to be degraded to contain a 
pentapeptide motif related to the amino acid sequence KFERQ. This motif is 
recognised by cytosolic chaperones which bring the protein to the surface of the 
lysosome where it docks with LAMP-2A. Once docked the protein unfolds and 
translocates into the lysosome (Kaushik et al., 2011). 
Microautophagy is a non-specific form of autophagy (induced via nitrogen 
starvation) in which cytoplasmic substances / organelles are engulfed by the 
lysosome and broken down into their components (Li et al., 2012). 
Macroautophagy involves a double membrane wrapping the targeted cytoplasmic 
region to form an autophagosome. The autophagosome then fuses with an endosome 
forming the amphisome. The amphisome then fuses with the lysosome forming the 
autolysosome which degrades the contained substances (Holt et al., 2011). 
The effect of inhibiting autophagy on ARPE19 cells (using CHQ) has been 
investigated by Yoon et al (2010). The results indicated that the main cause of cell 
death may be due to lysosomal dysfunction, where an increased accumulation of 
endocytosed proteins and lipids have cytotoxic consequences. Yoon et al (2010) also 
found that an increase in LC3-II occurred due to the inhibition of autophagosome and 
lysosome binding. Autophagic cell death however was not likely to be the cause of 
cell death found with CHQ treatment, since inhibition of autophagy using 3-MA 
failed to reduce levels of CHQ induced cell death, whereas co treatment with 
bafilomycin A1 (a lysosomal acidifier) attenuated cell death, indicating lysosomal 
dysfunction may be involved with the cell death found. Interestingly this study also 
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revealed that caspase dependent cell death was not the root cause of cell death, as the 
broad range caspase inhibitor z-VAD-FMK did not reduce CHQ induced cell death 
and no activation of caspase 3 was found. This could match research in this chapter 
which displayed a lack of caspase 3 activation with CHQ treatment, however 
contradictory to this TUNEL labelling did increase which could also indicate 
apoptosis may be involved. 
 
 
5.4 Conclusion 
 
This chapter aimed to investigate the best methods available to analyse cell death in 
the ex vivo human retina in order to assess the effects of the retinotoxin CHQ. 
Cell death was firstly assessed using the LDH and MTS assay, which revealed a 
significant increase in cell death and cell viability with 2mM CHQ treatment. The 
LDH assay showed an increased trend of LDH release at lower concentrations of 
CHQ treatment, indicating that the LDH assay is more sensitive at assessing levels of 
CHQ induced cell death. 
When immunohistochemical methods of analysing cell death were investigated, 
TUNEL positive cells displayed a significant increase from ≥200µM CHQ treatment. 
Active caspase 3 was also investigated, however no change in active caspase 3 
staining was found with any concentration of CHQ treatment. Finally, ganglion cell 
loss was investigated (levels of NeuN), however no change in NeuN was found with 
any concentration of CHQ treatment. This data showed that the most sensitive 
method utilised to assess cell death in respose to CHQ was the TUNEL assay.  
To explore specific cell sensitivities to CHQ, quantitative PCR was utilised to 
investigate expression of cell specific markers in response to CHQ treatment. This 
produced consistent increases in expression of all cell specific markers with 1 and 
2mM treatment, showing that measuring decreased expression of cell markers is 
unsuitable for the assessment of cell health / density in response to CHQ induced 
toxicity. 
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Further analysis was carried out to determine whether the route of cell death caused 
by CHQ toxicity could be investigated in HORCs. PARP cleavage was investigated 
as a measure of apoptosis, however no change in the ratio of whole PARP to cleaved 
PARP was found. 
Overall the research presented in this chapter has shown that cell death can be 
observed in the ex vivo retina through the use of medium assays such as LDH and 
MTS, with the most sensitive means of assessing cell death being TUNEL analysis. 
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Chapter 6 
6.0 Cyclin Dependent Kinase Expression in the Adult Human Retina 
6.1 Introduction 
Research presented in previous chapters has shown the effectiveness of both the 
extraction template (the five paramacula explants and the macula explant) and the 
planar sectioning technique in the process of identifying cell type and density 
through the investigation of mRNA expression. Whole explant analysis provided 
information about cell density within certain regions of the retina (paramacula and 
macula). Whereas analysis of planar sections showed the expression profile of cell 
specific mRNA was as would be expected in relation to positioning across the retinal 
layers. Using the latter technique the ganglion cell layer expressed peak levels of 
THY1 and other ganglion cell specific markers. The inner nuclear layer expressed 
peak levels of PKCA and other inner nuclear layer markers, and the outer nuclear 
layer expressed peak levels of RCVN compared to the rest of the retina. This shows 
that this technique could be used to assess the expression profile of specific genes of 
interest, including genes related to retinotoxic drugs. 
Cyclin Dependent Kinases (CDKs) are part of a family of heterodimeric serine / 
threonine protein kinases which are primarily involved in the cellular processes and 
signals which time the cell cycle (Malumbres and Barbacid, 2005). CDK’s are 
named so because of their dependence on cyclin subunits for activation. These 
cyclins are synthesized and degraded throughout the cell cycle in order regulate the 
activity of the CDK’s (Malumbres and Barbacid, 2005). There are 21 genes which 
encode for CDK’s and a further 5 genes which encode CDK-like proteins (Figure 
6.1) (Malumbres et al., 2009). 
Recent research has begun to show that the role of CDK’s are not strictly bound to 
the cell cycle. They also play roles within the regulation of RNA polymerase II 
(CDK7, 8 and 9) (Parry et al., 2010; Bregman et al., 2000) and, in the case of post 
mitotic neurons, cell migration and synaptogenesis (D.W. Rickman, 2005). Some 
CDK’s have also been shown to have important roles within photoreceptor activity, 
for example, CDK5 is involved in the recovery phase of phototransduction in frog 
and other vertebrate photoreceptors (Hayashi et al., 2000).  
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CDK inhibitors have been of interest recently due to their potential to be used as 
cancer therapeutics. This has stemmed from research which has found that CDK’s 
can be over expressed in many tumors (Nemunaitis et al., 2013). One such example 
of a successful CDK inhibitor is dinaciclib, a small molecule CDK inhibitor which 
has progressed through to human phase 1 clinical trials for patients with advanced 
malignancies (Nemunaitis et al., 2013) and has been used for early phase 2 trials for 
non-small cell lung cancer (Stephenson et al., 2014). Broad spectrum pan CDK 
inhibitors would be expected to have similar side effects as chemotherapy agents, 
 
Figure 6.1 - CDK family tree. CDKL = CDK like, for explanations of the genes 
highlighted in the red box, refer to the text (Malumbres et al., 2009) 
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with other rapidly dividing cells being affected such as those within the gut and bone 
marrow (Illanes et al., 2006). Interestingly it has been noted that the use of pan-CDK 
inhibitors can cause toxic side effects and cell death within non-rapidly dividing 
cells, and non-dividing cells. 
AG-012986 is a pan-CDK inhibitor which was found to cause photoreceptor toxicity 
in the mouse retina (Illanes et al., 2006). Since inhibition of CDK’s would normally 
prevail in toxicity related to dividing cells this was of interest, especially since 
photoreceptors are post-mitotic having an “arrested” cell cycle. This further 
demonstrates CDK’s potential involvement in non cell cycle roles. 
The research presented in this chapter investigates the expression profile of CDK 
isoforms in the retina. CDK mRNA expression was investigated in whole explants of 
the human retina to reveal firstly whether the CDK isoform was expressed and 
secondly whether any differences in regional expression throughout the retina 
(macula vs paramacula) were present. Following this, the mRNA expression profile 
of selected CDK isoforms was investigated throughout retina using the planar 
sectioning technique. CDK mRNA was analysed alongside three cell specific 
markers: THY1 to identify the ganglion cell layer, PKCA to identify the inner nuclear 
layer and RCVRN to identify the outer nuclear layer. 
The aims of this chapter are firstly to select CDK’s which might be potential 
mediators of retinotoxicity caused by the CDK inhibitor and to determine the 
expression profile of these genes in the human retina. Secondly, the effects of the pan 
CDK-inhibitor AG-012986 on the two retinal cell lines ARPE19 and MIO-M1 cells 
will be investigated. This research aims to aid in the future development of CDK 
inhibitors, providing information relating to which CDK’s may be the cause behind 
the toxicity of photoreceptors. 
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6.2 Results 
6.2.1 CDK Selection 
Due to large vast family of CDK’s and CDK-like proteins, the research was directed 
to a set of CDK’s agreed with AstraZeneca. In order to make a decision on which 
CDK’s to investigate, AstraZeneca provided data regarding the affinities of two pan-
CDK inhibitors with known neurotoxicity and one pan-CDK inhibitor and a selective 
CDK9 inhibitor which has no reported neurotoxicity. This data is shown in Figure 
6.2. 
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Figure 6.2 - Affinities of four CDK inhibitors towards different CDK isoforms. A 
and B (green dots) represent two CDK inhibitors with no recorded neurotoxic side 
effects. C and D (red dots) represent two CDK inhibitors with recorded neurotoxicity. 
Source: AstraZeneca. 
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The CDK’s agreed upon were CDK16, 17 and 18, and CDK11A and B. This was 
decided because both CDK inhibitors which cause retinotoxicity possessed higher 
affinity for CDK 16, 17 and 18 along with CDK11A and B, and it was believed that 
the combined effect of inhibiting these CDK’s may be the reason behind the 
retinotoxicity found. It was also agreed that CDK 5 would be investigated due to 
previous data suggesting the role CDK5 possesses in the retina. 
 
6.2.2 Whole Explant CDK analysis 
Whole explant analysis of CDK expression throughout the five paramacula explants 
and the macula explant was performed to investigate if CDK expression was present, 
and if any variation in regional expression occurred (Figure 6.3)  
 
 
 
 
Figure 6.3 - Expression of CDK’s throughout whole retinal explants. Relative 
expression of CDK 5 (A), 11 (B), 16 (C), 17 (D) and 18 (E) mRNA within paramacula 
and macula explants (n=5) ± SEM, * indicates significance (one way ANOVA with 
Tukeys multiple comparison test) (P<0.05). 
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CDK5 expression levels were consistent throughout the 5 paramacula explants, 
however the macula had significantly higher expression compared to paramacula 
explants (Figure 6.3 A). CDK11 expression levels were similar throughout the 
paramacula and macula explants (Figure 6.3 B). 
CDK16 and 17 expression levels were consistent throughout the paramacula and the 
macula explants. CDK18 displayed a reduced trend of expression in the macula 
compared to the paramacula explants, but no significant difference was seen (Figure 
6.3 C, D and E). 
This data indicates that each of the CDKs investigated are expressed within the 
human retina, and there is evidence to suggest that some of the CDKs may be more 
highly expressed in certain cell types, with CDK5 possessing significantly higher 
expression in the macula and CDK18 displaying a reduced trend of expression in the 
macula compared to the paramacula. Planar sectioning may be utilised to confirm 
any expression patterns that may occur throughout the nuclear layers of the retina. 
 
6.2.2 mRNA Profiling of the Macula and Paramacula Explants 
Planar sectioning allows assessment of mRNA expression in individual retinal layers. 
Expression of CDK5, 11, 16, 17 and 18 was assessed alongside cell specific markers 
to determine the expression profile. 
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Figure 6.4 - Expression of THY1, PKCA, RCVRN, CDK5, CDK11, CDK16, CDK17 and 
CDK18 mRNA throughout planar sectioned macula and paramacula samples. Mean ± 
SEM (n=4). The outer nuclear layer is represented by the purple bar, the inner nuclear layer by 
the blue bar and the ganglion cell layer by the green bar. 
ONL INL GCL 
Macula 
Explant 
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Figure 6.4 shows the mRNA profile of the cell specific markers and CDKs 
throughout the macula and paramacula explants. The cell specific markers THY1, 
PKCA and RCVN were located in their normal positions and helped identify the 
ganglion cell layer, the inner nuclear layer and the outer nuclear layer respectively.  
CDK5 expression was evenly distributed throughout the macula whereas in the 
paramacula, peak expression was found in the ganglion cell layer.  
CDK11 showed peak expression in the outer nuclear layer of both macula and 
paramacula samples, although this peak was more defined in the paramacula. 
CDK16 expression was low in the outer nuclear layer of both the macula and 
paramacula, before gradually increasing throughout the inner nuclear layer. 
Expression then remained high in the ganglion cell layer of the macula, whereas a 
decrease in expression was found in the ganglion cell layer of the paramacula. 
CDK17 displayed a similar expression pattern in both the macula and the 
paramacula, with low expression levels in the outer nuclear layer and the ganglion 
cell layer and peak expression in the inner nuclear layer. 
CDK18 expression was also very similar in both macula and paramacula samples, 
with a defined peak in the inner nuclear layer, no expression in the outer nuclear 
layer and little expression in the ganglion cell layer. 
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6.2.3 Effect of AG-012986 on ARPE19 and MIO-M1 Cells 
It is of interest to investigate the effect of AG-012986 on the retinal cell lines due to 
the toxicity found in vivo in mice by Illanes et al (2006). The photoreceptor 
degeneration found with AG-012986 may be caused as a side effect of RPE or 
Müller cell malfunction, therefore it is of interest to investigate the effect of the pan 
CDK inhibitor on the two cell lines ARPE19 and MIO-M1. 
 
The pan-CDK inhibitor AG-012986 was found to possess toxic effects on the MIO-
M1 cell line, but not the ARPE19 cell line. This was displayed by the significant 
 
Figure 6.5 - LDH release and Cell Viability of ARPE19 and MIO-M1 Cells in 
Response to AG-012986. A and B, LDH release in ARPE19 and MIO-M1 cells 
(respectively) in response to the pan CDK inhibitor AG-012986. C and D cell viability of 
ARPE19 and MIO-M1 cells (respectively) in response to differing concentrations of AG-
012986. * indicates a significant difference from the control (one way ANOVA with 
Dunnets post hoc test) (P<0.05) 
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increase in cell death found from 200nM treatment on MIO-M1 cells in both LDH 
and MTS assays. ARPE19 cells displayed a significant decrease in MTS with 60nM 
and 200nM treatment, however this is more than likely an anomaly as no other 
significant decrease in MTS followed and was not matched by an increase in LDH. 
 
6.3 Discussion 
Recent evidence has brought to light the role of CDKs outside of the cell cycle. The 
importance of this has been demonstrated by the development of drugs aimed at 
CDK inhibition which cause toxicity in post mitotic cells. An example of this is the 
pan CDK inhibitor AG-012986 which caused specific photoreceptor toxicity when 
applied to mice in vivo (Illanes et al., 2006).  
In order to investigate the distribution of CDKs within the human retina, mRNA 
expression levels were measured in whole paramacula and macula explants, 
providing an insight into firstly whether the CDKs were expressed, and secondly the 
expression pattern throughout the topographical regions of the retina. The CDK 
expression profile were then investigated throughout planar sectioned macula and 
paramacula explants. This provided a location of CDK expression within the nuclear 
layers of the retina, and details of the density of expression, all of which aid in the 
identification of the cell type expressing CDKs.  
Due to the large number of CDKs, it was decided that the research conducted would 
be focussed onto specific CDKs which were predicted to be the cause of the 
retintotoxicity found with AG-012986 (Illanes et al., 2006). In order to decide on the 
CDKs to investigate, AstraZeneca provided CDK affinity data from four CDK 
inhibitors. Two of these CDK inhibitors were known to cause retinotoxicity, and two 
had no reported retintoxicity. After review, the two CDK families that the retinotoxic 
CDK inhibitors possessed higher affinities for then the non-toxic inhibitors were the 
CDC2L family (CDK11A and 11B) which had higher affinities in the two neurotoxic 
CDK inhibitors, and the PCTK family (CDK16, 17 and 18) which also possessed 
high affinities in both neurotoxic CDK inhibitors (highlighted in Figure 6.2). It was 
also decided that CDK5 would be investigated, as previous data had suggested that 
CDK5 may possess a role in the RGC apoptosis in the rat retina (Chen et al., 2011a). 
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Each of the CDK’s investigated are discussed in turn, and any differences found 
interpreted. 
Whole explant CDK mRNA analysis (Figure 6.3) revealed that CDK5 had 
significantly higher expression within the macula explant compared to all 5 
paramacula explants (P<0.05). Referring back to chapter 3 it can be seen that the cell 
specific marker genes of ganglion cells (THY1, AHNAK2 and RBFOX3) all show 
significantly higher expression in macula samples compared to paramacula. This 
could indicate that CDK5 is expressed in ganglion cells. mRNA profiling revealed 
that in macula samples, expression was evenly distributed and showed no indication 
of peak expression within the ganglion cell layer (Figure 6.4). Interestingly however, 
within paramacula samples there was highest expression in the ganglion cell layer 
(Figure 6.4). This indicates that expression is not restricted to the ganglion cells, but 
that in the paramacula region, there is higher CDK5 expression in the GCL than in 
other layers of the retina. 
CDK5 has been found to play an important role within the CNS. It is expressed 
universally, however it has high activity within the CNS due to the distribution of its 
activators (P35 and P39). P35 and P39 are non-cyclins, with P35 being the main 
activator of CDK5. P39 possesses a 57% homology with P35 and can therefore also 
activate CDK5 (Dhariwala and Rajadhyaksha, 2008). CDK5 is known to play a role 
in neural development, aiding in neuronal migration and differentiation, axonal 
elongation and synaptogenesis. However it also plays a role in post mitotic neurones. 
This is because post mitotic neurones express P35 activity (Paglini and Caceres, 
2001; Chen et al., 2011a). CDK5 has also been linked with multiple neurological 
disorders such as Alzheimer’s Disease, Parkinson’s Disease, Amytrophic Lateral 
Sclerosis (ALS) and Huntington’s Disease (Dhariwala and Rajadhyaksha, 2008). 
Interestingly CDK5 has also been shown to play a role in rat RGC death within a 
model of glaucoma where it was found that CDK5 was upregulated significantly at 
day 21, which was matched by TUNEL positive cells. P35 expression was also 
elevated significantly on day 14 and day 21 of the glaucoma model, suggesting that 
the increase in P35 caused the increase in CDK5 expression. Intriguingly roscovine 
(a CDK5 inhibitor) significantly reduced levels of P35 and the number of apoptotic 
RGC’s, emphasising the importance of CDK5 in neuronal cell survival (Chen et al., 
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2011a). This is interesting in that roscovine (CDK5 inhibitor) possessed pro-survival 
properties for ganglion cells in a glaucoma model, whereas the pan-CDK inhibitor 
AG-012986 caused photoreceptor toxicity in healthy mice, potentially indicating that 
CDK5 inhibition may not be involved with the cell death found with AG-012986. 
Planar sectioning data showed that CDK5 was not expressed highly in the outer 
retina compared to the rest of the retina. 
CDK11 expression throughout whole paramacula explants was relatively consistent 
although the macula displayed a trend of slightly lower expression compared to 
paramacula explants. The cell specific markers that show a similar pattern of lower 
expression in macula vs paramacula are: the Müller cell marker; RLBP, the bipolar 
cell marker PKCA and the photoreceptor marker RCVRN (Chapter 3). Planar 
sectioning revealed higher expression of CDK11 in the photoreceptor layer of both 
macula and paramacula samples, although the difference was more noticeable in the 
paramacula. This indicates that CDK11 is more highly expressed in photoreceptors 
and that expression of CDK11 could be higher within rod photoreceptors, which 
become more densely populated as distance from the fovea increases.  
CDK11 has two isoforms p58 and p110, neither of which has been studied within the 
retina. The CDKp110 isoform is known to be expressed throughout the cell cycle and 
is involved in transcriptional regulation and RNA processing, whereas the CDKp58 
variant is specifically expressed at the G2/M phase (Rakkaa et al., 2014). Deletion of 
the CDK 11 gene in mice caused embryonic death at E3.5 and when further 
investigated, blastocysts showed proliferative defects and mitotic arrest (Hu et al., 
2007). As photoreceptors are terminally differentiated CDK11’s high presence 
within the photoreceptors is not likely to be due to its role within the cell cycle. 
Interestingly CDK11p58 has also been investigated for its role in apoptosis in PC12 
cells (rat neuronal cell line), in which a knockdown of CDK11 repressed neuronal 
apoptosis, and overexpression promoted neuronal apoptosis (Liu et al., 2013). This 
would imply that CDK11 found within photoreceptors might be involved in the 
regulation of apoptosis, however if effects were similar to that of the knockdown of 
CDK11 in the PC12 cell line, inhibiting CDK11 would repress apoptosis, not induce 
it. The literature combined with our data may indicate that photoreceptors possess 
higher levels of CDK11 to aid with transcription / pre-mRNA splicing of 
photoreceptor specific mRNA’s. 
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CDK16 expression showed no distinct pattern of expression between paramacula and 
macula explants. Interestingly mRNA profiling of macula sections revealed 
increasing expression within the inner nuclear layer before reaching peak expression 
in the ganglion cell layer, whereas in paramacula sections there was peak expression 
within the inner nuclear layer. This could indicate that CDK16 is expressed within a 
cell type which resides within both the inner nuclear layer and the ganglion cell 
layer, this may imply expression in amacrine cells. Interestingly, in howler monkeys 
(Alouatta caraya) displaced amacrine cell density reached its peak at 0.5mm from 
the fovea (Muniz et al., 2014). The macula sections in these experiments measures 
4mm in diameter and therefore would encompass this region of high displaced 
amacrine cells. This could explain the difference found between the macula and 
paramacula planar sections; with a high density of displaced amacrine cells in the 
macula, expression of CDK16 would display high levels in the inner nuclear layer 
and the ganglion cell layer, whereas the paramacula sections would show peak 
expression only in the inner nuclear layer. This, however, does not tie in with 
previous data regarding amacrine cells. When the mRNA profile of CHAT marker 
was assessed in Chapter 3, peak expression in macula sections was found in the inner 
nuclear layer, whereas peak expression in paramacula sections was found in the 
ganglion cell layer. This data could therefore indicate that CDK16 is expressed in 
amacrine cells which do not express CHAT. 
CDK16, also known as PCTAIR1 (PCTK1) is expressed in testes, skeletal muscle 
and terminally differentiated neurons (Shimizu et al., 2014). In the testes it is known 
to play a role in spermatogenesis (Mikolcevic et al., 2012) and the cell cycle. It is 
also thought to have interactions with p35 / CDK5. Cheng displayed CDK16’s ability 
to bind to p35 and that the two co-immunoprecipitated together and were found to be 
concentrated at neuromuscular junctions. The CDK5/p25 complex was also found to 
phosphorylate CDK16, this was re-enforced by CDK5 null mice which showed a 
significant reduction in CDK16 activity (Cheng et al., 2002) (Graeser et al., 2002). 
Interestingly CDK16 is important for melanoma cell proliferation, and it has been 
found in melanoma cell lines that high levels of CDK16 cause degradation of p27 (a 
tumor suppressor), whereas knockdown of CDK16 caused elevated p27 levels and in 
turn apoptosis (Yanagi et al., 2014). Whether inhibition of CDK16 could cause a 
similar effect and potentially apoptosis of photoreceptor cells such as that found with 
AG-012986 would need more research. 
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CDK 17 expression was evenly distributed throughout the whole sections (macula 
and paramacula). mRNA profiling of macula and paramacula samples showed low 
expression in the outer nuclear layer, with peak expression in the inner nuclear layer 
and very low expression in the ganglion cell layer. The higher expression within the 
inner nuclear layer is suggestive of expression in: horizontal cells, amacrine cells, 
bipolar cells or Müller cells. mRNA which showed similar distribution in planar 
sections and whole macula / paramacula explant expression were CHAT and CALB1. 
This data could indicate that the amacrine and / or horizontal cells possess high 
levels of CDK17, however, the cell specific mRNA for these cells (Chapter 3) shows 
a more defined peak, restricted to one nuclear layer, whereas the CDK17 peak is 
gradual. 
CDK17, also known as PCTAIR2 (PCTK2), is a poorly characterised protein which 
is expressed within terminally differentiated neurones, only appearing within the 
brain at development stages P-7 to P-15 upon neurones exiting the cell division cycle 
(Hirose et al., 1997). Hirose et al (1997) implied that due to the location of 
immunocytochemical analysis of PCTAIR2, it could be involved with cytoskeletal 
proteins of post mitotic neurones (Hirose et al., 1997). This would indicate that 
CDK17 may play a role in the cytoskeleton of amacrine and horizontal cells, 
however its potential link with the toxicity found with AG-012986 is still unclear. 
CDK18 mRNA showed even distribution throughout all 5 paramacula explants and 
lower expression in the macula explant. This is similar to the distribution of the inner 
nuclear layer markers PKCA (bipolar cells), RLBP and GLUL (Müller cells), and also 
the photoreceptor marker RCVRN. mRNA profiling of macula and paramacula 
explants showed no expression in the outer nuclear layer, high expression in the 
inner nuclear layer and very low expression within the ganglion cell layer. The peak 
of CDK18 expression within planar sectioned macula samples was seen at section 9, 
which matched RLBP expression (Figure 6.4). Planar sectioned paramacula samples 
also show CDK18 possesses a very similar expression profile as RLBP (Figure 6.4). 
Expression is most likely localised in Müller cells rather than bipolar cells because 
the peak of CDK18 expression lies closer to the ganglion cell layer than the peak of 
PKCA expression, as did the peak of RLBP expression (Chapter 3). 
CDK18, also known as PCTAIR3 (PCTK3) is another poorly described member of 
the CDK family. The activators of CDK18 are thought to be cyclin A2 (proposed to 
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aid in the transition from S to M phase) and phosphorylation by PKA (Matsuda et al., 
2014). Interestingly it is also believed that CDK18 plays a role in the progression of 
Alzheimer’s disease since it is found in high concentrations in pathological tissue, 
and is proposed to modulate Tau phosphorylation (Herskovits and Davies, 2006). 
Since CDK18’s peak expression matches that of Müller cells it is possible that 
inhibition of CDK18 by AG-012986 could have downstream effects in the support 
that Müller cells provide to the retina and in turn cause photoreceptor toxicity. 
 
Since AG-012986 is known to cause photoreceptor toxicity in vivo in mice, it is of 
interest to know if this may also occur in humans. When CHQ and the other 
retinotoxins were firstly investigated (chapter 4), the two cell lines ARPE19 and 
MIO-M1 cells were exposed to the retinotoxins and provided valuable information 
regarding the potency of the drugs. To utilise the cell lines further and provide 
information about the potency of the pan-CDK inhibitor, AG-012986 was applied to 
the two cell lines ARPE19 and MIO-M1 at various concentrations. The cell lines 
revealed an interesting feature about the toxicity of AG-012986, that the RPE cell 
line was not affected by AG-012986 whereas the Müller cell line was. This is 
interesting because photoreceptors rely on the RPE cells for maintenance and 
turnover of outer segments, therefore any damage to the RPE is likely to result in 
damage to the photoreceptors which could have explained the photoreceptor toxicity 
found with AG-012986.  
Müller cells are also known to play a crucial role in the support of photoreceptors as 
well as other neuronal cells of the retina. They provide anti-oxidative support to 
photoreceptors by the release of glutathione as well as providing photoreceptor 
protection by secreting neurotrophic factors, growth factors and cytokines 
(Reichenbach and Bringmann, 2013). The importance of the supportive role that 
Müller cells play for photoreceptors is emphasised by a study conducted by Shen et 
al (2012) in which Müller cell ablation caused photoreceptor apoptosis (Shen et al., 
2012). 
The data obtained from the ARPE19 and MIO-M1 cell lines suggests that the Müller 
cells are more sensitive to AG-012986 and therefore may also play a role with the 
photoreceptor toxicity found with AG-012986 treatment. 
175 
 
 
6.4 Conclusion 
 
The research presented in this chapter investigated CDK expression throughout the 
human retina. This could help identify the CDK which is inhibited by the CDK 
inhibitor AG-012986 that causes specific photoreceptor toxicity.  
One of the CDK’s investigated (CDK11) displayed higher expression in the 
photoreceptor layer. This occurred in both paramacula and macula samples, however 
the peak was more defined in paramacula samples. Whole explant analysis showed 
that CDK11 possessed lower expression in macula samples compared to paramacula 
samples, which was similar to the whole explant analysis of RCVRN. This indicates 
that CDK11 may be preferentially expressed within rod photoreceptors which are 
present at a much higher density within the peripheral retina, and at a lower density 
within the foveal region. 
Interestingly the pan-CDK inhibitor displayed a higher toxicity to the MIO-M1 cell 
line than the ARPE19 cell line, indicating that Müller cells may be more sensitive to 
the inhibitor than RPE cells. This may coincide with the planar sectioning data which 
showed CDK18 expression was high in Müller cells, and could indicate the cause of 
the photoreceptor toxicity may be downstream of damage to Müller cells through 
inhibition of CDK18 in Müller cells. 
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Chapter 7 
7.0 General Discussion 
7.1 Thesis summary 
The aim of this study was to develop the ex vivo human retina as a model to assess 
retinotoxicity. The need to develop this model comes from the high levels of ocular 
toxicity associated with drug development; data from Pfizer reported that 7% of 
therapeutic candidate attrition was due to ocular toxicity, of which 99% was due to 
retinal toxicity (Huang et al., 2015). 
Current models available for the assessment of retinotoxicity are in vitro models and 
in vivo models. The in vitro human models available for use are two human retinal 
cell lines, the MIO-M1 cell line (Müller cells) and the ARPE19 cell line (RPE cells). 
The cell lines are useful for early research stages such as drug discovery and 
preclinical development and provide a relatively easy way to perform investigative 
toxicology. However the toxicity of a potential drug cannot be based entirely on cell 
work and in vivo models are still required as a safety evaluation step in the 
preclinical development stage (Huang et al., 2015). 
Human organotypic models are desirable within drug development research as they 
provide a multicellular system which can be representative of the target tissue. They 
also possess advantages over in vivo work as they can be directly related to the 
species of interest and involve no animal studies. The disadvantage of these models 
is that human tissue is not always readily available, and they do not represent a multi 
organ system which may produce toxic metabolites. For this reason this human 
organotypic models are an ideal intermediate, bridging in vitro and in vivo studies to 
provide information regarding toxicity. This model has the potential to save the 
pharmaceutical industry vast amounts of money from investing further into a drug 
which may, or may not possess retinotoxic properties in humans. 
 
To investigate if the human ex vivo retina is a suitable model to assess retinotoxicity, 
multiple stages of research were conducted. Firstly, profiling of cell markers in the 
human retina, and the similarity between the living donor retina and the post mortem 
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retina was investigated. The profiling of cell markers showed which markers were 
suitable for the identification of specific cell types in the human retina. 
Immunohistochemically, it was shown that a suitable marker for the outer nuclear 
layer was recoverin as this stained photoreceptors within the outer retina. Suitable 
inner nuclear layer markers were calbindin and PKCα. Calbindin appeared to 
immunostain horizontal and amacrine cells within the inner nuclear layer, as well as 
cone photoreceptors outer segments, whereas PKCα solely identified rod ON bipolar 
cells, making PKCα a more suitable inner nuclear layer marker. Suitable ganglion 
cell layer markers were THY1, NeuN, β Tubulin III and AHNAK2. Further profiling 
of the retina was accomplished through the investigation of mRNA. It was shown 
that whole sample mRNA analysis could identify the density of specific cell 
populations, and that mRNA profiling of planar sections showed the cell markers 
were specific for the cell type accociated (shown with planar sectioning).  
This stage was important as it provided the basis for further research. The methods 
conducted to profile the human retina are able to be adapted for use as toxicological 
investigators. Immunohistochemical markers of specific cells could in future be co-
localised with cell death markers such as TUNEL to identify cell populations 
affected by retinotoxins. And whole sample mRNA could be used to identify changes 
in whole section cell populations. The assessment of changes in mRNA has been 
used before, and it was shown that decreases in THY1 expression occurred with 
NMDA excitotoxicity and preceded a decrease in NeuN immunohistochemistry 
(Niyadurupola et al., 2011), however this method has never been used to assess 
changes in other cell specific markers. This technique requires expression 
equivalence across the five paramacula samples in order for any changes compared 
to control samples to be assessed. For this reason expression equivalence throughout 
the five paramacula sections of cell specific markers was investigated. It was found 
that the photoreceptor specific marker RCVRN possessed expression equivalence 
throughout the five paramacula sections alongside the inner nuclear layer marker for 
horizontal cells (CALB1), bipolar cells (PKCA) and amacrine cells (CHAT). The 
ganglion cell markers THY1, RBFOX3 and AHNAK2 also showed expression 
equivalence through the five paramacula sections, allowing for investigation into the 
effect of retinotoxins on expression. 
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The next stage was to utilise the human retinal cell lines MIO-M1 and ARPE19 cells 
for the investigation of retinotoxicity with a variety of retinotoxins. The two cell 
lines were exposed to varying concentrations of hydrogen peroxide, indomethacin, 
tamoxifen and chloroquine. Both cell lines responded in a dose dependent matter to 
the retintotoxins and showed the usefulness of the LDH and MTS assay in the 
investigation of toxicity. Interestingly the cell lines displayed the highest sensitivity 
towards chloroquine which is also the most well documented of the retinotoxins. To 
further investigate the sensitivity of the cell lines and the cell death / viability assays, 
hydroxychloroquine and chloroquine were applied to ARPE19 and MIO-M1 cells 
and the responses measured over a 72h period. Data obtained from this displayed 
chloroquine’s more toxicological properties to the cell lines than 
hydroxychloroquine, reflecting three main points. Firstly, hydroxychloroquines 
better safety profile, secondly the sensitivity of the LDH and MTS assay in their 
ability to distinguish between the two drugs, and finally the usefulness of the cell 
lines in the investigation of retinotoxins. 
The effectiveness of HORCs in the assessment of retinotoxicity towards a known 
retinotoxin was then investigated. Out of the retinotoxins applied to the cell lines 
chloroquine proved to be the most potent. It is also a well-documented retinotoxin 
and therefore degenerative effects would be expected if applied to the ex vivo retina. 
For this reason chloroquine induced toxicity on the HORC was investigated. Medium 
based cell death assays (LDH and MTS) displayed a significant increase in cell death 
at 2mM concentrations. The immunohistochemical assay for TUNEL proved more 
sensitive, showing a significant increase in cell death at 200µM CHQ. The method 
with which this was analysed involved adapting the TUNEL assay for use with the 
Ventana Discovery (Roche, Burgess Hill, UK), an automated immunohistochemical 
platform. The TUNEL assay is normally analysed using fluorescence microscopy, 
with fluorescein-12-dUTP incorporated at fragmented 3’-OH ends through the use of 
rTdT. To convert this to the colormetric system used by the Ventana Discovery, HRP 
anti-FITC was applied to the samples post TUNEL assay completion. The 
advantages of using the colormetric system is that the analysis method of the slides is 
automated and has the potential to be used for rapid anlysis in toxicological 
investigations used throughout drug development. 
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After chloroquine had been shown to induce cell death, another method for analysing 
retinal cell health / density was also investigated. Previous data from Niyadurupola et 
al (2011) showed that NMDA excitotoxicity caused changes in THY1 expression 
levels which was related to changes in retinal ganglion cell population (Niyadurupola 
et al., 2011). However investigations into other cell specific markers has never been 
conducted. The mRNA markers investigated were THY1, CHAT, RLBP, PKCA, 
CALB1 and RCVRN. These markers were chosen for two reasons, firstly because 
they represent a marker of each one of the major cell groups of the retina, and 
secondly because they displayed expression equivalence across the five paramacula 
sections, allowing for changes in expression compared to a control to be assessed. 
The data obtained from this displayed that an increase in expression was common 
throughout the higher concentrations of chloroquine treatment, contrary to what was 
expected. The reason as to the increase in expression is unclear, however it has 
displayed that this method of analysis is not suitable for the assessment of 
chloroquine toxicity. 
The final area of research conducted in this project was into the expression of genes 
relating to a novel retinotoxin. Recently CDK inhibitors have come to light as 
potential cancer therapeutics, however when investigated in mice the pan CDK 
inhibitor AG-012986 displayed specific retinal toxicity localised to photoreceptors 
(Illanes et al., 2006). CDKs are normally associated with the cell cycle, and the 
intended target of this drug was rapidly dividing cells, therefore the reason as to why 
the drug is toxic to cells with an “arrested cell cycle” was of interest. With the help 
of AstraZeneca, the affinities of two CDK inhibitors that caused neurotoxicity, and 
two Pan CDK inhibitors which did not cause neurotoxicity towards CDKs were 
investigated. From this data it was decided that the CDKs to investigate further were 
CDK 5, 11, 16, 17 and 18. 
Investigation into mRNA expression from whole explants and planar sectioning of 
explants had been extremely valuable in confirming the position of peak expression 
of cell specific marker genes, therefore this method was adapted to show the position 
of peak expression of the CDK’s of interest. The data obtained from investigating 
CDK expression across the retina showed that CDK’s displayed differential 
expression across the retinal layers. One of the CDK’s investigated (CDK11) 
displayed higher expression in the photoreceptor layer of both paramacula and 
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macula samples, and the whole explant data showed lower expression in macula 
samples compared to paramacula samples. This was similar to the expression pattern 
of RCVRN, and as the higher expression was more pronounced in the paramacula 
regions, expression in rod photoreceptors is inferred. Further to this, if CDK11 is 
inhibited by AG-012986, this may play a role in the photoreceptor toxicity found in 
mice treated with AG-012986. CDK18 also displayed a defined peak of expression in 
the inner nuclear layer of both macula and paramacula samples, and a trend of lower 
expression in the whole macula explant compared to the paramacula explants. RLBP 
displayed a similar expression profile, indicating that CDK18 expression may be 
localised to Müller cells. 
The toxicity of AG-012986 was then investigated on the ARPE19 and MIO-M1 cell 
line. Interestingly the MIO-M1 cell line displayed a high level of sensitivity to AG-
012986 whereas the ARPE19 cell line showed no pattern of increased cell death with 
increasing concentrations of AG-012986. This is interesting because CDK18 
expression was high in Müller cells, therefore if AG-012986 can cause a detrimental 
effect on Müller cells through the inhibition of CDK18, a secondary effect of this 
may be photoreceptor toxicity such as that found in mice. 
 
7.2 Future work 
Research conducted throughout this thesis has the potential to be continued and 
opens a lot future work. Some of this work was planned and ready to be conducted, 
however due to unforeseen circumstances and the reformation of the transplantation 
service, the supply of donated human retinas was halted and the planned work was 
unable to be completed. 
One area of interest is the further development of whole section mRNA analysis in 
response to retinotoxicity. As described, this method of analysis was used to assess 
the effect of NMDA excitotoxicity on ganglion cell health / density (Niyadurupola et 
al., 2011). However when this method was utilised to assess the effect of CHQ on 
multiple cell specific markers, there was an increase in expression with high 
concentrations of CHQ treatment. The reason as to this increase in expression was 
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unclear, and it is of interest to perform further investigations, perhaps on other 
retinotoxins to investigate if this effect is similar. 
It would also be of interest to further investigate the mechanism of CHQ induced 
retinotoxicity. During this study PARP cleavage was assessed to measure levels of 
apoptosis, however there are many other mechanisms which would be interesting to 
investigate such as levels of autophagy. Levels of autophagy can be assessed via the 
relationship between two forms of microtubule associated protein 1 light chain 3 
(LC3-I and LC3-II). LC3-I is found diffusely throughout the cytoplasm (Rosenfeldt 
et al., 2012), however during autophagy LC3-I conjugates to 
phosphatidylethanolamine (a phospholipid found within membranes) forming LC3-II 
which is tightly bound to the membrane of the autophagosome. Upon the final stages 
of autophagy LC3-II is converted back to LC3-I via protease cleavage. The alteration 
in production of LC3-II throughout different stages of autophagy allows us to 
measurement of LC3-II to confirm that either; autophagy has been induced or that a 
build-up of autophagosomes has occurred (Holt et al., 2011), (Mizushima and 
Yoshimori, 2007). 
One major project which was planned, was a detailed investigation into the effect of 
two CDK inhibitors on HORCs. During this project, a selective array was planned in 
which whole sample and planar sectioned pan CDK inhibitor treated HORCS were 
going to be investigated for the effect on mRNA expression of multiple cell specific 
markers, CDK’s and cell death / stress markers. Unfortunately before this work was 
conducted the supply of donated tissue was halted. 
Another interesting project that has potential to be further developed is the analysis 
system of the colorimetric immunohistochemically stained slides using the Ventana 
Discovery platform. The analysis system (Image scope software) can be adapted to 
analyse certain areas, leaving the potential for the investigation of cell death levels 
(using the TUNEL assay) within specific nuclear layers. The TUNEL assay was 
shown to be the most sensitive means of assessing cell death within HORCS. This 
could be particularly useful if for example the CDK inhibitor was applied to the 
HORC, and a degenerative effect was found in the photoreceptor layer but not the 
other layers. This could then be quantified and expressed as percentage positive pixel 
within the specific nuclear layer. 
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7.3 Concluding remarks 
The work conducted within this thesis has displayed the suitability of the ex vivo 
human retina as a model to assess retinotoxicity. I have also shown the most effective 
methods of assessing and analysing the retinotoxicity. The most effective 
methodology appeared to come from TUNEL immunohistochemical staining, and 
the analysis through which this was completed. 
This research also showed that the model can be utilised for other research such as 
the investigation into genes associated with a retinotoxin. This was demonstrated 
with the investigation into the expression of multiple CDK’s throughout the human 
retina, and the association of CDK’s with specific cell types. The planar sectioning 
technique proved to be extremely useful within this research and opens up many 
possibilities of investigating other genes associated with retinotoxins. 
Overall this research has shown the effectivity of the HORC in the assessment of 
retinotoxicity, and the most suitable methods in which to determine cell death. It has 
the potential to be used as a bridge between in vitro and in vivo research, and 
potentially between animal and human studies to provide new information regarding 
the retinotoxicity of current drugs, and novel drugs under development. 
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Supplementary Data 
 
Supplementary data Figure 1 - Supplementary data (SPD) Figure 1 showing a 
whole macula section at 4mm across immunostained with PKC. This figure 
represents the starting point of the Rod ON bipolar cells and shows the density of the 
cells increasing as they progress further away from the fovea. 
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Abbreviations 
AHNAK2 AHNAK nucleoprotein 2 
AMD Age related macular degeneration 
ARPE19 Retinal pigmented epithelium cell line 
BCA Bicinchoninic acid assay 
BRB Blood retinal barrier 
BSA Bovine serum albumin 
CALB1 Calbindin 
ChAT Choline acetyl transferase 
CHQ Chloroquine 
CRALBP Cellular retinaldehyde binding protein 
CT Cycle threshold  
CYC1 Cytochrome c-1 
DLE Discoid lupus erythmatosus 
DMBI Desmethyldeschlorobenzoylindomethacin 
DMEM Dulbeccos modified eagles medium 
DMI Desmethylindomethacin 
DNA Deoxyribonucleic acid  
DPBS Dulbeccos phosphate buffered saline 
EOG Electrooculogram 
ERG Electroretinogram 
FBS Feotal bovine serum 
G-6-PD Glucose-6-phoshate dehydrogenase 
GCL Ganglion cell layer 
GFAP Glial fibrillary acidic protein  
GLUL Glutamate-Ammonia Ligase 
GS Glutamine synthetase 
GSH Glutathione 
GSH-PX Glutathione peroxidase 
GSSG Glutathione disulphide 
HCQ Hydroxychloroquine 
HORC Human organotypic retinal culture 
HPLC High performance liquid chromatoraphy 
HSP70 Heat shock protein 70 
IFT Intraflagellar transport 
INL Inner nuclear layer 
LAMP Lysosome associated membrane protein 
LC3 Microtubule associated protein light chain 3 
LDH Lactose dehydrodenase 
MIO-M1 Muller cell line 
M-PER Mammalian protein extraction reagent 
mRNA Messenger ribonucleic acid  
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4sulfophenyl)-2H-tetra-zolium  
NAC N-acetyleyteine 
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NeuN Neuronal nuclei 
NSAID Non steroidal anti inflammatory drug 
OCT Ocular coherence tomography 
OCT Optimal cutting temperature 
OGD Oxygen glucose deprevation 
ONL Outer nuclear layer 
PARP Poly (ADP-ribose) polymerase 
PBS Phospate buffered solution 
PCR Polymerase chain reaction 
PKCa Protein kinase C alpha 
PM Post mortem 
PVDF Polyvinylidene fluoride 
RA Rheumatoid arthritis 
RBFOX3 Neuronal nuclei (NeuN) 
RCVN Recoverin 
RGC Retinal ganglion cell 
RLBP Retinaldehyde binding protein 
RNA Ribonucleic acid  
ROS Reactive oxygen species 
RPE Retinal pigmented epithelium 
SDS Sodium docecyl sulphate 
SERM Selective estrogen receptor modulator 
SLE Systemic lupus erythmatosus 
TOP1 Topoisomerase I  
TRX-RED Thioredoxin 
TUNEL Terminal deoxynucleotidyl transferase-mediated 
biotindeoxyuridine triphosphate nick end-labelling 
U.S.A United States of America 
UK United Kingdom 
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